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Summary 
 
Briefly, the thesis describes extensive methods to characterize novel modified biomaterial 
surfaces in vitro, and investigate its short term implications at the artery interface in vivo.  The 
plasma technology has been previously deposited on a stainless steel biomaterial (316LSS) and 
investigated initially in the stent form in vivo. At the start of this thesis, histopathology 
characterizations to evaluate artery-stent interface interactions in vivo, were conducted with 
resin-artery-stents. The pilot study was followed by extensive material characterization on 
novel biomaterial cobalt chromium metal alloy L605, complying to ASTM F90 specifications 
- used to manufacture new generation cobalt chromium stents, to treat coronary artery disease 
(CAD). 
The plasma technology is unique for its ability to not delaminate from a biomaterial, while 
providing significant surface hemocompatibility as well as cytocompatibility, and allow 
covalent attachment of a bioactive protein in its native conformation. In accordance to previous 
studies, we chose tropoelastin (TE) as an ideal candidate, to bioengineer modified material 
surfaces via covalent protein binding. The initial investigation aimed to evaluate feasibility of 
PAC+TE stenting in an established rabbit iliac artery animal model. The primary hypothesis 
was that PAC+TE stents would assist enhanced endothelialization, reduce thrombosis and 
markers of inflammation, compared to alloy 316LSS bare metal stents (BMS). Although some 
results were in partial support of the hypothesis - indicating an improvement to early markers 
of thrombosis and neointimal hyperplasia, overall at 7 days there was no significant difference 
to endothelialization between the two stents (BMS vs. PAC+TE) investigated. Since 
preliminary investigations confirmed feasibility of PAC+TE stents in vivo for the first time 
herein, future studies were implicated with extended endpoints and larger animal cohorts for 
more robust translational studies. 
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Extensive investigations thereafter with the novel CoCr biomaterial, provided us opportunity 
to address two primary questions in relation to plasma technology: 
1. How does PAC adhere to a novel biomaterial (L605) surface to prevent delamination 
under compressive stress 
2. How does PAC-L605 maintain superior hemocompatibility and promote homogenous 
cell culture, compared to alloy L605.  
We first investigated the plasma modified biomaterial with plasma kinetics, nanoindentation, 
followed by surface roughness measurements. The aim was to characterize plasma 
modification extensively, and calculate coating integrity, compared to bare metal alloy via 
indentation/external compression. Once coating integrity was confirmed with nanoindentation, 
we investigated PAC-L605 interface with scanning electron microscopy (SEM), focussed ion 
beam (FIB), and transmission electron microscopy (TEM), to visualize PAC-CoCr interface. 
This led to greater understanding of the deposition process, and visualization of the ionic 
stitching buffer layer at the interface, that prevented delamination. Results were as theorized in 
plasma physics, and observed for the first time in response to question 1, on modified alloy 
L605 biomaterial. 
Following initial investigations on surface engineering, we analysed surface 
biofunctionalization with whole blood flow, platelet rich plasma (PRP) assays, surface shelf-
life, fibrinogen deposition, endothelial cell culture as well as plasma biomarkers of coagulation 
and inflammation. We observed markedly reduced surface blood coagulation for PAC-L605 
compared to alloy L605, followed by similar trends; of lowered fibrin deposition, improved 
cell culture and reduced markers of coagulation, platelet and complement activation. Given 
that both surfaces were equally subject to similar physiological conditions, the markedly 
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different biological results observed were explained in relation to surface characteristics, 
specifically hydrophilicity.  
The PAC surfaces showed significantly improved hydrophilicity compared to bare metal 
alloys. To address question 2, results were explained in accordance to in-depth protein-
biomaterial investigations previously conducted by Leo Vroman, discussed at length within 
thesis. The “Vroman effect” or phenomenon is summarized via five statements below, also in 
agreement with our study: 
1. The concentration of proteins available in plasma, decrease with increasing molecular 
weight (i.e higher molecular weight proteins are less abundant in plasma).  
2. Sequence of plasma protein deposition on a surface was: albumin, immunoglobin 
(IgG), fibrinogen, factor XII and HMWK (high molecular weight kininogen). 
3. Any surface-adsorbed protein species can only be removed by a molecule of the same 
species, i.e., forming a temporary dimer that forces the adsorbed molecule back into its 
original conformation, and into solution.  
4. However, on hydrophobic surfaces the sequence of proteins displacing each other stops 
at fibrinogen, preventing step 3, and leading to protein aggregation. 
5. Platelets adhere to surfaces where fibrinogen is adsorbed, therefore on hydrophilic 
surfaces platelets arrive too late to adhere, due to high turnover rate.  
It appears our studies on biofunctionalization were in agreement with the Vroman effect. 
Significantly higher deposition of fibrinogen was seen on L605 vs. PAC-L605 (hydrophobic 
vs. hydrophilic), alongside correlating higher blood coagulation and platelet activity on L605 
vs. PAC-L605. We therefore assume high turnover rate of albumin on PAC-L605 surfaces 
(compared to L605), prevent fibrinogen and low abundance HMWK protein aggregation, 
integral to progression of the coagulation cascade. This phenomenon may account for lowered 
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blood clot formation, and platelet activation for PAC-L605 in contrast to L605, in response to 
the 2nd question of our study.  
In the immediate future, we can conduct further studies to stain and identify surface proteins 
albumin and HMWK comparatively on the two biomaterials, to confirm this hypothesis.   Since 
we essentially confirmed superiority of PAC-L605 vs. L605 within this study, an optimized 
PAC recipe (suggested in context) can be deposited on a commercial stent platform for further 
in vitro investigations, as outlined herein. The alloy L605, ASTM F90 specifications of CoCr 
biomaterial utilized here meet specifications of the commercially available cobalt chromium 
coronary stent platform Multi Link 8 (ML8, Abbott Vascular). Further studies should aim to 
comparatively assess PAC-ML8 stents vs. ML8 stents in vitro, prior to any in vivo translational 
studies.  
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Chapter 1 – Introduction and Literature Review 
 
1.1 Biocompatibility of Coronary Stents 
 
Cardiovascular disease continues to be the leading cause of mortality [1, 2], with a vast majority 
of these deaths attributed to obstructive coronary artery disease (CAD) [3]. Depending on the 
severity of the disease, the main interventional options for revascularisation include 
angioplasty, stent deployment and in severe, diffuse occlusions (more than 70%), bypass graft 
surgery [3]. Narrowed coronary arteries were originally treated percutaneously with balloon 
angioplasty alone [4]. However, clinical complications including abrupt vessel closure from 
elastic recoil in the short term and significant neointimal hyperplasia, limited the applicability 
of this intervention. Improved results were observed following the insertion of an additional 
intravascular mechanical support, cylindrical metal scaffolds known as stents [5]. The first 
balloon expandable stents were designed from surgical grade stainless steel, and aimed to 
provide additional mechanical support, limiting vessel recoil and preventing acute occlusion 
[6].  
Stents were initially evaluated in a preclinical study relative to angioplasty alone,  
in canine coronaries to assess efficacy prior to human trials [5]. The extent of endothelial 
damage during angioplasty is proportional to the time of balloon inflation [5]. Since the balloon 
is immediately deflated after maximal inflation during stent implantation and 80% of the 
expandable wire mesh of the stent was open surface opposing elastic recoil, the process 
minimized endothelial damage compared to balloon angioplasty alone [5]. The first human 
clinical implantations indicated a high delivery success, low incidence of perioperative 
complications and a thrombosis incidence controllable with the use of anticoagulants [7, 8]. In 
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the absence of antiplatelet therapy, sub-acute thrombotic closure after stent implantation, was 
a notable risk [7]. 
Despite some benefits over angioplasty alone, stent deployment still results in significant injury 
to the vessel wall and disruption of the endothelium [9]. Disruption of endothelial monolayer 
integrity induces a cascade of pro-inflammatory events resulting in monocyte/neutrophil 
infiltration and smooth muscle cell proliferation; key contributing factors to neointimal 
hyperplasia. The rate of re-endothelialization following injury is a critical determinant of 
vascular lesion formation, and areas of injury that rapidly re-endothelialize have significantly 
less intimal thickening and restenosis [10], while also deterring thrombus formation [11]. In 
humans, bare metal stent struts are substantially endothelialized in 6–7 months, with significant 
coverage present after 2 months [12]. During reformation of the endothelium over stent struts, 
smooth muscle proliferation induced by injury contributes to neointimal formation and 
restenosis. The high rates of restenosis for bare metal stents are a significant drawback in their 
clinical application. 
Preliminary drug-coated stents were engineered with surface anticoagulants, such as heparin 
or warfarin to prevent sub-acute thrombosis and bleeding complications [13]. Despite attenuating 
thrombosis, restenosis was unchanged, requiring a pharmacological approach for its inhibition. 
Drug eluting stents (DES) releasing anti-proliferative agents such as sirolimus and paclitaxel 
inhibit neointimal hyperplasia but also substantially delay healing and re-endothelialization [12]. 
Consequently, DES are not only susceptible to early thrombosis like bare metal stents (BMS), 
but are also prone to both late (30 days–1 year) and very late (>1 year) stent thrombosis [14]. 
In stable single vessel disease patients, late stent thrombosis (LST) occurs at a constant rate 
(0.6% per year) [15], with even higher rates reported (0.9%–3%/year) in real world studies[16]. 
Accordingly, the safety of DES remains in question [17]. Hence the advent of DES has further 
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exacerbated the biocompatibility issues of coronary stent implantation. The unsatisfactory 
performance of both BMS and DES has led to continued investigation of novel stent 
modifications, focusing on improving stent biocompatibility. The innovations discussed 
include surface tissue engineering, endothelial regeneration mechanisms, nanotechnology, and 
plasma physics for biofunctionalization of coronary stents. 
 
1.2 Limitations of Bare Metal Stents (BMS) 
 
The metal alloys used to produce bare metal stents are fundamentally incompatible with the 
vasculature, promoting thrombosis due to their inherent surface properties [18], while exerting 
no inhibitory effect on smooth muscle cell hyperproliferation. The dominant mode of early 
BMS failure is acute thrombosis, which can be as high as 24% in the absence of the dual anti-
platelet therapy administered to stent recipients [8]. Stent thrombosis is defined as a composite 
30-day endpoint, which can present as an abrupt vessel closure, large non-fatal myocardial 
infarction or death [19]. Deaths attributed to cardiac causes within the first 30 days of stent 
implantation are usually adjudicated as stent thrombosis [20]. Neointimal hyperplasia, or 
restenosis, is a major cause of bare metal stent failure after the early thrombosis risk has abated. 
In-stent restenosis is driven by an uncontrolled immune response, triggered by the disruption 
of the native endothelium and damage to the vessel wall. The  
re-modelling of the vessel post-injury is characterized by hyper-proliferative smooth muscle 
cells infiltrating into the vessel lumen and secreting extracellular matrix components [21].  
BMS are made from surgical grade metal alloys, initially 316 L stainless steel (316 L SS), but 
more recently evolving to cobalt chromium and platinum alloys [22]. Stent strut thickness and 
alloy type play an integral role in the biological responses elicited. Changes to the metal alloy 
have facilitated thinner strut design while retaining sufficient radial strength, and led to the re-
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design of stent structures for increased deliverability. The first Palmaz-Schatz crown stent 
designed for flexibility has evolved significantly to the malleable S-shaped velocity-stent, 
currently in development [23]. Stent design has further developed to include the Multilink stents 
with still thinner struts, Microstents and GFX stents [24] made of sinusoidal element of stainless 
steel. Sub-acute thrombosis rates post stent implantation, have greatly reduced over the course 
of stent evolution, although the rate of in-stent restenosis remained high [4]. 
1.3 Drug Eluting Stents (DES): An Imperfect Solution 
 
Systemic drug administration post BMS implantation to reduce restenosis was ultimately 
unsuccessful due to low drug concentrations, non-specifically targeting the neointima [25]. 
DES locally releasing anti-proliferative agents were introduced in 2003 to reduce restenosis 
associated with stent implantation [26]. While DES have been highly effective in suppression 
of neointimal hyperplasia (up to 10-fold compared to BMS [27]) local vascular delivery of 
rampamycin analogues or paclitaxel is an untargeted approach, employing non-specific agents 
to inhibit all cell proliferation [28]. These drugs bind FK506 binding protein-12 (FKB12) 
which in turn blocks the cell-cycle specific kinase, mammalian target of rapamycin (mTOR), 
to halt mitotic progression in the juncture of G1 and S phases in all cell types [29]. This in turn 
deregulates tissue factor in endothelial cells and monocytes [30, 31]. The elution of anti-
proliferative agents is associated with a dramatic delay in healing and re-endothelialization at 
the stent deployment site; such that DES struts have less than 50% endothelial coverage at three 
years [12].  
DES development has focused on the major failings of current devices and has included 
modifications to the metal alloys, coating polymers and eluted drugs [32]. For example, Abbott 
Vascular have developed a 2nd generation everolimus-eluting XIENCE V stent, using a 
different stent alloy (cobalt chromium), polymer coating (fluoropolymer) and anti-restenotic 
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drug to its 1st generation counterparts. This resulted in enhanced endothelialization in vitro and 
in vivo compared to 1st generation DES [33]. In randomised clinical trials, the XIENCE V stent 
also exhibited improved safety outcomes compared to two iterations of first generation 
paclitaxel-eluting stents [16, 34]. Other approaches for second generation DES include the use 
of biodegradable polymers and selective coating of the anti-restenosis drugs solely on the 
abluminal surface of the stent [35]. Despite these innovations, significant rates of major adverse 
cardiac events persist, particularly in real world usage of DES incorporating a high proportion 
of patients with acute coronary syndromes [35]. 
The most recent innovations in DES development are combinations of existing technology; 
employing drug-elution from a resorbable stent platform [36], from an ultra-thin degradable 
polymer coating [37] or combined with endothelial cell capture [38]. These approaches are 
included in more detail, below.  
1.4 Underlying Causes of Stent Incompatibility 
 
The compatibility of bare metal stents is due both to the stent material and design, DES 
effectiveness is also affected by polymers used for coating, and the anti-proliferative drugs 
released. Design considerations such as strut thickness, stent design and mechanical properties 
have been steadily optimized, while polymer coatings and drug effects remain problematic, 
increasing inflammation [39], delaying re-endothelialization [12] and impairing endothelial 
cell function [40]. 
1.4.1 Inherent Thrombogenicity 
Stents are inherently foreign bodies in the vessel wall, inducing platelet adhesion and activating 
coagulation, leading to thrombosis. Inhibition of platelet activation is required following stent 
delivery. The currently low rates of early stent thrombosis (1%–2%) are predicated on tolerance 
and adherence to dual antiplatelet therapy with aspirin and a thienopyridine [41]. This is not 
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feasible for an increasing number of patients with high bleeding risk, or those requiring surgery 
[42]and is associated with increased risk of significant morbidity including gastrointestinal 
bleeding [43]. There is also risk of antiplatelet hypo-responsiveness, which increases stent 
thrombosis [44]. In the case of DES, management of LST is additionally problematic. To 
reduce the incidence of late thrombotic events, extended dual anti-platelet therapy is now 
recommended following DES placement, though no consensus on the effectiveness of an 
extended regimen has been reached [45, 46].  
In a recent large cohort study, new generation DES (n-DES) provided a modest improvement 
in clinical outcomes compared to old generation DES (o-DES) [47]. Old DES classified in the 
study, were first generation DES with bare metal platforms and sirolimus or paclitaxel drug 
elution [47]. New DES classified in the study diversely included; stents eluting non-
inflammatory drug zotarolimus coupled with a biocompatible polymer system (bioLinx™) [48] 
designed to extend the duration of drug exposure in the vessel (Endeavor Resolute), multi-layer 
coating technology (Xience V) [49] and self-expanding stents designed for compression 
resistance (Promus Element) [50]. The study compared long-term outcomes of PCI with n-
DES vs. o-DES and BMS to show comparatively lowered risk of restenosis, LST and mortality 
for n-DES, although no significant effect was observed for thrombosis [47]. The duration of 
recommended dual antiplatelet therapy to prevent thrombosis remains unchanged for both old 
and new generation DES in patients.  
1.4.2 Delayed Re-Endothelialization 
Following vascular injury, endothelial cells migrate from intact neighbouring coronary 
segments, or are recruited from circulating endothelial progenitor cells (EPC) [51] to re-
endothelialize the injured artery. However, both rapamycin and paclitaxel actively suppress 
endothelial cell growth in vitro [31, 52, 53] and impede EPC homing and proliferation in vitro 
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[54, 55], actively impeding re-endothelialization. A morphological autopsy study conducted to 
compare coronary artery segments from patients after DES and BMS implantation revealed 
delayed arterial healing and poorer endothelialization after DES compared to BMS 
implantation of similar duration [12]. Within the 1st generation DES cohort, 60% of patients 
had evidence of LST and a 45% rate of death was reported for patients suffering from LST [12, 
56]. Re-endothelialization was significantly higher in BMS compared to DES [40]. The 
impacts of 1st generation DES on vascular biology are schematically represented  
in figure 1.1. 
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 Figure 1.1 
 
 
Coronary stent types, and their mechanism of action. First generation drug eluting stents (DES) 
impact on vascular biology: Modified from [40], reduced neointimal formation (green arrows) but 
increased thrombogenicity at stent bio-interface. Sirolimus/paclitaxel inhibition of 
endothelialization, tissue factor induction and endothelial progenitor cells (EPC) homing 
prevention (red arrows). 
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1.4.3 Metal and Polymer Coating Hypersensitivity 
Hypersensitivity to metal alloys such as molybdenum and nickel has been previously observed 
in ~10% patients undergoing BMS implantation [57], although inflammatory response for 
stainless steel, is much less pronounced in comparison [58]. Hypersensitivity towards BMS 
alloys is associated with restenosis in the range of 15%–20% [40], with the extent of 
inflammation correlating to the degree of restenosis [59]. Marked hypersensitivity reactions 
have also been observed to the polymers coating DES. First generation DES coated with poly-
ethylene vinyl acetate polymer are demonstrably pro-inflammatory [60]. This was further 
verified in a preclinical study when the copolymer, used as an antigen delivery matrix elicited 
an inflammatory response in ~25% of rabbits [61]. The inflammatory response in patients with 
spontaneous coronary dissection, post DES implantation was characterized primarily with 
eosinophilic infiltrations in the adventitia [59]. In severe cases DES related clinical 
complications exhibit necrotic core prolapse, in-stent restenosis and LST, preventing arterial 
healing [62]. A preclinical study in a porcine model showed progressive increases in the 
eosinophilic, granulomatous infiltrate, post first generation sirolimus (Cypher) stent 
implantation, starting at 28 days, increasing to 60% at 6 months [40]. 
1.4.4 Poor Coating Integrity 
Another important, often overlooked aspect of stent safety is the coating integrity after 
crimping and expansion. Relatively few studies have evaluated the possibility of coating 
delamination [63, 64], despite it being widespread in commercially available DES and 
recognized as a safety concern by the Food and Drug Administration [65]. DES polymer 
coatings display widespread surface cracking, peeling and flaking at the polymer-metal 
interface [66-68]; exposing the underlying thrombogenic metallic substrate and contributing to 
chronic inflammatory and hypersensitivity reactions [39, 69]. Together, these failings highlight 
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the difficulty in simultaneously promoting re-endothelialization, while inhabiting neointimal 
hyperplasia and thrombosis. No current stent platform adequately achieves this goal, but some 
strategies are reviewed below and an updated summary is presented in chapter 6. 
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1.5 Novel Stent Modifications 
 
Coatings aimed at increasing the inertness of metallic implants have been effective at reducing 
thrombogenicity but have generally failed to reduce restenosis rates. Examples of these 
coatings include gold [70]; diamond-like carbon [71, 72]; pyrolytic carbon [72] and 
phosphorylcholine (PC). PC; exemplifying the flaws of an inertness approach was observed to 
be non-thrombogenic in vitro [73]. However; in vivo; it failed to encourage endothelialization 
and ultimately had no effect on the rate of stent thrombosis [74]. In parallel; enhancement of 
stent biocompatibility has been pursued by actively influencing the host response. These 
coatings have failed because they only seek to address one aspect of vascular biocompatibility 
(e.g., thrombogenicity alone) at the expense of other aspects. Heparin-coated stents are one such 
example; designed to reduce thrombosis but not neointimal hyperplasia [75]. Below, we describe 
some of the most recent attempts to develop biocompatible stents. 
 
1.5.1 Accelerating Endothelialization 
Given that re-endothelialization plays an integral role in vascular healing after stent 
implantation, coating stent with substances to accelerate endothelial cell coverage is an 
important therapeutic approach [40]. Preliminary studies designed to capture endothelial 
progenitor cells (EPCs) by coating stents with a polysaccharide intermediate and murine 
monoclonal anti-human CD34-positive antibodies showed feasibility in human clinical trials 
[76]. The Genous Bio-engineered R stent, similarly coated with immobilized anti-CD34 
antibodies aims to enhance endothelialization by capturing circulating endothelial progenitor 
cells (figure 1.2). The captured CD34-positive EPCs are proposed to differentiate into a mature 
endothelium, but the CD34-positive markers used are non-specifically shared by 
haematopoietic stem cells and immune complement cells. Circulating CD34-positive 
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mononuclear cells are also shown to differentiate into smooth muscle progenitor cells in 
patients with restenosis [77]. A higher rate of revascularization was observed in Genous stent 
compared to Taxus stent, in patients treated for coronary artery stenosis with a high risk of 
restenosis [78]. A recent proof-of-concept study shows some benefits for endothelialization 
and thrombogenicity, but leaves reduction of neointimal hyperplasia unaddressed and the 
platform reliant on drug-eluting technology [79]. A novel DES coated with integrin-binding 
cyclic Arg-Gly-Asp peptides was similarly utilized in a preclinical study to accelerate 
endothelialization via EPC attraction, using the same principles of EPC capture. In an initial 
porcine model evaluation, neointimal hyperplasia seems to be promisingly reduced [80, 81]. 
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Figure 1.2 
 
EPC capture stent mechanism of action: Modified from [82]. The CD-34 antibody immobilized 
on the stent surface polymer binds the CD-34 antigen on the EPC to promote rapid 
endothelialization. 
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1.5.2 Bioresorbable Stents 
Bioresorbable stents are proposed to solve the problem of long-term stent biocompatibility by 
degrading over time [81]. The first bioabsorbable, balloon expandable stents implanted in 
humans were constructed from poly-L-lactic acid (PLLA) [83]. The bonds between the 
repeating lactide units of the bioabsorbable stent hydrolyze to produce lactic acid, metabolized 
to CO2 and H2O [81]. Absorption occurs via bulk erosion throughout the implant not just on 
the surface, allowing the stent strut to retain its shape, until the process is well advanced [83]. 
The Abbott Vascular bioresorbable vascular scaffold (BVS), a PLLA stent, has so far 
demonstrated restenosis similar to bare metal platforms, as well as late scaffold shrinkage and 
non-uniform vessel support, due to uneven scaffold degradation [84]. Alloys of magnesium 
have also been explored as bioabsorbable stent platforms [85]. Absorption by surface erosion 
reduces the strut thickness as the stent is absorbed within 4 months of implantation, leading to 
loss of radial support [85]. 
The latest generation bioabsorbable stents are designed for prolonged radial support coupled 
with drug elution [85]. A number of different materials have been utilized to manufacture these 
stents ranging from metal alloys to a variety of polymers, including tyrosine-derived 
polycarbonate polymer, salicylate and a linker, as well as metal-cobalt chromium with n-butyl 
methacrylate coating [86, 87]. The BioMatrix stent incorporates the thin S-stent platform with 
a reduced percentage metal surface area (16.3%–18.4%) to elute anti-proliferative drug biolimus 
A9 [37]; a highly lipophilic semi-synthetic analogue of sirolimus. Furthermore, the stent is 
completely bioabsorbable degrading in vivo to lactic acid in 6-9 months post implantation [36]. 
The JACTAX stent (Boston Scientific Corporation, Natick, MA, USA) was designed on similar 
principles, coated with an ultra-thin, mixture of biodegradable PLLA and paclitaxel drug 
applied as microdots, per 16-mm stent [88].  
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The stents were comparable to preceding paclitaxel eluting stent (TAXUS Liberté, Boston 
Scientific Corporation, Natick, MA, USA), although further studies are underway to evaluate 
their potential for improved vessel healing. As yet, none have FDA approval for humans use, 
but some clinical trials are underway [89, 90]. Current bioresorbable stents have markedly 
inferior mechanical properties in terms of device profile, flexibility, deliverability, and defined 
duration of  vascular support to prevent recoil or radial strength, thereby dramatically limiting 
their capacity to be used for a large number of coronary lesion subsets, including bifurcation 
lesions, calcified lesions, tortuous coronaries and long lesions [90]. As a consequence of these 
profound limitations, metal alloy stents will remain the mainstay for endovascular stents in the 
foreseeable future. 
1.5.3 Nanotechnology for Controlled Release of Drugs and Novel Stent 
Design. 
Novel mechanisms of drug release include polymeric nanoparticles (NPs) to encapsulate 
pharmaceutical agents for targeted drug delivery to a tissue of interest [91-93]. For instance, d-α-
tocopheryl polyethylene glycol 1000 succinate (TPGS) is used as an emulsifier in the 
formulation of the biomaterial matrix poly(DL-lactide-co-glycolide) (PLGA). The biodegradable 
PLGA/TPGS NPs deliver controlled paclitaxel release with high drug encapsulation efficiency 
(EE), for the treatment of restenosis. The higher drug EE improves cellular uptake and 
cytotoxicity against SMC proliferation, and is being considered in the development of third 
generation, nanoparticle coated DES [94]. The Nevo-sirolimus eluting stent is designed from 
L605 cobalt-chromium alloy with a drug delivery system based on PLGA. It utilizes a multi-
channel reservoir system along the stent struts into which the drug-polymer (sirolimus/PLGA) 
matrix is loaded for elution [95] displaying superiority over traditional paclitaxel eluting stents 
(TAXUS Liberté) in clinical trials [96]. 
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In patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing PCI, 
sub-optimal myocardial reperfusion is common. Stents have therefore been specifically 
designed to prevent thrombus protrusion into the lumen after PCI, in acute myocardial 
infarction. The potential utility of a novel polyethylene terephthalate (PET) micronet mesh-
covered thin-strut metal stent (MGaurd), was evaluated in this regard for its functional design 
to trap and exclude thrombus and atheromatous debris to prevent distal embolization [97]. The 
stent showed superior rates of epicardial coronary flow and complete ST-segment resolution, 
compared to conventional metal stents. Larger clinical studies are required to determine 
consistency of improved clinical outcomes. 
1.5.4 Plasma polymerization 
Applications of plasma modified materials are emerging in the fields of medicine, for drug 
delivery and tissue engineered biocompatibility of medical devices [98] .  Plasma, the fourth state 
of matter is artificially generated when a dielectric gas ionized by free electrons is accelerated in 
a sufficiently strong electric field. The gas molecules separate on ion-impact, to create electrons 
and neutral gas atoms within a vacuum evacuated chamber. Subsequent collisions among these 
particles create more ions and electrons to interact with and modify the surfaces, including 
potential biomaterials [99, 100], modifying their surface energy, charge and surface chemistry, 
without altering bulk properties [101]. When argon and an increasing amount of acetylene are 
used in a plasma deposition system, a plasma activated coating (PAC) was created on a metallic 
biomaterial surface (figure 1.3) suitable for stent applications, utilized in this study. The thin 
carbon polymer layer on the biomaterial acts as a reservoir of free radicals, activating the 
surface for effective, covalent protein attachment (figure 1.4) [102, 103]. 
Pulse biased plasma polymerization has been adapted to metallic substrates, for one step  
covalent biomolecule immobilization, minimizing the otherwise complex process of chemical 
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linker based biofunctionalization discussed elsewhere [104]. The relationship between protein 
binding and biomolecule activity on PAC strongly adhered to stainless steel, has been 
demonstrated by direct covalent attachment of tropoelastin (TE), horseradish peroxidase (HRP) 
and catalase [104]. Surface characterization further elucidated the importance of surface free 
energy for effective biomolecule attachment [105]. Recent evidence suggests that PAC on a 316 
L SS stent covalently binds a dense layer of human recombinant tropoelastin, facilitating the 
growth of endothelial cells [105]. Plasma modified surfaces coated with tropoelastin have shown 
improved blood biocompatibility, significantly reduced clot formation and improved 
endothelialization in vitro [105]. Pre-clinical studies of PAC stents demonstrate feasibility and 
deliverability with great potential as a carrier for local biomolecule delivery [106]. 
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Figure 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma surface modification for coronary stents: from [101, 107]. Nitrogen, argon and 
acetylene plasma is introduced into a chamber under a vacuum and ionized by a power 
source such as an RF electrode. The charged ions in the chamber impact the substrate to 
modify the surface immersed in the plasma. 
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Figure 1.4 
 
 
 
 
 
 
 
 
 
 
Illustration of predicted free radical surface functionalization (orange circles/precursors) of a 
modified biomaterial. The figure illustrates covalent, linker-free protein attachment (green) 
on PAC surface.    
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1.6 Conclusions and Future Perspectives 
 
The development of coronary stents is an evolving process and a fundamental aspect of 
interventional therapy in the treatment of coronary artery disease (CAD). Stent biocompatibility 
is a multi-faceted process; having to be simultaneously hemocompatible, promote rapid re-
endothelialization and suppress restenosis. BMS have evolved considerably since their first 
human use, but remains both thrombogenic and susceptible to restenosis. DES elute powerful 
cytotoxic drugs to inhibit SMC hyper-proliferation, but delay healing and induce inflammation, 
resulting in an increased risk of late thrombosis.  
We have highlighted the latest strategies (updated in chapter 6) that appear to be most 
promising, including active promotion of re-endothelialization, bioresorbable stents, 
nanotechnology and plasma based modification. In light of the limitations still evident for each 
of these approaches, further development is required, with biofunctionalized combination 
devices and local biomolecule delivery (e.g., bioresorbable-drug-eluting stents and/or 
biocompatible stents underlying DES polymer), as the most likely to have success. Overall, 
many stent design innovations currently in development, promise to address the underlying 
lack of biointegration more directly, on the path to a truly biocompatible stent.  
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Chapter 2 – In vivo biocompatibility and efficacy of a 
plasma activated coronary stent coated with recombinant 
human tropoelastin.  
 
2.1 Introduction 
 
2.1.1 Translational animal models in cardiovascular disease studies 
Cardiovascular disease and related conditions are at present the primary cause of death 
worldwide [108]. Animal models are used in an attempt to increase knowledge, provide new 
approaches for diagnostic, and treatment of pathologies [109]. Different methods have been 
associated to address cardiovascular disease, although no exclusive method perfectly recreates 
a human complication, depending on various associated factors. However, animal studies are 
essential for cardiovascular device evaluation, prior to evaluating their performance and safety 
in humans.  
Clinically, failure of cardiovascular devices in vivo, are observed as thrombosis and restenosis 
[110].  Animal models used to evaluate cardiovascular devices should therefore include 
endpoints of endothelialization, thrombosis and restenosis. The next consideration is vessel 
location as this contributes to the endpoint measured. Additionally, the time course of 
experiment is critical to the specific endpoint [109]. The model can only predict the response 
in humans, based on specific endpoints chosen. Each device, and its specifications have 
multiple animal models, for preclinical evaluation in vivo [111].  
Rabbit and porcine animal models are most commonly established to evaluate stents [112]. The 
classical porcine method is the preferred model to measure restenosis, although rabbit iliac 
artery stenting has become an accepted alternative [113]. When late stent thrombosis arose as 
an unforeseen clinical complication with first generation DES, data from animal studies were 
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used to help explain the phenomenon [113]. Delayed and incomplete vascular healing was 
detected as a toxicity/hypersensitivity reaction to polymer/drug matrix. Preliminary 
translational studies led to continued development of biocompatible drug carriers, absorbable 
polymers or fully bioeresorbable scaffolds to assist the re-endothelialization; healing process.  
Initial investigations of novel stent coating technologies in a translational model are therefore 
recommended, to assess preclinical safety of any new stenting technology developed. 
2.1.2 Rabbit iliac artery model 
Rabbits are useful in evaluating stent performance, since they have vessels with dimensions 
similar to human coronary arteries, allowing direct evaluation of human stents [111]. Arteries 
are denuded prior to implantation, to injure and stimulate a healing response, similar to the 
response after stenting a human vessel [114]. The model allows testing for endothelialization, 
early neointimal hyperplasia, and at longer time points restenosis. High blood flow through the 
arteries is maintained through administration of aspirin, to reduce acute thrombosis of the stents 
[33]. There are similarities drawn between the vascular healing responses following 
angioplasty for animal vessels, as seen in human studies [114].  
The rabbit iliac artery model allows stent implantation into the common iliac arteries of rabbits, 
after injury was induced via endothelial denudation. The process entails removal of the luminal 
endothelial cell layer with an inflated balloon catheter, inserted into the artery, inflated and 
pulled back. The process intentionally damages the endothelial cells causing fragmentation and 
detachment of cells from the vessel lumen. The process is repeated twice for resulting denuded 
artery lacking an endothelium, with subendothelial matrix exposed to blood, as with injury 
occurring during PCI in human arteries with atherosclerotic plaques (figure 2.1).  As seen on 
figure 2.1, following removal of endothelium, thrombosis at vascular sites leads to smooth 
muscle cell (SMC) migration, SMC proliferation and neointimal hyperplasia (NIH); i.e. 
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proliferation of cells in the inner most lining of the artery[115]. Ultimately this would lead to 
restenosis.  
The bilateral iliac artery stenting model allows investigations in the left and right iliac arteries, 
allowing direct, controlled comparisons of different stent interaction with the vasculature. 
Previous studies have successfully utilized the translational animal model to test different stent 
materials [116], designs [117], drugs and DES [33], prior to clinical applications and 
commercial development.  
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Figure 2.1 
 
Implant induced removal of endothelium (endothelial denudation) to cause injury to 
vasculature. Followed by sequence of thrombotic, inflammatory events that contribute to 
vascular smooth muscle cell (VSMC) proliferation, neointimal hyperplasia, and restenosis in 
the long term. Image from [115].   
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2.1.3 Endothelialization  
Incomplete endothelialization of strut surface drives late stent thrombosis (LST), an infrequent, 
life threatening complication, seen with FDA approved drug-eluting stents [118]. Mechanisms 
of late stent thrombosis are not well known. However endothelial cell growth is essential to 
maintain long-term luminal patency, since ECs provide structural and antithrombotic functions 
[33].  To assess for LST, large randomized clinical trials, statistically powered for LST 
endpoints, or indirect methods of endothelial dysfunction assessed via nitric oxide 
bioavailability assays in humans, can be conducted [119, 120].  However, preclinical studies 
allow for more effective initial safety and feasibility testing of a medical device. Arterial repair 
after stent placement in animals occur more rapidly than in humans, although they retain 
predictive value due to the sequence of biological responses elicited after stenting that show 
remarkable similarity to humans [114]. Interpretation of results pertaining to translational 
studies is highly contingent on the timeline after stent placement. Examination of DES implants 
in rabbit/swine models is often done at 28 days, although earlier time point may reveal more 
on the healing characteristics pertaining to a novel device modification [33]. A timeline of 28 
days in a translational model is equivalent to 12-month coronary stent implants in humans 
[121].  
Disparities in arterial healing among species are equally notable for rates of re-
endothelialization after vascular injury [33]. Differences in shear stress, underlying 
atherosclerosis and use of juvenile animals may play a role in this regard. For instance, 
preclinical studies report complete endothelialization of DES at 28 and 90 days in the porcine 
model [122], but failed to predict complication of LST in humans after BMS implantation 
[123]. Relative to porcine studies, rabbits have slower endothelial regrowth, and are therefore 
a more desirable model to assess re-endothelialization of DES [121].  Aside from poor 
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endothelialization, several factors contribute to LST of DES, including malposition, 
overlapping stent placement, excessive stent length and bifurcation arterial lesions [121]. 
Commercially available comparator stents have little known rates of endothelialization and 
recovery, despite clinical applications worldwide [33].   
2.1.4 Restenosis and thrombosis  
Restenosis is the process in which a stented vessel becomes blocked again, usually 6 months 
after percutaneous coronary artery intervention (PTCA). This occurs as a result of neointimal 
thickening caused by smooth muscle cell hyperproliferation, extracellular matrix deposition 
and inflammation, known as neointimal hyperplasia (NIH), which also contributes to in-stent 
restenosis (ISR) [124]. Based on the length of restenosis in relation to stented length, ISR is 
defined as 1) focal, 2) diffuse 3) proliferative or 4) occlusive [125].  Thrombosis occurs as a 
result of the stent geometry, material, and coating, activating platelets and initiating coagulation 
[126, 127]. Based on severity, stent thrombosis (ST) is defined as 1) acute ST (thrombosis 
occurring 0-24 hours after PTCA) 2) subacute ST (1-30 days), 3) late ST (30 days to 1 year) 
and 4) very late stent thrombosis (VLST), >1year after stent implantation. Restoration of an 
intact endothelium by progressive endothelialization after implantation is integral to the stent 
biointegration process, and reduction of thrombosis and restenosis [128]. Clinically, bare metal 
stents (BMS) are limited by susceptibility to high rates of restenosis and drug-eluting stents 
(DES) are susceptible to high rates of very late-stent thrombosis as well as thrombus related 
in-stent restenosis [18, 129, 130].  
Although the primary aim of DES is to inhibit restenosis via attenuation of vascular smooth 
muscle cell migration and proliferation [131], common complications include inhibition of 
endothelial cell proliferation by DES drugs, signal transduction pathway activation, and 
impairment of the healing process up to 3 years after implantation compared to BMS [132]. 
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Generally, four key factors contribute to increased risk of stent thrombosis and restenosis, these 
include; device malposition [133], patient and lesion related factors [134], time course of dual 
antiplatelet therapy (DAPT) administration [135], and poor biocompatibility of stent material 
or polymer used for BMS and drug-loading in DES, in vivo [40]. Whilst interventional 
procedure-related risk factors can be minimized in conjunction with advanced imaging systems 
[133], and DAPT timeline-related risks minimized via clinical decisions individualized to each 
patient [135], the in-stent thrombosis and restenosis risk owing to incompatibility of stent 
material or DES polymer, largely remains to be addressed [105, 107].  
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2.1.4.1 Assisted endothelialization 
Efforts to improve surface biocompatibility of stents, for vascular compatibility focus on 
reducing early markers of ISR, and late-stent thrombosis (LST) [105]. We have previously 
demonstrated a strategy to modulate desired physiological responses at the implant-tissue 
interface by covalent linker-free immobilization of proteins. The plasma activated coating 
(PAC) with covalently bound human tropoelastin (TE) (a major regulator of vascular cells in 
vivo), has been applied to 316L stainless steel flat surfaces, demonstrating enhanced 
hemocompatibility and endothelialization in vitro [136-138]. Studies have also shown the 
ability of tropoelastin to stimulate increased endothelial cell migration and adhesion compared 
to smooth muscle cells (SMC) [139]. Given the unique ability of TE to modulate cellular 
response, coating intravascular stents with tropoelastin may stimulate in vivo 
endothelialization, reduce neointimal hyperplasia (NIH) to attenuate vascular remodelling, and 
improve device performance. We had previously applied PAC to 316L SS BMS, demonstrating 
its feasibility as a stent coating technology for 7 days in vivo [106]. 
2.1.5 Histopathology – Resin histology methods for stented arteries 
Comparative preclinical histological studies remain the most effective means of evaluating 
healing of vascular stent implants, after explanting them post euthanasia [33]. However, 
technical challenges precede histopathological evaluation at the stent-artery interface; 
including preservation of cellular morphology and arterial architecture [140]. For adequate 
histopathological staining, sections require a thickness of ~5-7 µm, with an intact tissue stent 
interface. Methacrylate resin methodologies offer adequate preservation of tissue-material 
although subsequent sectioning/processing methods remain largely obscure [141]. Previous 
studies have investigated technical challenges in resin histology, with different sectioning and 
visualizing methodologies [140, 141].  Conventional paraffin embedding and sectioning 
procedures demonstrated limitations in their application to the histological study of 
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endovascular stent implants [141]. Most embedding procedures that evaluate stent-artery 
interface require complete removal of the metal stent prior to tissue processing, which damages 
vascular architecture. At present therefore standard stent embedding procedures employ 
methacrylate resin media for stented arteries [141, 142].  Currently glycol methacrylate, methyl 
methacrylate (MMA), and a combination of MMA and n-butyl methacrylate (BMA) are widely 
used resins to process stented-tissue, or bone material [141]. Exact formulations of embedding 
procedure that serves preservation, sectioning, staining of stented-arteries differ among studies, 
and procedures are not definite.  
A number of technical requirements precede stent-artery evaluation in vitro. The embedding 
media should allow histological staining, immunohistology and immunofluorescence, with or 
without deplasticization (resin removal). The sections should be within a specific thickness 
range, to uptake stain and evaluate cellular reactions immediately surrounding stents [140]. 
The tissue immunoreactivity and histopathology should be similar to that of paraffin embedded 
sections.   
The aim of this study was to assess re-endothelialization with a focus on surface coverage, and 
relevant histological/immunohistochemical markers of thrombosis, and coagulation. We 
translated PAC+TE to a stent platform to perform a pilot endothelialization study by 
implantation of stents in denuded rabbit common iliac arteries; a well-established model of 
endothelialization. The study is a follow-up to our previous investigation with PAC vs. BMS 
[106]. Feasibility of PAC+TE implantation, coating integrity, rate of endothelialization, early 
markers of neointimal hyperplasia (NIH), thrombosis and inflammation will be investigated. 
Furthermore, embedding procedures, resin-artery sectioning procedures and arterial 
preparation for histological, immunohistochemical and microscopy will be described and 
optimized. 
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2.2 Materials and Methods 
 
2.2.1 Materials, Equipment, Suppliers and Facilities 
A list of chemicals, reagents, materials and their suppliers are presented in Table 2.1 
Table 2.1 Materials and their suppliers 
 
Chemical/Reagent/Material Supplier/Facility 
0.014” Route PTCA guide wire ASAHI INTECC, Aichi, Japan 
3.25 mm RX Sprinter Legend balloon 
dilation catheter 
Medtronic, Minneapolis, Minnesota, U.S.A 
5F Radiofocus Introducer (sheath)  Terumo, Tokyo, Japan 
Acetylpromazine Lyppards, NSW, Australia 
Albumin powder (egg white protein) Chemist Warehouse, Newtown, NSW, 
Australia 
Anti-Rabbit IgG CD31 raised in mouse Abcam, Cambridge, MA, USA 
Aniline Blue  Electron Microscopy Sciences, ProSciTech, 
QLD, Australia 
Aspirin (Aspro) Bayer, Pymble, NSW, Australia 
Buprenorphine Royal Prince Alfred Hospital, Sydney, 
NSW, Australia 
CD31/PECAM1 antibody JC/70A Novus Biologicals, Littleton, CO, USA 
DPX Mountant for Microscopy-10 BDH Chemicals, Kilsyth, VIC, Australia 
Electropolished customized 316LSS stent Laserage, Waukegan, Illinois, USA 
EnVisionTM G|2 System/AP, Rabbit/Mouse 
(permanent red)  
Dako Australia, North Sydeny, NSW, 
Australia 
EnVisionTM K4011 HRP, Rabbit (DAB+) Dako Australia, North Sydeny, NSW, 
Australia 
Eosin (alcoholic) Fronine, Taren Point, NSW, Australia 
Mayer Hematoxylin Fronine, Taren Point, NSW, Australia 
Ferric Ammonium Sulfate 5% Electron Microscopy Sciences, ProSciTech, 
QLD, Australia 
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Gelatin Powder Chemist Warehouse, Newtown, NSW, 
Australia 
Goat serum Sigma-Aldrich, St. Louis, MO, USA 
Hoechst trihydrochloride, trihydrate, 
FluroPureTM grade (MW 615.99)  
Sigma-Aldrich, St. Louis, MO, USA 
Image-Pro Premier 9.1 analysis software Media Cybernetics, Rockville, MD, USA 
Iodine Livingston International, Roseberry, NSW, 
Australia 
Isofluorane Lyppards, NSW, Australia 
Lethabarb Lyppards, NSW, Australia 
MAC387 Abcam, Cambridge, MA, USA 
Methyl methacrylate Sigma-Aldrich, St. Louis, MO, USA 
Microm  HM355S (rotary microtome) Thermo Fisher Scientific, Walldorf, 
Germany 
Monoclonal anti-actin α-smooth muscle 
antibody produced in mouse  
Sigma-Aldrich, St. Louis, MO, USA 
New Zealand White Rabbits IMVS, Adelaide, SA, Australia 
Normal goat serum (NGS) Sigma-Aldrich, St. Louis, MO, USA 
Omnipaque 240 mg I/mL (contrast)  GE Healthcare, Rydalmere, NSW, Australia 
Papaverine Sigma-Aldrich, St. Louis, MO, USA 
Paraformaldehyde Sigma-Aldrich, St. Louis, MO, USA 
Picric Acid-Orange G Solution Electron Microscopy Sciences, ProSciTech, 
QLD, Australia 
Ponceau Fuchsin Solution Electron Microscopy Sciences, ProSciTech, 
QLD, Australia 
Proteinase K stock  Sigma-Aldrich, St. Louis, MO, USA 
Sodium Azide (NaN3) 99.99% Sigma-Aldrich, St. Louis, MO, USA 
Sterile saline Pfizer, Perth, WA, Australia 
SuperFrost®Plus Menzel-Glaser; ProSciTech, QLD, 
Australia 
Taxus Liberte Stent Boston Scientific, Natick, MA, USA 
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA 
Tungsten carbide knife, profile D (16 cm) Leica Biosystems, Nussloch, Germany  
32 
 
Xylene LabTech Services & Supplies, Windsor, 
NSW, Australia 
2.2.2 Stent design 
The stent design was based on the dimensions of commercially available stents. The stents 
were laser cut from slotted tubes of 316L vacuum melted stainless steel and electropolished 
to remove surface contaminants (Laserage, Waukegan, Illinois, USA). 
2.2.3 Production of tropoelastin, stent design and synthesis of plasma 
activated coating  
Recombinant TE was expressed and purified from Escherichia coli as described previously 
[143, 144]. Plasma-activated coating (PAC) was made by graded deposition, from 100% 
stainless steel to 100% PAC, using reactive magnetron sputtering with sample rotation 
(sputtering voltage of 800 V, cathode current of 3 A) [106, 145], followed by pure stainless 
steel deposition and increasing fractions of the plasma polymer in the presence of acetylene 
(10 sccm), argon (4 sccm) and nitrogen (4 sccm) plasma until a pure plasma polymer layer was 
formed [106, 145]. Two plasma sources were included in the pulsed plasma deposition system 
1) radio frequency (RF) electrode at 13.56 Mhz and 2) pulsed direct current voltage source. An 
ENI-6B RF generator was used to power the RF plasma through an ENI Matchwork matching 
network. The pulsed DC voltage was generated using a RUP-3 pulse generator from GVS-
Elektonik (Dresden, Germany). The grounded plasma chamber acted as an anode electrode.  
The plasma energy and magnetron settings sputtering were altered to ensure PAC deposition 
on all surfaces of the stent to obtain homogenous coverage of the 3D stent sample. The stent 
PAC deposition had column like structures to prevent delamination.  
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2.2.4 125I-Radiolabelling tropoelastin 
Sterile filtered TE (2 mg/mL) in PBS was labelled with 125I using iodination beads (Pierce) as 
previously described [146]. Briefly, iodobeads with Na125I were used to label tropoelastin 
according to the manufacturer’s instructions. The labelled solution was desalted, to remove 
unreacted 125I-. A scintillation counter (Cobra II Auto Gamma, Packard Bioscience) was used 
to quantify radioactivity of the protein, before and after desalting. (The experiments were done 
by Dr. Anna Waterhouse – A.W). 
2.2.5 Surface coating with 125I- Radiolabeled tropoelastin to detect covalent 
binding 
The PAC+TE stents and BMS were incubated overnight at 4oC, with 50 µg/mL 125I-labeled 
TE. Samples were washed with sodium dodecyl sulfate (SDS), then blocked with 3% BSA. 
The radioactivity of the samples were measured before and after SDS, using a scintillation 
counter (Cobra II Auto-Gamma, Packard BioScience) to quantify level of covalently bound 
protein (Dr. A.W.) 
2.2.6 Rabbit endothelialization model 
Study approval was obtained from Sydney South West Area Health Animal Ethics Committee 
(protocol number 2008/036) and the University of Sydney Animal Ethics Committee (protocol 
number K00/12-2009/3/5243). Experiments were conducted in accordance with the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purpose. 
2.2.6.1 Animal housing  
The stent implantation procedure was performed as described previously [106]. Adult New 
Zealand White Rabbits were housed in cages (1x1 m wide and 1.6 m high) with bedding straw 
and environmental enrichment. The room was temperature controlled with a 12 h light-dark 
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cycle. The animals were fed standard rabbit chow ad libitum with free access to sterilized 
drinking water. 
2.2.6.2 Stent preparation 
The 316LSS bare metal stents (BMS) were sterilized by plasma etching, then transferred to a 
sterile container, immediately after treatment in a sterile environment. The PAC-316LSS stents 
were also transferred to a sterile container immediately after treatment in a sterile environment. 
The PAC-316LSS-TE stents were incubated with sterile filtered TE (100 µg/mL in PBS) for 
16 hours at 4oC and rinsed in saline prior to procedure. 
2.2.6.3 Stent implantation 
Fourteen animals underwent iliac artery intervention in total. The control group received 
denudation of 1 iliac artery with no manipulation of the bilateral artery (n=4), and the 
experimental group received denudation and implantation of a BMS and PAC+TE stent in 
bilateral iliac arteries (n=10). Briefly, rabbits weighing 3-4 kg were sedated, anesthetized and 
endothelial denudation was performed via a 5 F sheath catheter placed in the femoral artery by 
cut down. A 3.25 mm x 10 mm angioplasty balloon catheter (Sprinter®Legend RX) was placed 
into the aorta over a 0.014” guide wire, inflated to nominal pressure and withdrawn retrograde 
three times to the external iliac artery. The control animals received no further manipulation 
(n=4). A BMS or PAC+TE stent hand crimped onto a 3.25 mm balloon catheter, was placed in 
the common iliac artery (confirmed by angiography) and expanded (to a diameter of 3.1 mm). 
The procedure was repeated for the bilateral iliac artery, randomizing the type of stent, order 
and side of implantation. A single dose of heparin was administered at the time of surgery (100 
U/kg) and aspirin was administered orally 24 hours before surgery (40 mg/day) and maintained 
throughout the study [117, 147]. After 7 days, anaesthetized rabbits were exsanguinated by left 
ventricular puncture, perfused with lactated Ringer’s solution and given a lethal injection of 
35 
 
lethabarb (130 mg/kg). Stents were explanted, flushed with lactated Ringer’s solution and 
fixated in 4% (v/v) formaldehyde [106]. Scanning electron microscopy (SEM) and 
immunofluorescence analysis were carried out on 4 stent pairs and histology was carried out 
on 6 stent pairs. 
2.2.7 Scanning electron microscopy 
Biological sample processing for SEM was carried out on denuded and stented vessels. 
Samples were longitudinally bisected and half of each stent fixed in 2.5% glutaraldehyde for 2 
hours. Samples were fixed with 1% (v/v) osmium tetroxide, dehydrated with ethanol, mounted 
and coated with 20 nm gold. Stents were imaged with a Philips XL-30 CP scanning electron 
microscope (SEM). The percent cell coverage was quantified with Image J (MA, USA). (Dr. 
A. W) 
2.2.8 Immunofluorescence 
A longitudinally bisected stent half or artery segment, was fixed in 4% paraformaldehyde for 
16 h for immunofluorescence as previously described (24). Briefly, samples were incubated 
with 0.2 M glycine to quench fixative fluorescence (24 h at 4 oC) and blocked for 2 h at room 
temperature with 10% (v/v) goat serum in TBST (0.5% Tween in Tris buffered saline). Samples 
were incubated with rabbit anti-CD31 antibody raised in mouse (Abcam, 1:25 in TBS) or with 
mouse IgG1k (Abcam, 1:25 in TBS) for 16 h at 4
 oC, washed 4 times in TBS, stained with 
phalloidin-TRITC (0.1 g/ml) in TBS for 45 min, then washed 3 times with TBS. Stent sections 
were stained with 0.1 g/ml Hoechst in TBS for 10 min and imaged using a 10x objective (HC 
PL FL 10x/0.3 PH1, free working distance, 11 mm) on a Leica TCS SPII Multi-Photon 
Microscope. Multipoint positioning with wide field Z-stacks was used to image stents due to 
sample thickness. Projections from each channel were automatically generated and stacks were 
merged by mosaic stitching (Leica Microsystems, Germany) (Dr. A. W). 
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2.2.9 Histology: tissue collection and fixation 
For histological processes stented and denuded arteries were incubated in 4% 
paraformaldehyde for 24 h, then stored in 70% ethanol and embedded in methyl methacrylate 
(MMA) resin (all resin solutions were kept at 4oC and polymerized at -18 oC to -20 oC). For 
methacrylate embedding three separate solutions were prepared as the resin mixture. The 
reagents mentioned below were provided by the biomaterials and tissue engineering research 
unit at the University of Sydney (Dr. Hala Zreiqat, Tissue Engineering). Solution 1 infiltrate 
(4oC); and unwashed MMA. Solution 2a infiltrate (4oC); unwashed MMA (90 mL), 
dibutylphthalate (10 mL), and benzoyl peroxidase (0.25 g). Solution 2b (room temperature); 
unwashed MMA (95 mL), dibutylphthalate (5 mL), and benzoyl peroxidase (0.5 g). Tissue 
samples were first dehydrated through alcohol: 95% ethanol x 2 (4 hours apart), followed by 
100% alcohol. The samples were processed in solution 1 and 2a, at 4oC. Infiltrated stented 
segments were left in an upright glass vial, completely filled with the polymerization mixture 
2b at room temperature (exclude air). The samples were tightly capped and polymerized at -18 
to -20oC. Time of polymerization was dependent on sample size. Following adequate 
polymerization (~2 weeks), the specimen were removed by breaking the glass vials and pushing 
specimens out. The polymerized blocks were then shaped and trimmed off excess plastic with 
a grinder and sandpaper prior to sectioning (Polymerization was conducted by Miss Barbara 
James, research assistant, school of mechanical and aerospace engineering.) 
2.2.10 Histology: Sectioning of stented arteries 
The polymerized blocks were trimmed off excess resin with a linear precision saw (Buehler 
Isomet 5000) and polished with synthetic diamond paper (1200 m) (Struers Inc. OH, USA) 
to smoothen surface prior to sectioning with an automated microtome (Thermo Scientific, HM 
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355S). Transverse sections, 7-10 m in thickness were made using a D-profile tungsten carbide 
(TC) knife (Leica Microsystems, 16 cm). We investigated two different microtomes; Reichert-
Jung Polycut S microtome (Leica Microsystems) available at Anzac Institute, Concord 
Hospital, and the HM355S automated microtome. Since resin is hydrophobic, sectioning was 
facilitated with 30% methanol. Sections were adhered to 3% gelatin coated slides (ProSciTech 
super-frost plus adhesion slides). The sections were covered with thin plastic film and stacked 
together with a spring clamp, left overnight at 42 oC prior to staining.  
2.2.11 Histology: Slides  
Initially uncoated glass slides were investigated to adhere hydrophobic resin sections. The 
adherence was comparatively increased when glass slides were coated with 
aminopropyltriethoxysilane (AES), provided by the Anzac Institute, Concord hospital. Next 
we used albumin (egg white protein) with sodium azide on glass slides. After these trials, we 
used 3% gelatin (PBS) as our coating of choice on Superfrost Plus glass slides, for long term 
adherence of hydrophobic resin sections.  
2.2.12 Histology: Staining 
Sections were de-plasticized with 2-Methoxyethyl acetate (Sigma-Aldrich) for 1 h, cleared in 
2 washes of xylene for 20 mins, followed by hydration in descending grades of ethanol prior 
to staining with hematoxylin/eosin (H&E) for NIH and Carstairs’ stain for early markers of 
thrombosis, using the manufacture’s protocol [148]. Images were captured with bright field 
microscopy (Zeiss Imager 2.0, USA). To assess early NIH from H&E stained sections; the 
neointimal thickness between stent struts and lamina were calculated within cross sections (n=5 
per animal), and neointimal area between the lamina and internal elastic lamina (IEL) 
(inclusive of stent struts) was calculated using computerized morphometry (n=5 per animal, 5x 
magnification, Image J and Image Pro Plus Media Cybernetics, USA). When stained with 
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Carstairs’ stain, the fibrin, red blood cell and collagen content appeared red, yellow and blue 
respectively. The individual content of each component was quantified as a percent area within 
the NIH surrounding each stent strut (20x magnification), compared to the total NIH area (n=10 
struts, within 5 cross sections per stent); with the ‘smart segmentation’ analytical tool on Image 
Pro Premier version 9.0.3 (Media Cybernetics, USA). 
2.2.13 Immunohistochemistry (IHC) 
Resin-artery segments were trialled to identify presence of 3 biomarkers; CD31 (luminal 
endothelialization), α smooth muscle actin - α-SMA (smooth muscle cell (SMC) proliferation) 
and MAC 387 (neutrophil/macrophage infiltration). Sections were deplasticized as mentioned 
in 2.2.12. Two methods were trialled for antigen retrieval; heat induced epitope retrieval 
(HIER) and proteinase induced epitope retrieval (PIER).  Since tissue sections disintegrated 
during HIER, we selected PIER as the antigen retrieval step, prior to immunostaining for all 3 
biomarkers. Proteinase K was prepared in TE buffer (50 mM Tris base, 1 mM EDTA, 0.5% 
Triton x-100, pH 8.0) at room temperature and stored at -20oC (Proteinase K was kindly 
provided by Dr. Hamish Prosser, Immunobiology Group, HRI). Resin-artery sections of 
interest were incubated for 1 hour in proteinase K (1:125, with TE buffer), and blocked in NGS 
for 30 min. Depending on tissue thickness and size, we chose the following dilutions for 
primary antibodies: CD 31 (1:50 in TBST, 45 min), α smooth muscle actin (1:100 in TBST, 
overnight at 4oC), and MAC387 (1:50 in PBS, 1 hour). We used two secondary antibody kits; 
1) HRP-Rabbit (DAB+) for CD31 and MAC387 (brown dye), 2) rabbit-mouse linker with AP 
chromogen kit for α-SMA (red dye) (kits used in accordance to manufacturer’s instructions).  
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2.2.14 Microscopy 
Sections were imaged with transmitted light microscope, Olympus BX61 Microscope (SIS 
software), and Olympus IX70 inverted microscope (bright field microscopy).  
2.2.15 Statistics 
Data are expressed as mean ± standard error of the mean and indicated in figures as (*p<0.05, 
** p<0.01 and *** p<0.001). After in vivo experiments, compiled stent SEM images were 
scored for percentage cell coverage of stent struts and intersections and divided by the number 
counted. Stents were also analyzed for the area of CD31 positive labelling, neointimal 
hyperplasia and fibrin deposition (Image J and Image Pro Plus software respectively). The data 
were analyzed by paired t-test for statistical significance, using GraphPad Prism version 6.00 
(GraphPad Software, San Diego, California) for Mac OS X. 
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2.3 Results 
 
2.3.1 Covalent attachment of tropoelastin (TE) to PAC stents in vitro 
Covalent binding of TE to PAC stents was assessed by radioactively labelling tropoelastin 
with125I, measuring the amount bound to the surface, before and after SDS washes at 95oC [18]. 
The PAC stents bound 20617±42% cpm of radiolabelled TE which was reduced by 32.23% to 
13971.75±41% cpm after SDS treatment (Fig. 2.2). In contrast, BMS had 6887.75±8.8% cpm 
of 125I TE physiosorbed to the surface, this reduced by 79.82% to 1389.75±3% cpm after SDS 
treatment. The PAC stents bound more TE, retaining 67.77% on surface after SDS washing to 
indicate covalent attachment of protein to stent surface. 
2.3.2 In vivo assessment of stents: Feasibility of PAC+TE bioengineered 
stent 
We had previously established biocompatibility of PAC+TE surfaces in vitro [145, 146] and 
biocompatibility of PAC stents alone in vivo [106]. The present in vivo feasibility study was 
carried out with a total of 10 animals, each receiving a control BMS (316L SS stent) and a 
treated stent (PAC+TE) implanted in bilateral common iliac arteries for a period of 7 days. We 
aimed to comparatively quantify progressive response to bilateral artery stenting with a 7-day 
follow up study, to evaluate initial response as illustrated for BMS (Fig. 2.3). The vessel 
position, stent deployment and post-implant patency were confirmed for each animal via 
angiography [106]. All animals survived the in-life phase of the study. There was no infection 
or gross inflammatory response observed post-surgery or on explant of the stents. Animals 
were euthanized 7 days after stent implantation, and longitudinal and cross-sectional samples 
of the stent-artery interface of PAC+TE stents and BMS prepared for investigation.  
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2.3.3 Cellular coverage of stents after 7 days 
Experimental animals received a BMS in one common iliac artery and a PAC+TE stent in the 
bilateral common iliac artery for 7 days. Stent pairs from 4 animals were longitudinally bisected 
and analyzed by SEM. Seven days post implantation, all stents had cells partially covering the 
struts (Fig. 2.4 A). The percentage of strut cell coverage showed no significant difference 
between paired BMS and PAC+TE stents, 79±5% vs. 51±13% respectively (Fig. 2.4 B).  
2.3.4 Detection of endothelium 
Image analysis of stent sections stained with CD31, TRITC Phalloidin and Hoechst showed 
CD31 immunolabelling at cell peripheries on the intima, between struts and in some cases 
covering the struts in all samples (Fig. 2.5A and Fig. 2.5B).  Increased CD31 positive cells 
were observed at the end of the stents compared to the middle of the stents, however, there was 
no significant difference detected in the percent of CD31 staining between matched pairs of 
BMS and PAC+TE stents, 83% vs. 75% respectively (Fig. 2.5C).   Additionally, there were 
areas of struts in all samples in which the cells covering them were CD31 negative.  
2.3.5 Neointima formation 
Five cross sections each of the stent pairs from the 7 day study randomly chosen along the 
length of the stents were H&E stained to assess neointimal thickness and neointimal area. A 
schematic cross section of the stented arterial wall represents the stented vessel and area of 
interest used for analysis (Fig. 2.6). The thickness and total area between the stent/internal 
elastic lamina and the lumen at 7-day follow up was quantified for early neointimal 
proliferation/NIH. Representative images from the middle sections of stents are shown (Fig. 
2.7 A). Stent struts were observed as black-square shapes in the histological analysis. There 
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was no visible inflammatory response caused by either BMS or PAC+TE stents in the H&E 
stained sections and positive remodelling was not seen at day 7. Thickening of tissue on the 
luminal side of internal elastic lamina (IEL, indicated with white arrows), shows the presence 
of early NIH (Fig. 2.7 A). Neointimal thickness of images quantified with Image J, indicate 
lower thickness in PAC+TE stents (22.73±6.52 m) compared to BMS (31.77±6.95 m) 
(P<0.05) (Fig. 2.7 B). Total neointimal area was lower for PAC+TE (377.97±40.19 µm2) vs. 
BMS (433.69±62.39 µm2) (P<0.05) (Fig. 2.7 C).  
2.3.6 Early Markers of Thrombosis 
The sum of fibrin, red blood cell (RBC) and collagen content detected with Carstairs’ stain 
were used as markers of early in-stent thrombogenicity (Fig. 2.8 A). The fibrin content (red) 
within the neointima (indicated by black arrow) was higher in BMS (25.23±2.25%) vs. 
PAC+TE stents (18.32±1.94%) (P<0.05) (Fig. 2.8 B). There was no significant difference in 
the RBC content (yellow) in BMS (26.40±9.82%) vs. PAC+TE (23.52±8.43%) (Fig. 2.8 C) or 
collagen content (blue) for BMS (22.2±8.2%) vs. PAC+TE (28.82±10.9%) (Fig. 2.8 D), 
although a trend towards decreased RBC content and increased collagen content, was observed 
in PAC+TE vs. BMS respectively. The overall key morphological features at 7 day follow up, 
were schematically illustrated to compare BMS vs. PAC+TE stents (Fig. 2.9) 
2.3.6 Immunohistochemistry trials 
The IHC results were visualized to indicate positive antigen retrieval, and immunostaining 
uptake for MAC 387 (markers for macrophage/neutrophil) and CD31 (luminal 
endothelialization) (2.10 A, B respectively). Results for α SMA (smooth muscle actin) showed 
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non-specific staining uptake compared to the negative control (2.10 C). Results were not 
quantified due to limited number of sections.  
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Figure 2.2 
 
 
Covalent binding of 
125
I Tropoelastin (TE), Radioactivity count of 
125
I TE bound to PAC and 
BMS before (blue) and after (green) SDS treatment for 10 min at 95
o
C. 
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Figure 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
Illustration of key morphological features observed after stent implantation in BMS, immediately after implantation and at 7-day follow up. 
Early response is characterized by luminal endothelialization, in-stent platelet/fibrin deposition, smooth muscle cell (SMC) 
proliferation/migration and characteristic neointimal thickening. Illustration modified from Virmani et al  [114]. 
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Figure 2.4 
Cell coverage of paired implanted stents. A. Representative SEM images of cell coverage on paired stents, BMS (blue), PAC+TE (green), 7 days 
post stent implantation. Scale bars in low magnification images indicate 1 mm and scale bars in the high magnification images indicate 100 µm. 
B. Percentage of cell coverage on stent struts.
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Figure 2.5 
Representation of the stents: (A) merged projections of longitudinally sectioned BMS, (B) merged projections of longitudinally sectioned PAC+TE, 
and (C) percent endothelialization quantified with CD31 immunofluorescence for both stent types. Stents were immunofluorescently labelled for 
CD31 (green), phalloidin TRITC for actin (red), and Hoeschst for nuclei (blue) (b). Stent sections labelled with CD31 for endothelialization are 
magnified and imaged for each stent type (c-f) 
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Figure 2.6 
 
 
 
 
 
 
 
 
 
Representation of a stent-artery cross section, denuded at target procedure and 7-day follow-up with no observable positive arterial remodeling. 
At day 7, the site of interest for early neointimal hyperplasia (NIH) (red arrow, explained in detail inset) is the thickness between the lumen and 
the internal elastic lamina (IEL) inclusive of stent struts. The neointimal area of total vessel calculated is highlighted in green. Respective 
calculations were done with Image J and Image pro premier, results were compared between stent types. Image modified from Farooq et al [149]
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Figure 2.7 
A. H&E staining for the degree of early neointimal hyperplasia (NIH). B. Significantly lowered neointimal thickness BMS (31.77±6.95 µm) vs. 
PAC+TE (22.73±6.52 µm) and C. Significantly lowered neointimal area PAC+TE (377.98±40.19 µm
2
) vs. BMS (433.69±62.39 µm
2
) was 
observed.  
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Figure 2.8 
 
 
 
 
 
 
 
 
 
 
 
Carstairs’ staining for degree of fibrin, RBC and collagen deposition in stented rabbit iliac arteries. For accuracy, only the content of fibrin in the 
neointima surrounding the stent struts was quantified (20x magnification). Arrow indicates fibrin deposition (red), among the RBC (yellow) in the 
neointima for BMS. Collagen deposition (blue) dominant in the adventitia. Calculations of the media, were exempted from the study.  Percent 
fibrin content was significantly higher in BMS (25.23±2.25 %) vs. PAC+TE stents (18.32±1.94 %). There was no significant difference in the 
RBC and collagen content in stented arteries. 
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Figure 2.9 
 
 
Illustration of the key morphological features after stent implantation for BMS vs. PAC+TE, 
immediately after implantation and at 7-day follow up. Early response at 7 day is characterized 
by luminal endothelialization, in-stent platelet/fibrin deposition, smooth muscle cell (SMC) 
proliferation/migration and characteristic neointimal thickening. Positive arterial remodelling 
is not observed for either stent type at 7 day follow up. Illustration modified from [114] 
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Figure 2.10 
 
 
 
 
 
 
 
 
 
 
 
Cross sections were stained after antigen retrieval with PIER. A) MAC 387 antibody, marker of neutrophil activation was positive for both 
PAC+TE and BMS (BMS represented) (4x mag, 10x, 20x mag inset). B) CD31 antibody, marker of luminal endothelialization was positive for 
PAC+TE not BMS (PAC+TE represented) (4x mag, 10x, 20x mag inset). C) Non-selective staining seen for α SMA positive stented artery cross-
section (right), compared to negative control (left) (10x mag). 
 53 
 
2.4 Discussion 
This is the first investigation of a covalently immobilized monolayer of recombinant human 
tropoelastin on a PAC stent surface, to assess biocompatibility in an established rabbit bilateral 
iliac artery stenting model. The key outcomes of the study demonstrate strong covalent protein 
binding to a PAC stent, reduced early neointimal area, reduced neointimal thickness, reduced 
fibrin deposition, equivalent cell coverage and equal early endothelialization, compared to 
316LSS BMS, after 7 days in vivo.  The pilot study was feasible in vivo. 
2.4.1 In vitro evaluation of stent PAC 
Similar to original PAC previously analyzed, stent-PAC was able to retain covalently bound 
tropoelastin (TE), demonstrated by radioactively-labelled tropoelastin retention, after SDS 
washes in vitro (figure 2.2).  We used radioactive iodination of tropoelastin; an established 
method [146, 150], to label and quantify covalent attachment of proteins to the modified 
surface. The linker-free covalent binding observed, is consistent with previous studies [136, 
151], providing the robust surface adhesion required for in vivo application on cardiovascular 
stents. In the novel plasma-based coating process discussed, the biomaterial is completely 
covered by the thin layer of deposited plasma polymer, ensuring the chemical status of the stent 
surface is determined by the deposited material and not underlying bare metal alloy 
[106],[151]. Animal studies are necessary to fully evaluate medical device safety. Stent 
endothelialization is often investigated with porcine or rabbit, animal models. This study 
demonstrates implantation of PAC+TE stents and BMS into balloon denuded rabbit common 
bilateral iliac arteries. Endothelialization of this model would be at a slower rate compared to 
porcine model, allowing differences to be observed at 7 days [33].  
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2.4.2 In vivo evaluation of PAC+TE stent 
2.4.2.1 Pilot study 
The pilot animal experiment was designed to establish feasibility and safety of a PAC+TE stent 
compared to BMS in vivo. Stents were implanted in bilateral iliac arteries of rabbits for 7 days 
to assess endothelialization and PAC+TE integrity at primary endpoints. The model was 
chosen since its commonly used to assess healing response following arterial denudation and 
stent implantation [33], with results comparable to humans at chosen endpoints [114].  
Both stent types were sterilized during the deposition and cleaning process, to result in a 
homogenous surface. This is a common method of surface sterilization with plasma modified 
materials in medicine [98]. A diameter of 3.1 mm was chosen for balloon expansion during 
stent implantation, since rabbit common iliac arteries were approximately 2.5-2.75 mm in 
diameter, to result in a stent to artery ration of 1.13:1-1.24:1. This method is equivalent to 
overexpansion of stents during human implantation, although at a value below the ration of 
1.3:1, which can cause chronic vessel injury [152]. Animals were maintained on aspirin 
received daily in their drinking water, starting 24 hours prior to the procedure, and maintained 
throughout duration of the experiment, to prevent acute stent thrombosis [33, 117]. Animals 
were sacrificed at 7 days, the endpoints chosen based on literature showing near complete 
percent endothelialization for BMS by 14 days [33]. Earlier time points were chosen to detect 
a possible increase in endothelialization on PAC+TE compared to BMS.  
The control animals with one denuded iliac artery without stent implantation, and the bilateral 
iliac artery with no manipulation were chosen to assess success of the balloon denudation 
procedure. Denudation of the artery with a balloon catheter as a control, was successful 
resulting in comparable vessel healing response, as in literature [153]. Furthermore, each 
experimental animal had one BMS implanted in an iliac artery and PAC+TE in the bilateral 
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iliac artery. The order and side of stent implantation was randomized. No animals died as a 
consequence of either stent type and no observable infection was seen at the endpoint, owing 
to sterility of the stents. By day 7, stents were well tolerated, without fracture post-implantation.  
2.4.2.2 Addressing endothelialization and thrombogenicity. 
Our strategy to mitigate restenosis and thrombosis was to exploit the attributes of recombinant 
human tropoelastin (TE). TE is the monomer of the biopolymer elastin, which clinically 
regulates vascular cells. Elastin and TE have been shown to have low thrombogenicity, 
promote endothelialization and inhibit SMC proliferation [138, 139, 154] making it an ideal 
coating candidate to enhance biointegration of stents. Recombinant human tropoelastin has 
been produced from E. coli (36) and successfully used in a range of biomaterials [155]. 
Tropoelastin has potential advantages for vascular biocompatibility in comparison to other 
intravascular device coatings such as vascular endothelial growth factor (VEGF) and anti-
CD34 antibodies, shown to have adverse effects in clinical studies [139, 156]. To robustly 
immobilize TE to stents in vivo, we utilized covalent protein binding capability of PAC (38). 
We had previously angiographically established coating integrity of PAC stents in vivo [106] .  
2.4.3 Histopathology evaluation of PAC+TE stent 
Histopathological assessment after BMS and DES implantation in human arteries allowed 
evaluation of the arterial-stent interface, and has been well documented [114, 157]. The local 
response to 316L SS BMS implantation follows a similar pattern of arterial injury and repair, 
accompanied with neointimal formation and endothelialization in animals, and in humans 
[114]. However, timeline for healing response after BMS placement in a human is 5-6 times 
longer than in rabbit iliac arteries, and pig coronary arteries. In animals, peak neointimal growth 
is reached at 28 days, compared to 6-12 months in humans. Of note, the precise time course for 
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neointimal growth and healing in human coronary arteries with DES is unknown due to 
prolonged inhibition of neointima [114]. The rate of neointimal expansion is greatest between 
7-14 days in animal models.  
2.4.3.1 Early markers of neointimal hyperplasia and thrombosis 
The study shows increased early neointimal thickening and neointimal area, with H&E 
staining, for BMS compared to PAC+TE (figure 2.7). Although a characteristic peak in early 
neointimal growth is observed, as expected, neither stent type exhibited positive arterial 
remodelling or luminal compromise at 7 days [158]. In the early response, platelet and fibrin 
deposition occurs around the stent struts and scattered neutrophils within mural thrombi extend 
between struts [114, 128]. Excessive mural thrombogenic response was prevented by anti-
coagulation with aspirin.  
Histopathological results with Carstairs’ [148] showed lower fibrin deposition surrounding 
struts for PAC+TE stents compared to BMS, indicating comparatively improved arterial 
response at 7 days (figure 2.8).  At 7 days, percent content of red blood cells and adventitial 
collagen between stent struts did not vary significantly. The RBC area percentage in the stent-
strut/artery interface showed trends towards reduction in PAC+TE compared to BMS, whilst 
collagen content showed an increase in PAC+TE compared to BMS, following a distinct 
pattern of local arterial injury and repair, in response to stenting [114]. At 28 days, fibrin is 
expected to be absent, while neointima may gain a larger number of SMC, proteoglycans, type 
III collagen, and majority of inflammatory cells around stent struts, incrementally (figure 2.1). 
Extended studies would allow further evaluation of thrombosis and remodelling. 
Preliminary luminal endothelialization is expected to occur at the artery/stent interface by day 
7 [33]. Immunofluorescence analysis of CD31, and endothelial specific marker, on surface of 
longitudinal sections of PAC+TE showed equivalent cell coverage compared to BMS at 7 days, 
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at the proximal and distal ends of stents, as seen in previous studies of endothelialization [147, 
159] (figures 2.4 and 2.5). The expression of CD31 was concentrated at endothelial cell 
borders, where it engages in cell-cell binding, and is seen between and covering struts on BMS 
and PAC+TE stents. The presence of tropoelastin did not show an improved benefit for 
endothelial cell interaction in vivo. The CD31 negative areas observed could be due to 
uncovered struts, thrombus formation or early SMC proliferation and migration from the 
arterial lining. 
Documented timeline for cell proliferation peaks at seven days reducing in half at 14 days, to 
return to low baseline levels at one month [114]. A longer study time point of 14 or 28 days 
will be more conclusive of the arterial response in vivo, to assess impact of PAC+TE vs. BMS 
on endothelialization. The arterial wall was injured via denudation prior to stent deployment, 
for comparable arterial healing as seen in humans. This is a generalized estimation of arterial 
repair, given that most human arteries for stent implantation are associated with extensive local 
trauma [160]. However, arterial remodelling termed ‘Glagov’s phenomenon’ occurs regardless 
of atherosclerotic plaques in the arteries, since blood flow properties mediate remodelling after 
angioplasty, hypertension, flow diversion as well as atherosclerotic plaque progression [161]. 
2.4.3.2 Immunostaining of PAC+TE 
Immunostaining was conducted on resin stent-artery cross sections to visualize markers of 
endothelialization (CD31), smooth muscle hyperproliferation (α SMA), and neutrophil   
infiltration (MAC 387). For the purpose of antigen retrieval and antibody uptake, the resin had 
to be completely deplasticized. However, MMA resin posed several technical challenges, 
including incomplete deplasticization, which compromised complete antigen retrieval (figure 
2.10). By day 7, most biomarkers of endothelialization, neutrophil infiltration and smooth 
muscle cell proliferation, were at early stages of expression. Previous investigations showed 
 58 
 
absence of macrophage expression at 3-14 days, although neutrophil, not macrophage 
infiltration is shown to occur after endothelial denudation [162]. The antibody marker of 
inflammation MAC 387 used in this study, recognizes tissue macrophage as well as 
intracytoplasmic antigen expressed by day 7, which includes granulocytes and monocytes 
abundant during this timeline.  We observed staining up take with MAC 387 on BMS and 
PAC+TE by day 7, on a few sections, although inconsistently (figure 2.10 A). Virmani et al 
[114] have shown stent struts contain smooth muscle cells, macrophages with scattered 
lymphocytes, red cells, and luminal endothelial cells by day 7. Endothelialization is usually 
complete between 14-28 days [33], we observed partial luminal endothelialization with 
PAC+TE stent cross-sections at day 7 in agreement (figure 2.10 B). Rate of neointimal 
expansion is greatest between 7-14 days [114], since H&E staining indicated thickening of 
neointima in our study, we investigated smooth muscle cell hyperproliferation with α-smooth 
muscle actin (α SMA) antibody. Nonspecific staining uptake was observed for resin-stent 
artery cross sections, in comparison to negative controls (figure 2.10 C). The IHC limitations 
in this chapter, could be owing to resin type (MMA), incomplete deplasticization, lack of PIER 
optimization thereof, and lack of antigen retrieved for staining. Extensive trials were limited in 
this study, due to limited number of sections available. Furthermore, at day 7, antigens for 
endothelialization (CD31), neutrophil (MAC 387) and smooth muscle actin (α SMA), are likely 
to be at early stages of expression, or not available at all. Biomarkers of IHC staining, are 
likelier to be expressed completely during investigations with extended timeframes, as well as 
within different embedding media to minimize practical and technical limitations.  
2.4.3.3 Study Limitations  
The main limitations of the present study is the short 7-day time frame. This time point was 
chosen to primarily address feasibility and safety of a stent surface bioengineered with a 
bioactive monolayer of tropoelastin. Positively remodelled vessels predict increased likelihood 
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of restenosis, and were not observed at this earlier time point either. Complete evaluation of 
the morphological features mentioned, can be investigated with an extended timeline and larger 
cohort, given that feasibility of technique and stents have been confirmed herein. To minimize 
technical limitations discussed, different embedding media can be used, and techniques of 
antigen-retrieval optimized.  
 
2.5 Conclusion 
The PAC+TE stents showed covalent binding capacity for recombinant human tropoelastin in 
vitro compared to BMS. This is the first study to investigate the effect of PAC+TE stents in a 
rabbit bilateral iliac artery model of endothelialization in vivo. The PAC+TE stents showed 
equivalent cell coverage, equivalent endothelialization, reduced early neointimal thickness, 
neointimal area, and reduced early fibrin deposition compared to commercial BMS. The study 
of covalently immobilized tropoelastin on a PAC stent in vivo was feasible, showing no adverse 
early inflammatory or thrombogenic effects. A larger cohort, within an extended 14-28 day 
study timeline, is essential to verify long-term impact of PAC+TE stents vs. BMS in vivo. The 
results presented demonstrate PAC+TE stent coating as a promising approach to improve 
biocompatibility of coronary stents in vivo. 
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Chapter 3 – Bioengineering alloy L605 cobalt chromium 
cardiovascular stent biomaterial for surface enhancement 
and characterization 
 
3.1 Introduction  
 
3.1.1 Cobalt chromium material for surgical implant applications 
A principal requirement for biomedical alloys in device implantation is in vivo corrosion 
resistance, combined with optimal mechanical properties at implant interface. The ideal metal 
alloy would have “the elastic modulus of magnesium, strength of cobalt chromium, corrosion 
resistance of titanium and formability of stainless steel”[163]. Biocompatibility has been re-
defined in the material context, as the ability of a material to perform with an appropriate 
response in a specific application [164]; the definition highlights device response variation is 
probable in varied biological conditions. 
The stiffness of a material, also known as its elastic modulus, is an important concern during 
in vivo applications of biomaterials. Implanted alloys take a disproportionate share of the load 
(stress), to cause stress shielding; as a result in orthopaedic applications of biomaterials, the 
bone associated with implant becomes comparatively stronger [163]. Cobalt chromium also 
exhibits improved corrosion resistance; for example, hip implants originally made of stainless 
steel were replaced with cobalt-chromium alloys as the material of choice for long-term safety 
and associated durability [165]. 
At present, cobalt chromium alloys are commonly incorporated as implant materials in 
dentistry, orthopaedics and cardiology [166]. The alloys have found applications with blood 
contact in pacing leads, AAA stent grafts and self-expanding stents for over a decade [163]. 
The driving force to select these super alloys as laser-cut commercially available 
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cardiovascular stents is due in parts to, reduced strut thickness for improved deliverability and 
reduced total stent volume (without compromising radial strength or radiopacity), combined 
with acceptable biological response in vivo. As outlined in chapter 2, four key factors contribute 
to implant device performance in vivo, including device position, patient lesion-related factors, 
time course of DAPT and device material characteristics. Device characteristics are directly 
linked to material composition. Biocompatibility, X-ray/MRI visibility, radial strength, arterial 
recoil mechanisms, axial/radial flexibility, deliverability, profile and long term durability of an 
implant device are dependent on overall physical, chemical and mechanical properties of 
material used for implant device manufacture [167]. Cobalt-chromium based biomaterials are 
covered by several ASTM (American Society for Testing and Materials) approved 
specifications, with ASTM F75 Co-28-6-Mo and ASTM F90 Co-20Cr-10Ni, predominant for 
cast alloys and wrought alloys respectively [168].  
The ideal stent material will be fully corrosion resistant, biocompatible, fatigue resistant, and 
visible with X-ray/MRI methodology.   
3.1.1.1 Microstructure of Cobalt Chromium Alloy L605 
Investigating the microstructure of metal alloys used as biomaterials, predominantly examines 
the physical and chemical composition at the elemental, supramolecular and atomic levels of 
the material of interest. The ASTM F90 wrought alloy Co-20Cr-10Ni utilized in this study is 
comprised of the chemicals seen in table 3.1. The metal L605 alloy used in this study meets 
ASTM F90 and UNS R30605 specifications; i.e. chemical, mechanical and metallurgical 
requirements for wrought cobalt chromium alloy, for use in surgical implants.  Several alloys 
of cobalt chromium are used in commercial CoCr stent production, including MP35N, 
Phynox/Elgiloy and L605. Selected physical and mechanical properties of the 3 CoCr alloys 
and stainless steel alloy 316L are comparatively represented in table 3.2, replicated from [166].  
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Table 3.1 Chemical Analysis of wrought Co50-Cr20-W15-Ni10 Alloy for Surgical 
Implant Applications [utilized in this study]. 
 
 
Table 3.2 Comparing physical and mechanical properties of annealed CoCr alloys vs. 
316L stainless steel alloy [table from [166]] 
 
  
Element Percent Weight (Wt%) 
Carbon (C) 0.112 
Chromium (Cr) 20.10 
Cobalt (Co) BAL 
Iron (Fe) 2.40 
Manganese (Mn) 1.51 
Nickel (Ni) 10.70 
Tungsten (W) 14.70 
Phosphate (P) 0.010 
Sulphur (S) <0.002 
Silicon (Si) 0.20 
Specifications: AMS 5537, H; ASTM F90-09 Chemistry only, UNS# R30605 
Alloys Specific  
Mass 
(g/cm3) 
Elastic 
Modulus 
(GPa) 
UTS  
(MPa) 
Yield  
Strength  
(MPa) 
Tensile  
Elongation 
(%) 
316 L SS 7.95 193 670 340 48 
Phynox / 
Elgiloy 
8.30 221 950 450 45 
MP35N 8.43 233 930 414 45 
L605 9.1 243 1000 500 50 
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Cold work and annealing conditions contribute to the typical mechanical properties observed 
for the metal alloys, a small grain size of ASTM 7 or finer obtained in manufacture. The 
requirement for small grain size is imperative in stent production with thinner strut size 
requiring a minimum of 3 grains through the strut as a rule of thumb [166]. Alloy L605 utilized 
within the present study has a fine grain size of ASTM 5 within material microstructure, 
twinning grain boundary, and a material thickness of 250 µm. The microstructure of alloy L605 
has been studied via transmission electron microscopy (TEM), energy filtering transmission 
electron microscopy (EFTEM), electron spectroscopic diffraction (ESD) for surface analyses, 
and selected area electron diffraction (SAED) to display twinning boundary microstructure in 
the CoCr material matrix herein. Among the 3 CoCr alloys mentioned, alloy L605 stands out 
as the most favourable material for stent production due to higher density, stronger elastic 
modulus, radiopacity and recoil. The underlying stent material for commercially available 
drug-eluting coronary stent system Xience PrimeTM is a medical grade L605 CoCr alloy (FDA 
summary of safety and effectiveness data, 2011).  Of note, new generation innovative bare 
metal stent Multi-Link8 coronary stent system (Abbott Vasculature) is also manufactured with 
cobalt chromium technology for thin struts and improved deliverability [169].  
Previous studies conducted on the manufacture of cobalt chromium alloy L605 have shown the 
variability of material based on cold work and final anneal temperatures, with a described cold 
work range of 0-45% and temperature window of 900-1175oC, allowing stent designers a 
selection of optimal material properties for their device [166]. Studies investigating the link 
between stent design and its performance conclude that optimized material properties are 
overall dependent on device design [170, 171]. 
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3.1.2 Impact of stent design on restenosis and intimal hyperplasia: 
 
Several practical considerations are made during applications of a material in a coronary stent 
system. Commercially available stents are either balloon expandable or self-expanding during 
implantation. The ideal stent material for balloon expandable stents, would have an infinite 
elastic modulus to prevent recoil, a low yield strength to allow crimping/expansion of the stent 
delivery system, high ductility to withstand deformation during expansion, and high tensile 
properties (ultimate tensile strength -UTS) to permit thinner struts for an overall lower 
volume/profile [167]. Thinner strut size and lower profile, alloy L605 stents improves 
flexibility, and access to smaller vessels. Stent strut size is also associated with greater clinical 
benefits as discussed below. The material properties outlined above are interrelated; therefore 
require careful compromise to prevent contradictions. For example, materials with higher 
tensile strength permit thinner struts but typically also have higher yield strengths, and the latter 
may result in acute recoil during balloon deflation. Whilst alloy 316L SS, is a reference material 
for successful stent applications despite weak radiopacity, the cobalt based alloy L605 exhibits 
comparatively higher density, elastic modulus, strength and difference between yield and UTS, 
with similar ductility compared to stainless steel. Alloy L605 has therefore received much 
interest as a stent material. However, no available material at present is known to demonstrate 
ideal features, therefore compromises have been made to sacrifice some material properties 
over others during practical applications of the alloys in cardiovascular stents.  
The main benefit of stenting compared to balloon angioplasty alone is the ability to 
comparatively reduce restenosis [4]. However, in-stent restenosis is a major limitation of stent 
therapy, predominantly in bare metal stents, with intimal hyperplasia being the mechanism of 
stent restenosis, as seen mainly with stainless steel stents within multivariate study models 
[172, 173]. Simple, cost-effective strategies have been rigorously employed to address clinical 
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complications and understand mechanisms of in-stent restenosis [174, 175]. Although relation 
between strut thickness and vascular wall reaction seems intuitive, very little attention has been 
paid to the phenomenon. The effect of strut thickness on restenosis has been investigated within 
clinical trials with stents of similar design and material composition, but reduced strut size 
(ISAR-STEREO trials) [176]. The primary endpoint of the trial - angiographic restenosis 
showed a 42% risk reduction for thin strut patients (15%) compared to patients with 2x strut 
size (25.8%) [176].  
The usefulness of cobalt chromium coronary stent alloy, investigated during its first clinical 
experience after deployment further exemplifies that novel thin strut stents maintain 
radiopacity and radial strength, without compromising long-term results, as seen with thicker 
strut stainless steel or gold-coated stents [177]. The effect of strut thickness on restenosis 
outcome and neointimal hyperplasia has been further investigated within several other clinical 
studies, comparing various stent types including cobalt chromium stents [176, 178]. At 6 month 
follow-up a comparative intravascular ultrasound study investigating intimal hyperplasia 
among 3 types of commercial stents show stent type as the only independent predictor of 
intimal hyperplasia thickness within human atherosclerotic coronary arteries [178]. Among the 
stents compared, cobalt chromium stent Multi-Link proved to result in less tissue proliferation 
at 6-month follow-up, compared to 316-L stainless steel Palmaz-Schatz and InFlow stents 
[178].  
The acceptable biocompatibility and reduced adverse proliferative response has made cobalt 
chromium alloy a suitable stent platform for drug eluting stents as well. Clinically, after drug-
elution the residual polymer matrix and stent should maintain biocompatibility in patients, to 
prevent restenosis and device failure. Based on this rationale, thin-strut cobalt chromium is 
often utilized as the underlying biomaterial for drug eluting stents [95, 179]. Clinical trials 
 66 
 
comparing two types of DES have shown NEVO sirolimus eluting stent (NEVO SES) with a 
cobalt chromium backbone more superior to TAXUS Liberte paclitaxel-eluting stent with 316L 
SS backbone (TAXUS Liberte PES); in relation to neointimal hyperplasia suppression, less 
positive remodelling and decreased morphometric abnormalities surrounding stent or at stent 
margins [95].  
3.1.3 Clinical effects of drug eluting stents and cobalt chromium stents: 
A broad spectrum of clinical trials have demonstrated that restenosis, in-stent neointimal 
hyperplasia and major adverse cardiac events (MACE; death, myocardial infarction, stroke and 
target lesion revascularization (TLR)) were significantly reduced with the use of DES 
compared to BMS [27, 180]. While the clinical benefits of DES reported are entirely due to the 
highly significant reduction in repeat revascularizations, concerns about late events associated 
with DES have surfaced, suggesting discriminate usage of DES [181, 182]. The incidence of 
late stent thrombosis, a potentially fatal complication, is associated with an increased risk post 
DES implantation, compared to restenosis predominant in BMS, as illustrated in figure 3.1 
[183]. Parallel to the variation in vascular disease severity within patients undergoing stent 
implantation, the role of adjunctive antiplatelet therapy is also integral to stent bio-integration. 
Although originally a science advisory including the American Heart Association, American 
College of Cardiology and Society for Cardiovascular Angiography and Interventions et al, 
recommended a 12 month regime of dual antiplatelet therapy, as published in 2007 [184], 
recent investigations still debate the optimal duration of DAPT, which has not yet been 
precisely determined [135, 185]. While patients with coronary artery disease worldwide have 
received immense health benefits via coronary-artery stent implantation, potentially serious 
albeit uncommon complications such as stent thrombosis and internal bleeding need aggressive 
examination, risk assessment and development of preventative measures [183].   
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Whilst DES successfully addressed the issue of in-stent restenosis predominant to early BMS, 
the stent type is held back by late stent thrombosis (LST). The use of DAPT was recommended 
for a period of 6-12 months after implantation of DES to combat LST, although adherence to 
therapy beyond 12 months [135], or non-adherence to therapy prior to 6 months [185], result 
in adverse bleeding risks. The clinical outcome for DES requires patient-based individualized 
decisions, and indiscriminate administration of stent type. In contrast, clinically, thin-strut 
cobalt chromium stents (CCS) have shown superiority to thick-strut BMS via reduced 
restenosis [176], is cost-effective, and bears similarity to DES in relation to MACE as well as 
rates of stent thrombosis [186], therefore increasingly incorporated as the underlying 
biomaterial for new-generation DES [179]. As a result we chose cobalt chromium alloy L605 
(ASTM F90), as our biomaterial of interest for plasma modification and investigation in this 
study.  
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Figure 3.1: 
  
Potential complications of coronary stenting: Restenosis observed in a traditional 
bare metal stent and late stent thrombosis observed in a drug eluting stent. Arrows 
indicate blood flow. Image is from www.nejm.org. An animation showing 
restenosis and stent thrombosis can also be viewed on the same site. 
 69 
 
3.1.4 Plasma activated coating on cobalt chromium alloy L605: 
 
3.1.4.1 Mechanism of PAC – Applied Physics for Material Modification: 
An energetic ion-assisted plasma process that can make any surface hydrophilic, enables 
covalent immobilization of biological molecules in their native conformation (without 
chemical linkers), as demonstrated on an alloy 316L stainless steel platform [103, 187]. The 
proprietary plasma activated coating [172], introduced in chapter 1 and 2, is a unique material 
modification method [107]. The applied plasma physics technique creates free radicals that 
migrate to the surface from a reservoir beneath, the radicals bind biomolecules, via covalent 
bonds with amine groups, to form a full protein monolayer [103]. The process is illustrated 
schematically in figure 3.2. Applications of PAC with a monolayer of covalently bound protein 
on a 316L SS coronary stent, within an in vivo translational study, was extensively discussed 
in chapter 2 (Manuscript in preparation for Biomaterials). The kinetics and number densities 
of free radicals in the reservoir govern the shelf life of the modified biomaterial and its’ 
covalent binding capacity [103]. The reservoir can be formed on any solid material (polymer 
and metal included) activating the surface for biocompatibility, this approach has various 
medical applications, as seen with a cardiovascular stent surface [101, 106].  
The ion treatment creates a free radical reservoir on the surface of a material. Surface 
modification can be quantified with plasma kinetics for hydrophilicity and surface energy. 
Chemically, free radicals have an unpaired electron and an associated electron spin. The 
electron spin density created via plasma modification has been quantified previously - 
immediately after deposition and over 8 weeks with electron spin resonance (ESR), in both 
ion-implanted and plasma deposited low-density polyethylene (LDPE) polymer surfaces [103]. 
Kinetic studies have already shown the number of unpaired electrons within the reservoir 
migrating to the surface decrease over-time, either due to migration internally or due to 
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quenching in the bulk/via surface oxidation reactions to environmental exposure. Previous 
studies also show that annealing modified surfaces in a vacuum after ageing restored free 
radical density to its original EPR (electron paramagnetic resonance) intensity within pulse-
biased polymers [145]. Radical density, thickness of plasma coating and covalent binding 
capacity are correlated, furthermore high levels of covalent immobilization of surface 
biomolecules have been observed after a period of 1 year shelf storage [145].  The ability to 
retain an attached biomolecule on the surface of a modified biomaterial is conventionally tested 
after vigorous washing with a detergent - sodium dodecyl sulphate (SDS), and enzyme linked 
immunoabsorbent assays (ELISA) [187]; discussed further alongside surface biocompatibility 
in chapter 4. 
3.1.4.2 Surface coating characterization after plasma modification of biomaterial 
– polymer biocompatibility: 
The microstructure of plasma modified alloy 316L stainless steel surfaces have been 
characterized previously, to investigate surface coating integrity [103], coating composition 
[106] and plasma polymer adhesion to a material surface [145], prior to its applications on a 
metallic coronary stent platform and investigations in vivo [106]. As discussed within this 
chapter, drug eluting stents have several short-comings, DES consist of three major 
components; 1) the drug, 2) the polymer coating and 3) the stent. Generally polymer coatings 
are necessary for drug adherence to stents, with multiple layers to dictate drug kinetics and 
optimal release over time [188]. The polymer coating is consistently optimized after being a 
major limiting factor for DES, owing to in vivo incompatibility; inflammation, and correlating 
neointimal proliferation [188]. Polymer damage/delamination may predispose to in-stent 
restenosis (ISR) due to altered drug kinetics and be potential nidus to sub-acute stent 
thrombosis [175] [189, 190].  
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Several experimental studies have reported problems with coating delamination [191], 
including recent reports on abluminal biodegradable polymer delamination of a biolimus-
eluting stent, delivered through a calcified coronary artery, figure 3.3 [192]. It appears that the 
high levels of deformation developed at the plastic hinge of a stent during its deployment create 
a significant mechanical challenge to achieve an intact bond between the coating and the DES 
[193]. Computational studies in biomedical engineering have investigated the stent-coating 
interface to understand de-bonding during stent deployment, revealing that coatings de-bond 
from the stent surface in tensile regions, during deployment [193, 194]. The process of coating 
delamination is a critical challenge for commercially available DES, as such in vitro 
compression experiments (stent crimping/expansion) show webbing effects, revealing bare 
metal underneath with commercially available Cypher and Taxus (early-generation DES), 
figure 3.4 [190]. The coating delamination simulated in computational studies closely correlate 
to experimental images seen [193]. Investigations conclude the following parameters initiate 
stent coating delamination: 1) coating thickness and stiffness, 2) interface strength between 
coating and stent surface, 3) curvature of DES plastic hinge [193], these parameters must 
therefore be governed during the engineering process of manufacturing coated 
stents/biomaterial surfaces.  
The aims of this work are to 1), modify commercially available ASTM F90 alloy L605 material 
with PAC 2), physical and chemical characterization of modified surface 3), nanotechnological 
characterization of surface coating at an atomic and supramolecular level (nanoindentation) to 
analyse coating roughness, thickness and stiffness i.e. coating integrity 4) Investigate 
microstructure of the cross-sectional interface between coating and stent surface to affirm its 
application in cobalt chromium stent technology.  
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
Free radicals diffuse to the surface and form covalent bonds with physiosorbed proteins. First 
step is the physisorption of a protein to the surface, second step is the direct, linker-free 
covalent bond formation. Imaged modified from Bilek et al [103] 
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Figure 3.3 
 
 
 
 
 
 
 
 
 
Scanning electron microscopy shows damage to polymer of the biolimus-eluting stent that 
would not advance to the lesion (A to D). Note that most of the damage to the polymer is 
delamination of abluminal polymer (B to D). Image from [195] 
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 Figure 3.4 
 
 
Taxus Express deployment separates struts and draws the in-continuity polymer out to form 
‘webs’ after in vitro compression experiments. Polymer is pulled off the stent leaving areas of 
bare metal exposed. Image from Ormiston et al, TCTMD conference 2005 [190] 
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3.2 Materials and Methods 
 
3.2.1 Materials, Equipment, Suppliers and Facilities 
A list of chemicals, reagents, materials and their suppliers are presented in Table 3.3 
Table 3.3 Materials and their suppliers 
 
 
  
Material/Equipment Supplier/Facility 
Agilent Nano Indenter G200 Civil Engineering, University of Sydney, 
Australia 
Atomic Force Microscopy - Pico 
scanning probe microscope (SPM) 
Australian Center for Microscopy and 
Microanalysis, University of Sydney, Australia 
Cobalt chromium alloy L605 sheets  
(ASTM F90, AMS 5537, 250 µm) 
High Temp Metals, Inc. Sylmar, California 
91342, USA 
JEM-2200FS - Transmission Electron 
Micrsocope  
Australian Center for Microscopy and 
Microanalysis, University of Sydney, Australia 
Kruss contact angle goniometer 
(DSA10-Kruss GmbH) 
Applied Physics, University of Sydney, 
Australia 
NanoMap 1000WLI  Interferometry Civil Engineering, University of Sydney, 
Australia 
Plasma Activated Coating (PAC) 
technology 
Applied Physics, University of Sydney, 
Australia 
Point Probe® Plus Force Modulation 
Mode [PPP-FM],  Model A 
Nanosensors, Neuchatel, Switzerland / 
Nucletron Pty. Ltd, Newtown, Sydney, 
Australia 
Surface profilometer  Applied Physics, University of Sydney, 
Australia 
Zeiss Ultra - Field Emission Scanning 
Electron Microscope 
Australian Center for Microscopy and 
Microanalysis, University of Sydney, Australia 
Zeiss Auriga - Focussed Ion Beam – 
Scanning Electron Microscope 
Australian Center for Microscopy and 
Microanalysis, University of Sydney, Australia 
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3.2.2 Surface coating metallic samples  
 
3.2.2.1 Preparation of cobalt chromium alloy L605 
Samples of alloy L605 and alloy 316L SS (10 cm x 8 cm x 0.025 cm) were washed in 3 
reagents; 70% ethanol, acetone, and phosphate buffered saline (PBS) for 15 minutes each, prior 
to PAC deposition. All experiments were carried out with freshly made PAC (used within 2 
weeks) unless stated otherwise.  
3.2.2.2 Synthesis of plasma-activated coating 
The pulsed plasma deposition process described in chapter 2 was slightly altered and optimized 
for PAC deposition in this chapter.  Fused silica (10 cm x 8 cm x 0.05 cm) was also coated 
with the same PAC recipe, as a reference material. The cleaned substrates were mounted onto 
a stainless steel cylindrical ccrf reactor. Base pressure of the system was pumped down to 10-
6-10-5 Torr, a reactive mixture of argon, nitrogen and acetylene plasma introduced in the upper 
part of the reactor. The flow, Q, of each gas for alloy L605 surface; QArgon = 3 sccm, QAcetylene 
= 1 sccm and QNitrogen = 10 sccm (500 v, t = 20mins), is controlled individually, using mass 
flow controllers and maintained constant during deposition (PAC1 recipe). We also trialled a 
second recipe for PAC deposition on alloy L605 sample of similar dimensions (10 cm x 8 cm 
x 0.025 cm) QArgon = 3 sccm, QAcetylene = 2 sccm and QNitrogen = 10 sccm (1000 V, t = 10 mins) 
(PAC2-recipe). Plasma was sustained at a total pressure of 80 mTorr, rf power 50 W and 
deposition time of 10-20 mins. The time of deposition correlated to thickness as specified prior 
to characterization. 
3.2.2.3 Surface Profilometry 
The thickness of the PAC recipe deposited on L605 and reference Si wafer surface was 
measured on the reference material with surface profiler Dektak 3030 (Bruker, Germany).  
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3.2.3 Plasma kinetics – Contact angle goniometry and surface energy 
The sessile drop technique was used for contact angle measurements with DS10 Kruss contact 
angle goniometer (Kruss GmbH, Germany). Within a time-frame of 15 mins post PAC 
deposition (hitherto refered as PAC-L605); the PAC-L605 (0.5 cm x 3 cm, thin strip) was 
placed on the goniometer platform, a water drop was introduced to the surface through a 
microsyringe. The three phase contact line of the drop was made with drop shape analysis 
software (DSA), and measured with a microscope at room temperature, for three liquids; water, 
diiodomethane and formaldehyde respectively. Measurements were conducted within a 15 min 
time-frame post PAC-L605 modification, upto 40,320 mins (4 weeks). For drop shapes that 
were > 90o and < 90o we used equations 3.1 and 3.2 respectively from ref [196], to manually 
compute the contact angles. 
tan 𝜃 =
√2𝑟ℎ−ℎ2
𝑟−ℎ
          for 𝜃 > 90o    
 or                                           
 tan 𝜃 =
2𝑟ℎ
𝑟2− ℎ2
                 for 𝜃 < 90o    
The average contact angle for 5 measurements, at each time point, of two liquids (water and 
diiodomethane) were used to compute correlating surface energy and its components (polar 
and dispersic parts) with regression method/Owens-Wendt-Rabel-Ström kinetic model (DSA 
software), within the same timelines (15 mins – 40,320 mins). Results were compared with a 
similar PAC recipe deposited on alloy 316L SS within a 15 min – 20,160 min (2 week) time-
frame. 
3.2 
3.1 
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3.2.4 Electron Dispersive X-ray Spectroscopy – Surface Chemistry 
Characterization 
Samples of PAC-L605 (recipe 1 and 2) were comparatively imaged alongside alloy L605 bare 
metal (0.8 cm x 0.8 cm), using a Zeiss-Ultra field emission scanning electron microscope 
(Zeiss, Germany). The surface chemistry at the nanoscale was analysed with Aztec software 
(Oxford Instruments, UK) at an acceleration voltage of 2 kV, working distance of 11 mm and 
2000 X-ray cps. The percent weights of the elements predominant on the three different sample 
surfaces were quantified independently for an average of 3 sites on the 3 surfaces.  
3.2.5 Scanning Probe Microscopy (SPM) – Atomic Force Microscopy 
(AFM) 
The multi-purpose scanning probe microscope PicoSPM (Molecular Imaging, Agilent 
Technologies, AZ, USA) was operated in the atomic force microscopy (AFM) mode. Force 
modulation mode AFM was first operated with multipurpose scanner, MAC mode and MAC 
III controller to obtain an AC tune plot for point probe plus –force modulation (PPP-FM) for   
silicon nitride SPM cantilever (225 µm length x 28 µm width x 3µm thickness)(Nanosensors, 
Switzerland). The cantilever was tuned to its resonance frequency (ranged between 45-115 
kHz) to ensure calibration, prior to conducting AFM trace/retrace plots of the modified PAC-
L605 (0.8 x 0.8 cm) metal surface; for surface imaging and roughness measurements. Using 
the plot of resonant frequency, the quality factor (Q) was computed for the cantilevers at half 
power-bandwidth, via equation 3.3 modified from [197], where 𝑓𝑟 is the resonant frequency 
and Δ𝑓 is the half-power bandwidth.  
𝑄 =  
𝑓𝑟
Δ𝑓
 
3.3 
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The Sader method [198] was used to calibrate the spring constant K of the rectangular 
cantilever. The parameter was computed via equation 4 on Ref [198], using an online calibrator 
[199]; i.e no code was written by the user. After cantilever calibration, the surface roughness 
of a PAC-L605 modified material (0.8 x 0.8 cm) was computed with Nanoscope AFM 
instrument (Molecular Imaging, Agilent Technologies, AZ, USA) in the contact force 
modulation mode, with a 20 µm scanner for imaging in air. Surface topographical 3D images 
and raw deflection images of PAC surfaces, obtained by AFM were constructed using the 
image processing software Nanotec Lab WSxM version 4.0 Beta 8.0 (Nanotec Electronica) 
[200].  The nanoscale surface roughness (RMS) of PAC-L605 surface at 20 x 20 um areas, 
were computed via equation 5 in [201], using automated WSxM version 4.0 nanotechnology 
app [200]. Frequency distribution of the surface roughness was also simulated using same 
software. Images of the surface were obtained at five different locations of PAC L605 material 
via which the average RMS roughness was determined automatically for the modified material. 
3.2.6 Nanoindentation – Surface Stiffness 
Surface stiffness of a modified PAC L605 sample surface was calculated and compared to a 
sample of bare cobalt chromium alloy L605 (2 x 1 x 0.05 cm) by force-controlled 
nanoindentation, using a Hysitron Triboindenter (G200, Agilent) fitted with a Berkovich 
diamond indenter (TB22122, m0 24.7772) with a radius of curvature R. Nanoindentation was 
conducted at a maximum load of 50 mN for 100 indents, at randomly chosen positions, for 
each surface. The indentations were made under the same conditions to confirm uniformity of 
mechanical properties of the entire coating. Surface stiffness was measured as a log function 
of the unload depth (D) (nm) vs. load, as a function of force (F) mN, equation 3.4 from [202] 
  
𝑆 =  
∆𝐹
∆𝐷
 3.4 
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The unloading displacement for 21 indentations were batch processed using a Matlab 
Mathworks version 8.5 (MA, USA) algorithm to calculate surface stiffness; developed by Dr. 
Yixiang Gan’s group, Civil Engineering, University of Sydney (Appendix A).  
3.2.7 NanoMap White Light Interferometer (WLI) – Surface Roughness  
A second method was trialled for surface roughness measurements of a modified PAC-L605 
surface using NanoMap-1000WLI 3D optical profilometer (AEP technology, Santa Clara, CA, 
USA). The PAC-L605 sample (0.6 cm x 0.6 cm) was mounted to computer controlled sample 
stage, located on a vibration isolated table (air pressure controlled at 1 atm). The sample was 
magnified with a 10 x objective, optical microscope. Field of view was chosen using the 
computer controlled motorized NanoMap Optical software (serial #500226), for a 100 µm Z 
range, and 1 mm x 1 mm scanning area of sample at a 1 x scan speed run.  The optical image 
obtained was opened in image software PIPS 6.0.14, to generate a 3D image of topographical 
data with Zero background and global levelling. The optical image was next opened in 
Gwyddion 2.41 software for SPM data analysis (Dept. of Nanometrology, Czech Metrology 
Institute), using the automated ‘Statistical quantities’ tool, the roughness measurements (RMS) 
for sample surface at 5 different surfaces were calculated and averaged. 
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3.2.8 Tripod Polishing and Focussed Ion Beam (FIB) milling – preparation 
of thin metal PAC-L605 lamellae 
 
A cross-section of the modified PACL605 metal was prepared for TEM using tripod polishing 
and focussed ion beam milling (FIB). The metal was sectioned to obtain a small sample 
(approx. 3mm x 3 mm x 2 mm), progressively thinned down to 5-10 µm and 20 nm using the 
two techniques. For tripod polishing, the metal sample was fixed to a Pyrex tripod stage, with 
a piece of Si wafer (5 mm x 5 mm x 0.5 mm) attached to cover the modified surface. The 
sample was initially ground in turn on 30, 9, 3 µm diamond films (approx. 60 mins in total). 
The specimen was removed from the Pyrex stage and cleaned carefully in acetone to remove 
the thin sample of interest with a 5-10 µm thickness. The sample was mounted to a copper half-
grid for focussed ion beam (FIB) milling. 
The sample material mounted on a half-grid was inserted vertically to the FIB chamber (Zeiss, 
Auriga). Before milling, a platinum (Pt) line was deposited over the area of interest, marking 
position of target area.  An initial incidence angle of ± 4o was used in perpendicular exposure 
of the sample at a 30 kV milling voltage and 25 pA current, for sample milling down to about 
150 nm thickness. The incidence angle was increased to ± 6o at a voltage of 5 kV and 10 pA, 
until a further thickness of 80 nm was achieved. Residual milling to obtain a cross-section of 
20 nm thickness was conducted at ± 8o, 5 kV for remaining material.  The final electron 
transparent lamellae seen from top looks like a cross bar in the letter ‘H’, referred to as the H-
bar technique during lift out and transfer to HRTEM. The electron transparent 20 nm PAC-
L605 sample lamellae cross-section prepared within FIB was lifted out, and attached to a 
copper half-grid for high resolution transmission electron microscopy (HRTEM). 
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3.2.9 High Resolution Transmission Electron Microscopy (HRTEM) – 
Metal Coating Interface Analysis 
The FIB sample was placed on the JEOL double tilt high background TEM sample holder, for 
JEM-2200 FS HRTEM - (JEOL, San Francisco, CA, USA). The 20 nm thin PAC-L605 
lamellae cross-section was imaged at 200 kV field emission gun acceleration voltage, 95.5 µA 
(dark current), and 52.0 µA (Emission current) up to 1.1 Å atomic resolution and 1.2 M 
magnification. The alloy L605 bare metal, beneath the PAC deposition was imaged separately 
to visualize the alloy microstructure with selected area electron diffraction (SAED). We 
obtained an inverse fast Fourier transform (IFFT) pseudo colour image of the interface imaged 
for PAC-L605 cross section, and conducted an electron energy loss spectrum (EELS) with 
zero-loss peak (ZLP) omega filter, for quick reliable measurement of local thickness to verify 
interface chemical composition. The thickness was calculated as mfp*In(I/I0), where mfp is the 
mean free path of electron inelastic scattering, tabulated for most elemental solids and oxides 
(Gatan Inc, Japan) [203], and I/ I0 are integrals under the whole spectrum and under the ZLP, 
respectively.   
3.2.10 Statistics 
Data were analyzed for statistical significance as described in Chapter 2.2.15.  
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3.3 Results 
 
3.3.1 Surface coating thickness 
The surface coating profilometer trace for PAC-L605 modification, indicated a 20 nm surface 
thickness (details provided by PhD candidate Mr. Miguel Santos, Applied and Plasma 
Physics, University of Sydney).  
3.3.2 Plasma Kinetics 
The initial water contact angle, 15 mins post PAC-L605 modification was 44.4o±3.41, by 2 
weeks the contact angle increased to 89.98 o±3.78, by 4 weeks to 92.96o±1.38 (figure 3.5 A). 
Correlating surface energy calculated 15 mins post PAC deposition was 62.35±2.43 mJ/m2, by 
2 weeks 32.22±2.88 mJ/m2, and by 4 weeks 28.96±1.20 mJ/m2. Results were compared with a 
similar PAC recipe deposited on alloy 316L SS within a 15 min – 20,160 min (2 week) time-
frame (figure 3.5B). The water contact angle for PAC-316LSS was 57.86 o±0.48, by two weeks 
the contact angle increased to 84.66 o ±0.33. Correlating surface energy calculated 15 mins post 
PAC-316LSS deposition was 52.02±0.05 mJ/m2 and decreased to 37.68±0.01 mJ/m2 at two 
weeks, summarized in Table 3.4. Figure 3.6 illustrates wetting angles for both water and 
diiodomethane, used to calculate surface energy of PAC-L605, initially very low at 15 mins 
post PAC deposition (44.5o and 39.48o respectively), increasing up to 89.98o for water and 
58.9o for diiodomethane within 2 weeks. Figure 3.7 illustrates variation of the components of 
surface energy (polar+dispersive) summing up total surface energy. The polar energy 
decreased significantly over time from 22.62 mJ/m2 to 3.15 mJ/m2, although the dispersive part 
did not change much from 39.622 mJ/m2 to 29.11 mJ/m2. 
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3.3.3 Surface Chemical Composition 
Initially the chemical composition of stainless steel alloy 316L was compared to cobalt 
chromium alloy L605 (ASTM F90). Alloy 316L SS had a predominant Iron (Fe) percentage 
weight (48.50%), in contrast alloy L605 had reduced Fe content (1.77%) and significantly high 
percent weight Cobalt (Co) (34.96%).  In this chapter, we compared the surface chemistry of 
PAC recipe 1 (C-1, N-10, 500 V, t – 20 mins), PAC recipe 2 (C-2, N-10, 1000 V, t - 10 mins) 
and L605. The PAC-L605 modified surface of our choice had a predominant Nitrogen (N) 
(3.033%) and Carbon (C) peak (9.20%) compared to the alloy L605 surface, Figure 3.8.  
3.3.4 Surface roughness – Atomic Force Microscopy and NanoMap white 
light interferometer (WLI) technique 
Surface roughness was measured for 5 separate positions on PAC-L605 modified surfaces at 
20 x 20 µm areas. Prior to imaging the Si3N4 (silicon nitride) cantilevers were calibrated, the Q 
factor calculated as 383, from the resonant frequency peak of 76.5 kHz obtained from the AC 
tune plot, shown in figure 3.9. The force constant K of the cantilever was computed as 5.04 
N/m, using the online Sader method. The AFM 3D surface topography and corresponding 
deflection images are seen in figure 3.10. The frequency profile simulated for surface 
roughness via WxSM Nanotec software fitted Gaussian function, the average roughness is 
69.19 nm for RMS roughness measured for modified surfaces at a 20 µm x 20 µm areas, figure 
3.10. 
Similarly surface roughness was measured for 5-10 separate positions on the PAC-L605 
modified surface at 100 µm x 100 µm areas with NanoMap WLI technique. The NanoMap 3D 
topography images constructed are seen in figure 3.11. The average roughness RMS computed 
with the WLI mechanical profiler Gwyddion software was 0.272 µm.
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
(A) Water contact angle for PAC-L605, increased over a time-frame of 15 mins - 40,320 mins to plateau, correlating surface energy decreased 
over a time-frame of 15 mins – 40,320 mins to plateau.  
(B) The PAC-L605 results were compared with PAC-316LSS, to indicate similar trends for both plasma modified biomaterials, over a time-
frame of 15 mins – 20,160 mins for water contact angle and surface energy respectively.  
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Figure 3.6 
 
 
Water (H2O) and diiodomethane (CH2I2) of PAC-L605 with time after plasma treatment, until 
2 weeks (20,160 mins). Contact angle recovers shortly after plasma treatment.   
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Figure 3.7 
 
 
 
Variation of total surface energy and its parts (polar and dispersive) - 2 weeks after plasma 
treatment (20,160 mins) for PAC-L605. 
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Table 3.4 Comparative water contact angle and surface energy for PAC modified 
biomaterial alloys L605 and 316LSS within a time-frame of 15 min – 20,160 mins (2 
weeks) and/or 40,320 mins (4 weeks). 
Biomaterial 15 mins 20,160 mins 40,320 mins 15 mins 20,160 mins 40,320 mins
PAC-L605 44.4o±3.41 89.98o±3.78 92.96o±1.38 62.35±2.43 32.22±2.88 28.96±1.20
PAC-316L SS 57.86o±0.48 84.66o±0.33 52.02±0.05 37.68±0.01
Surface hydrophilicity Surface energy mJ/m2
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Figure 3.8 
(A) Surface composition of cobalt chromium alloy L605 (ASTM F90) 
and stainless steel alloy 316LSS (ASTM F138) – showing predominant Co and 
Fe peaks respectively.  
(B) Plasma recipe 1 (C-1, N-10, t=20 mins, 500 V), modified PAC-L605 
surfaces show predominant C and N peaks, compared to bare metal alloy L605 
and PAC-2 (C-2, N-10, t=10 mins, 1000 V). 
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Figure 3.9 
 
 
The AC tune plot for PPP-FM Silicon nitride cantilever indicate a resonance frequency of 76.5 
kHz. The Q factor was calculated as 383, representative of the sharp peak. The force constant 
K was calculated as 5.04 N/m (Sader method).   
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Figure 3.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The AFM images were traced/retraced within a 20 um x 20 um area, converted to 3 D images of surface topography. Frequency distribution 
simulated for surface roughness measurements, fitted a Gaussian function, representative of isotropic surface engineering. The average roughness 
for each surface topography is represented with roughness profile (WSxM software, Nanotec Electronic). 
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Figure 3.11 
 
 
 
The NanoMapWLI images of PAC-L605 were imaged at 10 x objective, within a 100 µm x 
100 µm scanning area, the images were converted to 3D topographical surface representations 
(Gwyddion software) and roughness measured with statistical tool (measurements not shown). 
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3.3.5 Nanoindentation – Surface stiffness 
The surface stiffness of a 20 nm PAC-L605 coating was compared to the surface of an alloy 
L605 bare metal. The maximum load indentation was 50 mN. Figure 3.12 shows the surface 
stiffness at lowest indentation load 0.19 mN (~2 mN), to be 0.0036 mN/nm for PAC, and the 
comparative surface stiffness at lowest load indentation for bare metal alloy L605 to be 0.051 
mN/nm. With increasing indentation load, surface stiffness increased similarly for both 
surfaces. At maximum load 50 mN, surface stiffness for PAC-L605 was 0.013 (0.012492) 
mN/nm and 0.013 (0.012652) mN/nm for L605.   
3.3.6 The PAC-L605 coating interface preparation for HRTEM analysis 
The tripod polished sample resulted in a smooth, 5-10 µm thick cross section of PAC-L605 
interface. Further milling of the sample via FIB resulted in a 20 nm thick cross section of PAC-
L605, creating an electron transparent lamellae suitable for interface imaging with HRTEM, 
figure 3.13 A, B. Figure 3.14 A shows HRTEM image at the cross-sectional interface of a 
plasma polymer deposited on a crystalline cobalt chromium material. The white (electron 
transparent) layer is PAC, which was capped with a thin platinum layer during TEM cross-
section preparation via FIB (not shown). The inverse fast Fourier transform (IFFT) image of 
the PAC-L605 interface showed a distinct buffer layer/ion stitching at PAC-metal interface 
(green), as described in theory for PAC deposition and free radical surface functionalization  
[103]in figure 3.14 B. The plasma coating (yellow) adheres to alloy L605 (blue) via ionic 
stitching/buffer layer (green), at the metal-plasma interface. Figure 3.15 shows the bare, 
crystalline cobalt chromium selectively imaged via electron diffraction to show twinning 
between grain boundaries in the material matrix, previously only described via SEM imaging 
[166]. The EELS indicated overall thickness of 47.84 nm for platinum (Pt), 35 nm for carbon 
(C), and 66.67 nm for cobalt (Co), confirming surface elemental thickness/composition as seen 
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on TEM image, figure 3.16. For simplicity of presentation we colour segregated three regions 
of the material interface to represent the materials on a TEM image identified via EELS (spectra 
not included for simplicity).   
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Figure 3.12 
 
Nanoindentation for surface stiffness conducted on a 20 nm PAC L605 coating vs. alloy L605 
surface, for 20/100 indents each. The maximum load was 50 mN, minimum load 0.19 mN. The 
surface stiffness computed for an average 20 indents show PAC-L605 surface stiffness is lesser 
than bare metal alloy L605 stiffness at first (at 0.19 mN PAC L605 is 0.0036 mN/nm vs bare 
alloy L605 0.051 mN/nm). With increasing load, stiffness of the coating remains the same as 
metal alloy, confirming integrity and coating non-delamination at a force of 50 mN. 
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Figure 3.13 
A) Sample preparation for HRTEM: Smoothly polished PAC-L605 sample on Pyrex stage 
of tripod (10 x mag), between two Si wafers, with copper grid (O) for thickness 
approximation.  
B) The FIB milled PAC-L605 sample, with two regions at the modified material interface, 
milled to 20 nm thickness (red arrows, 2.3 K x mag, 5 kV).   
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Figure 3.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Cross section of PAC-L605 surface: HRTEM image with white (electron transparent) polymer deposit, crystal metal 
alloy (black) and ionic stitching at interface (grey).  
B) Corresponding IFFT image shows plasma coating (yellow) adheres to alloy L605 (blue) via ionic stitching buffer layer 
(green) at metal-interface (1.2 M x mag, 1.1 Å resolution, 200 kV) 
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Figure 3.15 
 
Selected area electron diffraction of the alloy L605 cobalt chromium metal matrix; i.e. region 
below the thin cross-section of PAC-L605 interface. The material matrix shows presence of 
crystal twinning as predicted for metal alloy microstructure.  
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Figure 3.16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical composition of the PAC-L605 cross sectional interface represented via colour 
segregation on a TEM image (2.3 K x Mag). Thickness of elements were confirmed with 
electron energy loss spectra EELS (spectra not represented).  
 
 
Pt 47.65 nm 
C 35 nm 
Co 66.67 nm 
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3.4 Discussion 
Several aspects of the plasma activated coating for use on alloy L605 cobalt chromium stent 
were characterized within this chapter. These include physical and chemical characterization 
of the surface coating, micro/nanoscale assessment of surface roughness and stiffness, 
mechanical stability of modified material, and coating integrity at PAC-L605 interface to 
prevent delamination; as necessary for a robust coronary stent coating. Biofunctionalization of 
the surface coating will be addressed in chapter 4. This is a first study investigating PAC as a 
surface coating on cobalt chromium flat metal alloy L605. Key outcomes of this study include 
physical, chemical characterization to confirm surface modification at the microscale, 
characterization of PAC-L605 interface via nanotechnology to explain unique PAC 
technology, support non-delaminating coating technique, and its suitability for alloy L605 
coronary stent applications.  
3.4.1 Investigating PAC properties on alloy L605. 
The plasma chemical composition was similar to the coating deposited on an alloy 316L 
stainless steel and coronary stent platform, discussed in chapter 2, although a coating time of 
20 min was utilized, for a 20 nm coating, at a deposition rate of 1 nm/min. Electron Dispersive 
X-ray spectroscopy (EDS) is a surface specific technique, allowing analysis of the chemical 
composition with a penetration depth of as little as 5 Ǻ [204]. The qualitative and quantitative 
microanalytical X-ray technique provides information on the chemical composition of a 
sample, for elements with atomic number (Z). The electron beam of 2 keV was focussed on the 
sample surface in field emission scanning electron microscopy (FESEM). We used a very low 
accelerating voltage of 2 kV to ensure electrons from the primary beam only penetrated the 
modified surface of material, to interact with atoms of the surface and not underlying 
biomaterial - to obtain X-ray intensities specific to surface coating chemical composition. The 
interaction volume of a low acceleration voltage provided information of the surface coating 
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alone, indicating a higher peak for percent element weight of both carbon and nitrogen on the 
modified PAC-L605 surfaces compared to bare alloy L605. The purpose of plasma assisted 
surface modification is to change the physical, chemical or biological properties of a material 
for biocompatibility. Physical properties of the surface modification include variation to 
surface texture, roughness and wettability, which significantly influence the behaviour of 
material with fluids and vasculature, in vivo. Chemical and biological surface properties 
influence the process of absorption and biomedical reaction investigated in chapters 4-5.  
We focused on the physical and mechanical characteristic changes of a modified metal alloy 
surface at micro scale, including surface roughness and surface hydrophilicity. Earlier studies 
indicate high surface roughness decreased spreading of a liquid on low energy solids [201, 
205]. Emerging technologies on surface engineering technology for MEMS and lab-on-chip 
devices have led to a rapid growth of mechanical and electrical fabricating systems at the 
microscopic and nanoscale levels [206]. Roughness change of a solid material substrate is 
usually realized by material removal and adding processes, i.e. simultaneous etching and thin 
film deposition, as well as energetic ion implantation [145, 207]. When viewed at the nanoscale 
via AFM and WLI optical profilometry, surface roughness of PAC was immediately apparent. 
The inconsistent, isotropic micro-scale surface coating is attributed to the proprietary plasma 
polymerization process of deposition and consecutive etching [145]. The PAC-L605 surface 
developed in our study, enhance favourable mechanical adhesion properties for in vivo 
applications, and increase overall amount of surface area for bearing loads.  
Of the two techniques trialled, NanoMap WLI technique resulted in faster, more accurate 
surface imaging within a larger surface area. The roughness analyses were computed in the 
nano/micro scale for AFM and NanoMap respectively. Additionally, surface imaging with 
AFM required calibration of Si3N4 cantilevers, which showed a sharp resonant peak at 76.5 Hz 
and a correspondingly high Q factor, these parameters were used to compute force constant of 
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the cantilevers, for accurate calibration prior to imaging. NanoMap ensured complete noise 
elimination for high sensitivity imaging, which was a significant limitation with AFM. The 
maximum possible scanning area with AFM was only within the 20 μm x 20 μm range, which 
did not allow for wide-range surface mapping, while NanoMap allowed larger scanning area 
of 100 µm x 100 µm utilized (up to 150 mm).  AFM images limited the ability to accurately 
estimate surface roughness of PAC-L605, which was higher. It was also visually apparent that 
PAC surface coating of 20 nm thickness, had a micro scale average roughness, as imaged in 
figures 3.10-11.  For most engineering surfaces contact type instruments such as optical 
profilometry based on the physical principle of the wave properties of light, is widely used. We 
therefore chose NanoMap WLI for future roughness measurements of plasma modified 
biomaterial.  
Surface roughness has a strong influence on wetting characteristics of a modified material. 
Water contact angles as high as 150o have been observed on hydrophobic polymer surfaces 
such as PTFE (polytetrafluoroethylene) and PE (polyethylene) [201]. The untreated alloy L605 
is also strongly hydrophobic with a water drop wetting angle approximating >100o. 
Immediately after plasma treatment, the water contact angle decreased significantly, near 45o, 
indicative of a hydrophilic surface modification. The same sharp changes were observed for 
wetting angles of formamide and diiodomethane. In correlation, the total surface energy 
increased to ~65 mJ/m2 immediately after PAC deposition (figure 3.5 A). Similar trends were 
observed within a 2 week time-frame for PAC-316LSS surfaces - compared to PACL605; in 
relation to both parameters of surface hydrophilicity measured (figure 3.5 B). The initial 
variation for wetting angles of water and diiodomethane were similar, although by 2 weeks, 
values changed significantly (figure 3.6). Random variation in wetting angle for the two liquids 
at comparatively similar early time-frames, is due to inconsistent surface roughness. Most 
realistic engineering surfaces are random, either isotropic or anisotropic; since roughness of 
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our PAC-L605 engineered surfaces fit a gaussian profile (figure 3.10), they are isotropic [208]. 
Furthermore, contributions of polar and dispersive components to total surface energy also 
varied with time; whilst the polar energy decreased significantly, the dispersive part did not 
vary similarly with time (figure 3.7). The random variations observed, could also be due in part 
to isotropic surface engineering. The dispersive component of surface energy represents 
surface oxidation, and polar component represents surface free radicals, with time of exposure 
to air [103]. The plasma kinetics study had a similar time-line and experimental set up to 
Kondyurin et al [209].   
Chemical reactions are a common process in surface engineering, with ability to change surface 
roughness of materials by removing or generating a new material layer on the substrate via 
microfabrication [210, 211]. The decrease in wetting angle and increased surface free energy, 
post PAC modification of alloy L605, is caused by chemical transformations on the plasma 
coated surface, as verified with EDS surface chemistry analysis, and visualized via imaging 
with AFM/NanoMap at the Nano/micro scale. With time, surface hydrophilicity decreases, in 
response to changes to surface chemistry of the coating [103]. As Bilek et al explains with 
previous electron spin resonance (ESR) studies; surface free radicals are quenched by oxidation 
during exposure to air, resulting in a plateau of the oxygen group. As observed herein with 
dispersive surface energy calculations. The ageing surface chemistry can be verified further 
with EDS as before, or with X-ray photoelectron spectroscopy on a metal. Surface energy 
values for PAC-L605 stabilize at a higher value than the hydrophobic untreated alloy L605.  
Surface hydrophilicity is important to biofunctionalize a stent coating, since hydrophobicity 
influences blood viscosity [212] and interaction of blood/protein components on surfaces, 
whilst extreme hydrophilicity interacts poorly with proteins and cells [213]. Mildly hydrophilic 
surfaces are therefore at an advantage in vivo, as they display favourable interactions with 
proteins, cells and blood, and decrease platelet adhesion as seen with polymer/surface 
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modifications of stainless steel stents [106, 214]. Several commercially available stent surfaces 
such as PBMA (Cypher), SIBS (Taxus) PVDF-HFP (Xience V) are comprised of hydrophobic 
polymers with contact angles in the range of 112o, 118o, and 129o respectively. Even the 
commercially available stents termed to have ‘hydrophilic’ polymer surfaces, such PC 
(Endeavor) and BioLinx (Resolute) have contact angles in the range of 81o and 94o respectively 
[215]; well above surface hydrophilicity observed on PAC-L605 or PAC-316LSS surfaces 
herein. Polymer biocompatibility for DES is essential; for example the vascular response to 
inflammation induced by residual polymer can overwhelm biological effects of drug elution, 
resulting in late formation of neointima, as seen with CypherTM sirolimus eluting stents [216]. 
Although BioLinx stent polymer has slightly higher hydrophilicity in comparison to Cypher 
and shows lower inflammation scores, the effects could be due to extended period of drug 
elution (180 days), than polymer biocompatibility [215]. Despite hydrophobic PVD-HPF 
copolymer,  Xience VTM stents have shown safety for over 2 years in preclinical [217] and 
clinical assessments [218]. Of note, the coronary stent system has an underlying thin-strut 
cobalt chromium coronary stent, which as mentioned on introduction and seen in assessments 
[217, 218], may have contributed to maintain lowered restenosis outcomes after the first 120 
days of everolimus drug elution.  
3.4.2 Unique features of proprietary plasma technology suited for a stent 
coating 
Atherosclerotic vessels treated via vascular stents, commonly involve fatty lipid deposits, 
plaques and arterial calcification. For revascularization, stents are expanded in vivo, and 
commonly undergo a process of crimping and expansion. Polymer coatings on DES undergo 
large strains and must remain as a permanent scaffold, these mechanical challenges must be 
taken into account to ensure long-term safety during DES device development and deployment 
[219]. Clinically, new generation biolimus-eluting stents have displayed inability to withstand 
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certain complications/challenges; resulting in damage to the abluminal polymer and stent 
replacement [192]. Polymer layer integrity has been a persistent concern with commercially 
available stents, as has been observed with BiodivYsio, Taxus and Cypher stents via SEM 
analysis [189, 190]. Several negative clinical complications can result from stent coating failure 
in vivo, including increased risk of thrombosis, interruptions to pharmacokinetics of a drug 
dose released by the polymer coating, inflammatory response as well as micro embolisms [193, 
220].  To adequately design stent coating that withstand large deformations; mechanisms 
underlying delamination must be understood. Parameters governing delamination initiation 
include; coating thickness, stiffness and interface strength/integrity between the coating and 
stent surface [193].  
Indentation, a traditional method is used to quantify mechanical properties of materials as well 
as thin films or coatings [221, 222]. The phenomena allows to diagnose surface 
cracking/delamination  of hard, brittle surfaces, since they cause jumps, or kinks in the raw 
data of load vs. depth [223]. Complexities are also generated since investigated systems are 
usually composed of at least two materials with different mechanical properties. Failure of 
integrating different systems include plastic deformation, cracking of the coating, or failure of 
the interface [221]. The main emphasis in this investigation was to extract quantitative data of 
the surface stiffness post PAC modification in comparison to bare metal alloy L605. The PAC 
stiffness was lower than alloy L605, at initial minimum load (0.20 mN), since it is composed 
of a 20 nm thick, soft coating. However, with increasing load, the coating does not delaminate 
or crack; instead the PAC-L605 vs. L605 surface stiffness shows similarity from 3 mN onwards 
to 50 mN, indicating the coating is well adhered to underlying metal surface.  There were no 
jumps, plateaus or kinks in the load-displacement raw data, used to compute surface stiffness 
(figure 3.12). 
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We chose to include unloading displacement (nm) for 21 indentations only (100-79; equally 
for both surfaces) for stiffness calculations, since they provided sufficient detail of surface 
overall. Incidentally, for unloading displacement data at ~60 indents, the Matlab indentation 
code generated negative values of surface stiffness, for both alloy L605 and PAC-L605 
surfaces. We ruled out coating delamination as a cause of the occurrence since the phenomenon 
was common to both surfaces. It appears that, since our original sample is a 0.8 cm x 0.8 cm x 
0.025 cm flat metal for nanoindentation tests, the surface may have bent after the berkovich tip 
passed the 60th indentation, along both PAC-L605 and alloy L605 surfaces. Resulting in 
negative values, not incorporated herein. Since stiffness is directly proportional to young’s 
modulus (E), this parameter E, can be calculated, according to the Oliver-Pharr method [202].  
To observe cross-sectional microstructure, and reconfirm individual layer thickness of 
deposited coating at interface, we characterized the PAC-L605 interface with high resolution 
transmission electron microscopy (HRTEM) and electron energy loss spectroscopy (EELS).   
The cross-sectional TEM sample was methodically prepared by grinding down a 250 µm thick 
PAC-L605 material to 10-15 µm via tripod polishing, the remainder milled with FIB to create 
a 20 nm thick electron transparent metal lamellae for HRTEM (figure 3.13). The TEM image 
of the PAC-L605 interface at high magnification and high resolution, showed presence of a 
distinct ionic buffer layer at the interface, detailing ionic stitching attachment of PAC to the 
metal surface, also clearly seen with the fast inverse Fourier transform (IFFT) image, in colour, 
(figure 3.14 A, B). This explains in visual detail the non-delaminating nature of PAC, as 
theorized in applied/plasma physics [187, 224] and computed via nanoindentation in this study.  
Further, we characterized the alloy L605 material, just beneath the cross-section of PAC-L605 
interface/lamellae, with selected area electron diffraction (SAED), to obtain atomic level detail 
of the cobalt chromium metal matrix. Figure 3.15 is representative of the characteristic 
twinning between grain boundaries of cobalt chromium crystals, with similarity to SEM images 
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of grain boundary microstructure previously observed for alloy L605 [166]. The metal alloy 
remains unchanged post-surface modification. Finally, we used electron energy loss 
spectroscopy (EELS) to reconfirm individual layer thickness, and chemical elements present 
in the cross-section of PAC-L605 interface. The thickness calculated via electron inelastic 
scattering (mean free path – MFP), and interface elements at the PAC-L605 cross-section were 
re-confirmed as platinum (deposited during FIB milling), carbon (acetylene plasma 
polymerization), cobalt (bare metal alloy, underlying material) (figure 3.16). 
The combined results for 1) PAC surface stiffness preventing delamination and 2) integrity of 
coating interface observed with HRTEM, also in support of (1), re-establish the suitability of 
PAC as a non-delaminating, robust stent coating on alloy L605 cobalt chromium.  
 
  
 108 
 
3.5 Conclusion 
 
Overall, these results demonstrate that modification of a commercially available alloy L605 
material with PAC, alters surface chemistry and improves surface hydrophilicity. 
Micro/nanostructured surfaces were developed with the intention of improving biomimicry 
during interactions with micro/nanoscale living tissue in vivo. Isotropic roughness at the 
microscale observed imparts surface ability to bear loads, and interact favourably with 
biological molecules (investigated in vitro in chapters 4-5). We showed here for the first time 
via coating stiffness, the surface modification is non-brittle, soft and strongly adhered to 
underlying metal alloy L605. The interface HRTEM cross-section, also detailed for the first 
time in this study, showed robust adhesion of PAC to alloy L605, via ionic stitching. This PAC 
will be used for all further experiments.  
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Chapter 4 – Plasma based biofunctionalization of alloy 
L605 
 
4.1 Introduction 
 
4.1.1 Micro and Nanotechnology in Tissue Engineering Materials 
The rationale to develop micro/nanostructured biomaterials for tissue engineering is for 
improved interaction with natural tissues. Natural tissues and associated extra cellular matrix 
are fundamentally nanostructures in composition themselves (cells are in the microscale, 
compared to nanoscale proteins) [225]. A complex set of interactions control cell proliferation, 
differentiation and apoptosis pathways, resulting in cell fates [226]. Evaluating biological 
design from an engineering perspective aid researchers develop surfaces for improved 
biomimicry and biocompatibility, for clinical applications.  
4.1.1.1 Biomaterial – Cell interactions 
Intracellular structural architecture of the cell or the cell cytoskeleton, modulates cellular 
responses at the microscale, including transport and binding-reactions. Generally structural 
behaviour of cardiovascular, endothelial, smooth muscle cells (SMC) as well as neural and 
osteoclast cells on a biomaterial, are heavily influenced by the filament systems of the 
cytoskeleton [227]. The initial anchorage between cell and biomaterial involves extracellular 
matrix proteins, intracellular cytoskeleton and cell membrane proteins [228]. Successful cell-
material interaction is represented by cell attachment, proliferation and spreading, to evaluate 
biocompatibility of materials for tissue-engineering applications [229].  
4.1.1.2 Biomaterial – Protein interactions 
Proteins are the first biological entities to interact with a biomaterial surface post-implantation, 
and adsorb on hydrophobic surfaces, as seen with fibrinogen and fibronectin [230]. Protein-
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surface interactions are fundamentally responsible for the biocompatibility or lack thereof of 
implant surfaces, in vivo. Mechanistically, proteins absorb rapidly to implant materials; 
saturating surfaces to prevent healthy interactions with living cells. The key to controlling 
positive cellular responses lie in the ability to control the orientation, and conformation of 
proteins attached on a biomaterial; a challenging issue in tissue engineering, given synthetic 
biomaterials are not generally biocompatible in composition [231]. The adsorptive behaviour 
of proteins highly depend on surface properties of a biomaterial, including topography, 
hydrophilicity, surface energy, charge and surface chemistry, characterized in chapter 3 (for 
PAC-L605). A core limitation at present of protein-biomaterial anchorage is the inability to 
control the amount, conformation and type of protein adsorbed in vivo. A vascular device such 
as a stent, capable of immobilizing proteins, should have a biocompatible surface, bind a high 
concentration of candidate protein - in their native conformation, and retain protein 
functionality as seen with PAC-316LSS stents in vivo, in chapter 2.  
4.1.1.3 Biomaterial – Blood interactions 
Surface bioengineering and roughness parameters regulate material/device hemocompatibility 
[212]. The immediate biological response after medical device implantation is blood 
coagulation, which precedes wound healing, in vivo. However, a synthetic material surface can 
activate intrinsic/extrinsic coagulation as well as complement system, resulting in unnecessary 
coagulation and inflammation at the implant/tissue interface, schematically represented in 
figure 4.1 [232]. The adverse thrombogenic effects after device implantation although 
prevented with aggressive dual antiplatelet and/or anticoagulation therapy, increases 
susceptibility to inconsistent bleeding risks [135, 185]. Fundamentally, surface bound 
fibrinogen and platelet activation are markers of coagulation cascade initiation [232]. Surfaces 
inert to platelet adhesion and activation of coagulation achieved through surface engineering, 
may potentially avert an adverse biological response [233].  
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A biofunctionalized material facilitates bioactive attachment of proteins, promotes cell 
proliferation and thromboresistance. Surface engineered materials are investigated in vitro, 
prior to transferring modification technique to an implantable device for pre-clinical testing, to 
decide suitability for clinical applications. Practically, basic biological responses of a modified 
biomaterial are evaluated by simulating clinical conditions in vitro [234, 235].  
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coagulation cascade: an overview of the intrinsic, extrinsic and common coagulation 
pathways. Factors activated via platelets are denoted by circles ●, factors activated via 
complement proteins denoted by open squares □ (Image from Waterhouse et al [232]). 
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4.1.2 Facilitating stent endothelialization  
A single layer of endothelial cells (ECs) known as the endothelium, line the vascular wall 
lumen and maintain vascular homeostasis [236].  Stent implantation causes significant injury 
to the endothelium and vascular wall, resulting in inflammation, as well as neointimal 
hyperplasia (NIH), detailed in chapter 2 [237]. The process of endothelium repair depends on 
migration of surrounding mature ECs, and circulating endothelial progenitor cells (EPCs) to 
site of injury for endothelialization. DES therapy attenuates the natural response to damage; 
causing acute inflammation and subsequent NIH at site of implantation  Accelerating re-
endothelialization post stent implantation is a suitable strategy to assist natural process of 
repair, as it reduces NIH and late stent thrombosis (LST) exhibited [114, 183, 237]. Many 
clinical investigations have therefore examined assisted endothelialization at the host-implant 
interface for cardiovascular stents [76].  
Cultured cells are regularly used in vitro, to investigate cell-biomaterial interactions such as 
cell adhesion and proliferation [105, 238]. The choice of human umbilical vein endothelial 
cells (HUVECs) and human coronary artery endothelial cells (HCAECs) have been verified 
previously for biomaterial testing [239], as ECs play a fundamental role in vivo at the host-
implant surface. Endothelialization assists 3 key processes of device biointegration including; 
1) formation of neointima, 2) reduced thrombogenicity and 3) device patency [239].  Specific 
in vitro studies for enhanced biomaterial-cell interactions include; HUVEC culture on titanium 
oxide films modified via plasma immersion ion implantation (PIII) [240], plasma treated PET 
(polyethylene terephthalate) and PTFE (polytetrafluoroethylene) with human ECs [241], 
surface-modified titanium alloys with passage2/3 HUVECs [239] and studies with plasma 
modified alloy 316LSS for assisted endothelialization [138]. Overall, surface-engineered 
biomaterials show superior cell-interactions, compared to their original (pre-modified), 
hydrophobic state. Protein adsorption on a hydrophobic material surface may enhance EC 
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adhesion, but the process requires controlled protein adsorption with their bioactive sites 
exposed, and is therefore tedious [242]. 
4.1.3 Stent thrombosis / blood biocompatibility 
Stent thrombosis is a rare but catastrophic event, predominantly associated with DES as 
late/very late stent thrombosis (VLST) [183]. Meaningful comparisons between clinical trials 
were conducted to form standardized definitions of clinical thrombosis based on time elapsed 
after device implantation - proposed by the Academic Research Consortium (ARC) [243] 
(chapter 1). The frequency of stent thrombosis is similar in the first year post-implantation for 
both BMS and DES, with recommended DAPT continuation. The risk of thrombosis is 
however longer for DES, requiring prolonged DAPT administration due to delayed neointimal 
coverage [40]. Investigations on clinical VLST for both DES and BMS, conclude that different 
biological mechanisms underlie the phenomenon depending on stent type [244].  
Mechanistically both DES and BMS surface polymer/metal alloy induce platelet adhesion, 
activation and thrombus formation, requiring mandatory antiplatelet therapy effective for an 
unknown period of time (individualized for patients, usually 6-12 months) [135]. Platelets play 
a pivotal role in thrombus formation and coagulation [232]. High platelet activity is a risk factor 
for many thrombotic events (figure 4.1), with involvement in the conversion of fibrin to fibrin 
clot deposition; the final step in blood coagulation [245], and clinically increased platelet 
turnover is seen in patients with previous definite thrombosis [246]. Several clinical studies 
including a recently concluded five year follow up, indicate direct correlation of stent 
thrombosis to associated cumulative incidence of stent thrombosis elevation and myocardial 
infarction (STEMIs) [247], and a correlation was also seen between DAPT dose (high not low), 
and mitigation of acute stent thrombosis [248].  
 115 
 
Since formation of fibrin clots is directly influenced by platelet activation and vice versa, 
implication of fibrinogen and fibrin structure is investigated in treatment of thrombosis [245]. 
Biomaterial surface-related fibrinogen and fibrin deposition plays a role in stent/vascular 
implant thrombosis, investigated in vitro for novel biomaterials, alongside surface-platelet 
deposition, and surface-whole blood interaction.  Factors underlying stent thrombosis and 
related multiple adverse reactions are categorized in Table 4.1 [249]
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Table 4.1. In vivo clinical mechanisms and factors leading to adverse reactions of 
coronary stents. Factors tabulated are related to DES and BMS, from Kristensen et al 
[250]. Highlighted components are factors directly related to stent-material induced 
adverse reactions. 
 
 
CLINICAL FACTORS 
Procedure-related parameters Patient 
characteristics 
Stent 
characteristics 
Anti-platelet therapy 
Use of multiple stents Diabetes Metal/polymer 
incompatibility 
Inadequate intensity 
of therapy: 
time/dose 
Small vessel diameter Acute coronary 
syndromes such as 
STEMI 
Polymer 
defects: non-
uniform drug 
release 
Non-compliance 
Coronary dissection/long 
lesions 
Left ventricular 
dysfunction 
Hypersensitivity 
inflammation 
Premature cessation 
of DAPT 
Geographic miss  Renal failure Time course of 
drug elution 
 
Stent malapposition Advanced age  
Underexpansion of the 
stent/slow flow 
High platelet 
reactivity 
Stent design – strut thickness, 
polymer/alloy type 
 
Bifurcation lesions 
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4.1.3.1 In vitro biocompatibility investigation 
During the initial investigation of complex biological systems in vitro, biomaterial-blood 
interactions are investigated via static and/or flow assays within simulated physiological 
parameters.  The chandler loop model used in flow studies determine hemocompatibility [105] 
[251] for in vitro coronary flow investigations [105, 252]. The model is appropriate due to 
geometric/fluid mechanics characteristics, flow rate to simulate coronary blood flow, and loop 
configurations similar to arterial curvatures, approximating curved flow [253]. The model is 
simple, clinically relevant, forms physiologically similar thrombi, and supported by previous 
investigations (with both biomaterials and stents) [252, 254, 255]. Figure 4.2 is a schematic 
depiction of the modified circulating loop as a theoretical and experimental model [252].   
Blood anticoagulation is integral prior to any in vitro experiment to prevent air-induced 
thrombosis. The most commonly used anticoagulants are citrate and heparin, with heparin the 
lesser-potent anticoagulant, only partially inhibiting platelet activation [256].   
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Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
Theoretical model for modified experimental chandler loop with blood sample and model 
stent. Image from [252].  
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4.1.4 Protein-biomaterial interaction dynamics 
Theoretically an ideal biomaterial will show absolute protein resistance. However, this is 
impractical, therefore applications of biomaterials require simultaneous anticoagulative 
therapy [257]. A key aim of bioengineering surfaces is to prevent nonspecific protein 
adsorption to improve biocompatibility [257]. In order to design and develop rationale 
strategies for biocompatible materials, theoretical understanding of surface kinetics and protein 
binding dynamics is essential [258]. Major players in protein-biomaterial surface adsorption 
are water mediated hydrophobic and hydration forces, culminated in a concept known as 
“Berg’s law” or “Berg’s limit”. Berg’s limit is a quantitative definition of surface 
hydrophilicity/hydrophobicity, in relation to protein adsorption [257, 259]. According to 
Berg’s limit, surfaces with θ < 650 are hydrophilic, have repulsive forces and prevent long-
range attractive forces with proteins (as opposed to hydrophobic surfaces with θ > 650). 
However the same principles don’t apply to bioinert surfaces, discussed elsewhere [257]. In 
brief, mechanism of surface protein adsorption is energetically favoured on hydrophobic 
surfaces, whereas the mechanism is energetically unfavourable for hydrophilic surfaces. 
Mammalian cell attachment process, is distinct from protein adsorption, and occurs efficiently 
on hydrophilic, but not on hydrophobic surfaces [259]. 
Whilst non-selective protein adsorption to a surface results in adverse effects in vivo, controlled 
covalent attachment of a specific protein candidate (available in the subendothelial ECM) to a 
modified material, can increasingly influence its biocompatibility [187]. Successful completion 
of a specific biomedical task as a result of protein surface retention, should allow a quantitative 
measure between material chemistry and biological response in vitro and in vivo [259]. The 
structure-reactivity relationship is the foundation of biomaterials research [259]. Plasma based 
methods generate linker free protein binding sites for medical applications [103, 187] .
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4.1.5 Tissue Engineering Biomaterials 
Different strategies are utilized in tissue-engineering to form 2-dimensional, micro and 
nanofeatured polymer materials [225]. Responsive polymer surfaces adapt to environmental 
stimuli in relation to surface wettability, species adherence, protein binding and convert 
chemical/biochemical signals into optical, electrical and mechanical signals [260].  
Applications of modified nanomaterials include, drug delivery, diagnostics, tissue engineering, 
and surface coatings [260]. Polymer surfaces on DES manufactured for controlled drug 
delivery and release systems, must also interact positively with environmental stimuli [261].  
Surfaces that can modulate biomolecule activity, facilitate protein immobilization, cell 
adhesion and migration at the aqueous-material interface of medical devices and stents [262]. 
Fabrication of thin polymer films are mediated via several deposition techniques with varying 
degrees of complexity. Techniques such as spin-coating, plasma deposition, chemical vapour 
deposition, and polymer brushes are currently employed for surface modification, with diverse 
medical applications [262, 263].  
Bioengineering a stent surface for biocompatibility aims to attenuate three clinical 
complications; 1) inflammation, 2) thrombogenicity and 3) neointima formation/in-stent 
restenosis (ISR), while promoting surface endothelialization [264].  For surface modification 
of cardiovascular metal stents, constructing a buffer layer at the interface of organic and 
inorganic materials (as observed in our study), is very important to obtain a robust surface with 
long-term biocompatibility [244]. Table 4.2 outlines tissue engineering techniques for 
cardiovascular stent surfaces, to address specific clinical complications, commonly 
encountered during PCI.   
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Table 4.2 Cardiovascular stent materials, modifications and applications. Anti-
thrombosis modifications are shaded in orange, anti-restenosis modifications shaded in 
green. 
 
Cardiovascular stent material Modification Technique Application 
Titanium oxide film (Ti-O) 
on titanium metal.  
Phosphorous ion implantation and 
vacuum annealing [265] 
Anti-thrombosis 
Plasma immersion ionization 
(PIII) [266] 
Anti-thrombosis 
Substrate nanocrystalization [267] Anti-thrombosis 
Stainless steel (316L SS) Cyclic potentiodynamic 
polarization (CPP) [268] 
Anti-thrombosis 
Allylamine film on 316LSS Pulsed plasma polymerization 
followed by heparin bonding [269] 
Anti-thrombosis 
Tantalum oxide film (Ta-O) 
on 316L SS 
RF magnetron sputtering [270] Anti-thrombosis 
Gold stent Biotinylated boophilin (B-
boophilin) immobilized on SAM 
via neutravidin [271] 
Direct thrombin 
inactivation for  
anti-thrombosis 
Stainless steel wafers Glow discharge plasma mixed N2 
and O2 at different molar ratios 
[272] 
Apoptosis to limit ISR 
Anti-restenosis 
Micropatterned Nitinol 
surface  
Plasma nanocoating between 40-
50 nm [273] 
Cell adhesion and 
endothelialization. 
Anti-restenosis 
Nitinol and Teflon (for 
radioactive stents) 
Plasma modification and covalent 
immobilization of HA-DTPA with 
yttrium/indium radionuclide [274]  
Anti-restenosis 
Bioeresorbable polymers on 
Nitinol stent 
Bioabsorbable abluminal layer of 
polyactic acid and biolimus A9 
[275] 
Anti-restenosis 
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4.1.5.1 PAC-L605 biofunctionalization  
The proprietary plasma based technology on polymer/metal surfaces biofunctionalize a 
material to 1) covalently bind a protein, 2) reduce surface thrombogenicity, and 3) facilitate 
cell proliferation in vitro and in vivo [106], with or without surface protein tropoelastin [103, 
187] 
The N-terminal segment of tropoelastin in a buffer solution is theorized to facilitate its 
integration to a surface/scaffold [276], while the exposed C-terminal allows cell adhesion via 
integrins [277]. Previous investigations have proven this with adherence of  HUVECs and 
HCAECs (human coronary artery endothelial cells) to recombinant fragments of tropoelastin 
for cell proliferation [278].  Tropoelastin is a cell-adhesive, subendothelial, extracellular matrix 
(ECM) protein [277], which can specifically promote endothelial cell adhesion, and 
proliferation, to form a cell monolayer on a biomaterial [279, 280]. The same investigations, 
have also accounted for its ability to inhibit smooth muscle cell growth/recruitment from intima 
[280]. Tissue-engineered surfaces with endothelial cells adhered to small-diameter vascular 
grafts, risk in vivo detachment during coronary flow, to cause thrombosis and graft failure 
[280]. For in vivo applications therefore, natural recruitment of endothelial cells to an ECM 
surface, is a desirable option at the site of implant.  
Most surface modifications discussed above (table 4.2), have addressed one of the two clinical 
complications; either thrombosis or restenosis. The PAC modification allows simultaneous 
anti-thrombotic applications, facilitates endothelialization to minimize restenosis, and 
promotes covalent binding of a desired protein in its native conformation [276].  
The aims of this work are to 1) determine covalent binding capacity of tropoelastin (TE) to 
PAC-L605 surfaces 2) visualize cell proliferation on PAC-L605, PAC-L605/TE and alloy 
L605 surfaces in vitro, 3) investigate plasma based biofunctionalization on thrombogenicity 
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for PAC-L605, PAC-L605/TE and alloy L605 in vitro; with or without surface immobilized 
tropoelastin (TE).  
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4.2 Materials and Methods 
 
4.2.1 Materials, Equipment, Suppliers and Facilities 
A list of chemicals, reagents, materials and their suppliers are presented in Table 4.3 
Table 4.3 Materials and their suppliers  
Chemical/Reagent/Material Supplier/Facility 
4’,6-Diamidino-2-phenylindole (DAPI) Sigma-Aldrich, St. Louis, MO, USA 
6 mm Tygon tubing ND-100-65, Class VI (ID 6.35 
mm, O.D. 7.93, 50 FT) 
Saint-Gobain Performance Plastics, PA, USA 
Absolute ethanol Sigma-Aldrich, St. Louis, MO, USA 
Anti-elastin antibody (BA-4) raised in mouse Sigma-Aldrich, St. Louis, MO, USA 
Anti-mouse IgG-fluorescein isothiocyanate (FITC) 
raised in goat 
Sigma-Aldrich, St. Louis, MO, USA 
Bovine Serum Albumin (BSA) Sigma-Aldrich, St. Louis, MO, USA 
Crystal Violet Sigma-Aldrich, St. Louis, MO, USA 
Culture flasks Greiner Bio One (Cell Star) Kremsunster, 
Austria 
Culture plates Greiner Bio One (Cell Star) Kremunster, 
Austria 
Diammonium 2,2-azino-bis(3-ethylbenzothiazoline-
6-sulfonate) (ABTS) 
Sigma-Aldrich, St. Louis, MO, USA 
Fibrinogen from Human Plasma, Alexa Fluor 488 
Conjugate (F13191) 
Life Technologies Australia, Victoria, 
Australia 
Foetal Bovine Serum (FBS) Sigma-Aldrich, St. Louis, MO, USA 
Formaldehyde 37% v/v Sigma-Aldrich, St. Louis, MO, USA 
Glutaraldehyde (25%) Sigma-Aldrich, St. Louis, MO, USA 
Glycine Sigma-Aldrich, St. Louis, MO, USA 
Goat Anti-Rabbit IgG Fc (Alexa Fluor® 488) 
(ab150089) 
Abcam, Cambridge, MA, USA 
Graduated pipettes Greiner Bio One (Cell Star) Kremunster, 
Austria 
Heparin sodium salt (porcine intestinal mucosa, 
H3393, 180 U/mg) 
Sigma-Aldrich, St. Louis, MO, USA 
Hexamethyldisilazane (HMDS) Sigma-Aldrich, St. Louis, MO, USA 
Hydrogen peroxide ThermoFisher Scientific (BDH), Scoersby, 
VIC, Australia 
MesoEndo medium Cell Applications, Inc, San Diego, CA, USA 
Osmium tetraoxide (OsO4) ProSciTech, Thuringowa, QLD, Australia 
 125 
 
Phalloidin-TRITC (Tetramethyl Rhodamine Iso-
Thiocyanate) 
Sigma-Aldrich, St. Louis, MO, USA 
Phosphate Buffered Saline (PBS) Tissue Culture, Heart Research Institute 
Polyclonal swine Anti-Rabbit Immunoglobin-
G/FITC (F0205) 
Dako Australia, Pty. Ltd, Victoria, Australia 
Polyclonal Rabbit Anti-Human vWF (A008229) Dako Australia, Pty. Ltd, Victoria, Australia 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, St. Louis, MO, USA 
Silicon tubing (ID 10 mm, 10 FT) Masterflex John Morris Scientific Pty Ltd, NSW, 
Australia 
Trypsin/EDTA Sigma-Aldrich, St. Louis, MO, USA 
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA 
 126 
 
4.2.2 Preparation of PAC-L605 
Preparation of alloy L605 and PAC deposition was carried out as described in chapter 3.2.2, 
for PAC1-L605 (C-1, N-10, 500 V, t = 20 min) and PAC2-L605 (C-2, N-10, 1000 V, t = 10 
min) surfaces respectively. Prior to all experiments, metallic samples (with or without PAC) 
were sterilized by washing 3x with 70% ethanol, acetylene, and PBS sequentially for 15 min 
each. Unless specified, two recipes of PAC (PAC1/PAC2) were investigated simultaneously to 
detect optimum biofunctionalization in cell culture and hemocompatibility assays. 
4.2.3 TE coating for SDS-ELISA 
Recombinant human tropoelastin (TE) was expressed and purified from an E.coli expression 
system [281]. The PAC-L605 and alloy L605 samples (0.8 x 0.8 cm) were incubated overnight 
with 250 µl of 50 µg/mL tropoelastin in phosphate buffered saline (PBS), at 4oC, within a 24 
well plate.   
4.2.4 ELISA detection of TE 
An enzyme-linked immunoabsorbent assay (ELISA), using an anti-elastin primary antibody 
was employed to detect tropoelastin bound on non-modified alloy L605 and PAC1-L605, with 
and without SDS treatment. The samples were placed into the wells of a 24-well plate. 
Tropoelastin was incubated with samples as described in section 4.2.3. Unbound tropoelastin 
was removed by aspiration and samples washed thrice with PBS. The samples were transferred 
to 5% SDS (w/v) in PBS and incubated at 90oC for 10 min. Non SDS-treated samples were 
washed in PBS alone. Following SDS treatment, samples were returned to the 24-well plate 
and washed thrice with PBS. Non-specific binding was blocked with 3% (w/v) BSA in PBS 
for 1 hour at room temperature (RT). Following BSA blocking samples were incubated with 
the anti-elastin antibody BA-4 raised in mouse (1:2000) for 1 hour at RT [282]. The primary 
antibody was removed and samples washed 3x with PBS and incubated with anti-mouse IgG-
 127 
 
HRP conjugated secondary antibody raised in goat (1:5000) for 1 hour at RT. The secondary 
antibody was removed and samples washed three times with PBS. The samples were 
transferred to a new 24-well plate, ABTS solution (40 mM ABTS in 0.1 M NaOAc, 0.05 M 
NaH2PO4, pH 5, containing 0.01% (v/v) H2O2) was added and incubated at RT for 45 mins. 
The plates were agitated and 100 µl aliquots of the ABTS transferred to a 96-well plate, 
absorbance was read at 405 nm using a microplate reader (Biorad) [138]. Surfaces without 
tropoelastin were used as blank controls for both PAC-L605 and alloy L605.  
4.2.5 Cell culture 
Human coronary artery endothelial cells (HCAECs) were provided at the tissue culture lab, 
HRI. Endothelial cells (passages 2 to 5) were grown to 90% confluence in a humidified 37oC 
incubator with 5% carbon dioxide. The medium was aspirated and cells washed twice with 
PBS. Cells were lifted from the surface by incubation with trypsin/EDTA (0.0025% (v/v) 
trypsin, 0.02% (v/v) EDTA) for 4 min at 37oC, with gentle tapping to dislodge cells. Once cells 
were lifted, trypsin/EDTA was inhibited with the addition of mesoendothelium media (10 mL). 
The cell suspension was centrifuged for 5 min at 1500 rpm then cells resuspended and plated 
for growth in Mesoendo medium or counted for experimental work. 
4.2.6 Cell attachment assay on metallic samples 
Cell assays were performed in triplicate in tissue culture plastic (TCP), 24 well plates 
containing 0.6 x 0.6 cm samples of L605, PAC-L605 and PAC-L605-TE respectively (PAC1 
recipe). The PAC-L605 with TE were incubated with TE (50µg/mL) in a volume of 0.25 mL 
overnight at 4oC. Prior to cell seeding, wells were washed 3 times with PBS and blocked with 
heat denatured (80oC, 10 min) BSA (10 mg/mL) for 30 min, then washed 3 times with PBS 
again. HCAECs were lifted as described in 4.2.5 and counted using a haemocytometer. The 
cell density was adjusted, 5 x 104 cells seeded into each well and left to attach for 1 hour at 
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37oC. Wells were washed 3 times with PBS and fixed in 3.7% (v/v) formaldehyde for 30 min. 
All samples were washed 3 times with PBS and stained with crystal violet (0.1% for 1 hour). 
After staining all samples were washed 3 times with RO water, the stain was solubilized with 
10% (v/v) acetic acid, and absorbance determined with a spectrophotometric plate reader 
(BioRad) at 570 nm.   
In parallel, cells were cultured on alloy L605 and alloy 316L SS for 1 hour cell attachment, for 
visualization with DAPI. Samples were washed 3 times with PBS and treated with 0.2 M 
glycine for 20 mins and 0.2% Triton X-100 for 10 min before staining nuclei with 0.15 µg/mL 
DAPI for 15 mins. Images from 5 random fields per sample were obtained with an Olympus 
IX70 inverted microscope using a filter set for excitation between 350-380 nm. Cell nuclei 
were counted using Image J [283].  
4.2.7 Cell proliferation assay 
Wells with L605, PAC-L605 and PAC-L605-TE (PAC1 recipe) were set up as described in 
section 4.2.6. HCAECs were seeded in 24-well plates at a density of 2x104 or 5x104 based on 
cell count as described in section 4.2.6, and left to proliferate for 3 or 5 days. Medium was 
changed on day 3. At each time point, cells were fixed with formaldehyde and quantified with 
crystal violet as described in section 4.2.6.  
4.2.8 Immunofluoroscent detection of vWF and filamentous actin (F-actin) 
Metallic samples with or without TE (50 µg/mL) were seeded with cells as described in section 
4.2.7. For F-actin visualization 5 biomaterial surfaces were investigated: 1) PAC1 recipe 2) 
PAC2 recipe, 3) PAC1 recipe with tropoelastin, 4) PAC2 recipe with tropoelastin, 5) cobalt 
chromium bare alloy L605. After 5 days of culture, cells were washed thrice with PBS and 
fixed for 30 min in 3.7%-4% formaldehyde in PBS. Formaldehyde was aspirated, cells washed 
3 times in PBS and subsequently treated with 0.2 M glycine for 20 min. The samples were 
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washed thrice in PBS and incubated with 0.2% (v/v) Triton X-100 for 10 min. The cells were 
blocked with 5% (w/v) BSA in PBS for 1 hour, incubated sequentially with human anti-vWF 
antibody (1:400) for 30 min. The primary antibody was removed, samples washed 3 times in 
PBS, and incubated with goat anti-rabbit IgG Fc (Alexa Fluor® 488) (1:90) for 1 hour. The 
secondary antibody was removed, cells stained with phalloidin-TRITC (0.1 µg/mL) in 3% BSA 
for 45 min, washed thrice with PBS and stained with 0.15 µg/mL of DAPI in PBS for 15 min. 
Samples were mounted onto glass slides with DAPI fluoroshield and coverslipped for imaging. 
The cells stained with phalloidin-TRITC and DAPI were merged and visualized first on all 5 
biomaterials, followed by vWF (IgG Fc Alexa Fluor), phalloidin-TRITC and DAPI staining. 
Fluorescent staining uptake was imaged with an Olympus IX70 inverted microscope, using a 
mercury lamp. For DAPI visualization, an excitation between 350-380 nm, and emission of 
470 nm was used. For Alexa Fluor 488 visualization, an excitation between 450-490 nm and 
emission of 525 nm was used. For phalloidin-TRITC visualization, an excitation between 557-
560 nm and emission of 576 nm was used. Sequential imaging eliminated potential bleed-
through fluroscence from other channels, allowing convergence of images to visualize all 3 
stains merged.  
4.2.9 Scanning Electron Microscopy 
HCAECs were cultured for 2 days on L605, PAC-L605 and PAC-L605-TE as described in 
section 4.2.7 (optimum PAC recipe chosen after 4.2.8 results). Samples were washed thrice in 
PBS and fixed in 4% formaldehyde in 0.1 M phosphate buffer (PB) for half hour at RT. Cells 
were dehydrated in ascending grades of ethanol (from 30% (v/v) to 100 % (v/v)) before 
chemical drying with hexamethyldisilazine (HMDS). The samples were mounted to stubs using 
carbon tape, sputter coated with 20 nm gold and imaged with Zeiss Ultra field emission 
scanning electron microscope (FESEM).  
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4.2.10 Thrombogenicity analysis 
4.2.10.1 Blood sampling 
Whole blood was obtained from healthy, non-smoking, male volunteers with informed consent 
in accordance to the Declaration of Helsinki. Volunteers had not taken aspirin or any 
anticoagulant 2 weeks prior to donation. Blood was taken by a trained phlebotomist using a 21 
G butterfly needle to prevent platelet activation and a 20 mL syringe. Donated blood was anti-
coagulated with 0.5 U/mL heparin (180 units/mg). Approval of this work was granted by the 
University of Sydney, Human Research Ethics Committee (2012-2015). All experiments were 
conducted in triplicate samples at least thrice with different donor’s blood.  
4.2.10.2 Platelet rich plasma (PRP) isolation 
Samples of L605, PAC-L605 and PAC-L605-TE (0.8 x 0.8 cm) were placed in a 24 well plate 
previously blocked with 3% BSA in PBS for 1 hour, at RT and washed thrice with PBS. Blood 
was anti-coagulated with 0.5 U/ml heparin and centrifuged for 15 min at 1000 rpm. The 
supernatant was removed and 250-500 µl was incubated with each sample for 60 min at 37oC 
while rocking. Samples were processed for SEM as described in 4.2.9. An additional step was 
included during biological preparation of blood/platelet/fibrinogen surfaces for SEM. The 
surfaces were post fixed with 0.1 % OsO4 in 0.1 M PB for 1 hour, prior to dehydration.  
4.2.10.3 Ageing study on thrombogenicity 
An ageing study was conducted on different samples, with PRP assay to analyse 
thrombogenicity over time. The samples were 1) 1-month old PAC-L605, 2) 1 month old PAC-
L605 incubated with TE stored for 2 weeks at -20oC, 3) 1 month old PAC-L605 incubated with 
TE stored overnight at 4oC 4) bare alloy L605 (control). Samples were placed in a 24 well plate 
and incubated with PRP isolated as mentioned in 4.2.10.2 incubated at 37oC for 60 min. 
Samples were processed for SEM as described in 4.2.10.2 
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4.2.10.4 Whole blood adhesion analysis 
A 24 well plate was blocked with 3% BSA in PBS for 1 hour at room temperature and washed 
thrice with PBS. 0.8 x 0.8 samples of L605, 316L SS, PAC-L605 were incubated with 500 µl 
of heparinized whole blood (0.5 U/mL) for 60 mins at 37oC, while rocking, to observe variation 
of hemocompatibility on different biomaterials. In parallel, 0.8 x 0.8 samples for L605 and 
PAC-L605 were similarly incubated with 500 µl of heparinized whole blood for a period of 30, 
60, 90 mins at 37oC to observe time variation effects on surface hemocompatibility. Samples 
were processed for SEM as described in 4.2.10.2  
4.2.10.5 Modified Chandler loop 
Coagulation under flow conditions were investigated using a modified chandler loop [105, 251, 
252]. The sample dimensions for L605 biomaterial inserted to the model were calculated to 
achieve an area-to-volume ratio between 0.5-6 cm2/mL to meet ISO10993-12 requirements. 
The corresponding blood sample volume per loop, for the finalized dimensions of the 
biomaterial were calculated according to the volume constraint A/6 ≤ V ≤ 2A presented in 
Gaamangwe et al [252] (A is sample area, V is volume of blood). To implement the chandler 
loop model, a rotor was used to drive a turntable, and the rotor speed set at 34 rpm. The turn 
table had a holder attached vertically, approximately 60 mm from its centre to hold sample tube 
loops (Biochemistry, University of Sydney). The blood sample loops were made of medical 
grade Tygon silicon tubes (Internal diameter (ID) 6.35 mm, outer diameter (O.D) 7.93 mm). 
The length of the spliced sample tubes were 300 mm, with a 20 mm silicon connector 
(MasterFlex, ID 10 mm) used to hold the two ends of the medical grade tubing together, 
forming a loop.  The wall shear rate for the model was previously defined by Gardner [284], 
and converted to wall shear stress by considering blood as a Newtonian fluid, seen in equation 
4.1 [252].  
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𝜏W =  
2𝜋𝑅0𝜔𝜇
15𝑅
 
 
Where τw is wall shear stress, R0 loop curvature radius, R tube internal radius, ω angular 
velocity in RPM, and µ is blood dynamic viscosity. Wall shear stress derived earlier was 
applied to our model, to assess shear stress on alloy L605 sample biomaterial, compared to 
shear stress on the tube wall. 
The tubes were randomized and filled with the appropriate volume of heparinized whole blood. 
Heparin concentration of 0.5 U/mL was used (Anna Waterhouse, Dissertation 2011). The loops 
were placed on the sample holder and rotated at 34 rpm at 37oC for 60 min. The blood, 
thrombus and metal from each loop were removed, the metal + any thrombus washed twice in 
PBS, blot dried for imaging and weighing. Initially, we assessed thrombogenicity between 
PAC-L605 recipe 1 (500 V), PAC recipe 2 (1000 V) and alloy L605 at 60 mins, 37oC. Based 
on initial results, the next flow assay investigated thrombogenicity of 1 week old PAC, PAC 
with tropoelastin (overnight, 4oC) and alloy L605. Flow assays were repeated with 5-month 
aged PAC-L605 vs. L605, to assess effects of ageing on thrombogenicity.  
4.2.10.6 Surface fibrinogen deposition – Flow assay 
Fibrinogen staining assay was done to visualize surface fibrin on biomaterials after flow assay 
in a chandler loop. A 24 well plate was blocked with 3% BSA/PBS for 1 hour at RT. The plate 
was washed thrice with PBS. A stock solution of fibrinogen was prepared (5 mg fibrinogen in 
3.3 mL of 0.1 M NaHCO3, pH 8.3 at RT), and gently agitated for 1 hour. Samples of PAC-
L605 and L605 were removed from chandler loop after 1 hour flow assay at 37oC, weighed 
and imaged. These samples were incubated in a 24 well plate with a volume of 250 µL 
fibrinogen-Alexa Fluor 488 (F-13191), per well, for 15 mins. Working solution was prepared 
4.1 
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in distilled water (1:60 dilution). The solution was removed, washed once with PBS and the 
biomaterials in wells were incubated with DAPI (0.15 µg/mL) for 15 mins, without light 
exposure. The samples were imaged with an Olympus IX70 inverted microscope using a 
mercury lamp and a filter set for excitation between 500-524 nm.  
4.2.11 Statistics 
Statistical analysis was carried out as described in Chapter 2.2.15 
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4.3 Results  
4.3.1 SDS resistant binding of TE to PAC 
Tropoelastin (TE) was bound to PAC-L605 (500 V) and L605 surfaces to comparatively assess 
theory of covalent protein binding on modified surfaces for enhanced biomimicry; as seen 
previously on PAC-316LSS [105]. In the absence of TE, the background levels of absorbance 
were 0.012±0.009 on PAC-L605 control and 0.010±0.014 on alloy L605 respectively, figure 
4.3. In the presence of TE without SDS treatment, both PAC-L605 and L605 had increased 
absorbance readings at 0.202±0.01 and 0.138±0.005 respectively, indicative of TE binding, 
figure 4.3. After SDS treatment, absorbance readings decreased to 0.142±0.011 for PAC-L605 
(31.40% reduction) and 0.041±0.009 for L605 (70.04%). The PAC-L605 surfaces displayed 
covalent binding by retaining 68.6% of the bound tropoelastin after SDS detergent washing, 
figure 4.3.  
4.3.2 HCAEC count on alloy L605 and alloy 316 L SS  
Cell attachment on alloys L605 and 316LSS were conducted in parallel to HCAEC attachment 
visualized with DAPI staining for Image J quantification. Five random fields of the imaged 
surfaces were quantified. Within 1 hour the cell count on alloy L605 surfaces was 269.1±28.53 
and on alloy 316LSS was 299.4±40.36, the values were not significantly different, figure 4.4. 
DAPI staining showed that cells homogenously covered a large proportion of both 316LSS and 
L605 surfaces.  
4.3.3 HCAEC attachment on biomaterials 
To comparatively determine cell adhesive and proliferative capacity of L605, PAC-L605 and 
PAC-L605-TE respectively with HCAECs at passage 3, cell attachment and proliferation at 1 
hour, 3 days and 5 days respectively were quantified by crystal violet staining. The crystal 
violet assay has been previously validated for ECs (Anna Waterhouse, Dissertation 2011).  
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Human coronary artery endothelial cell (HCAEC) attachment on L605, PAC-L605 and PAC-
L605-TE were quantified by crystal violet staining after BSA blocking relative to the positive 
control tissue culture plastic (TCP). After 60 min, the absorbances for TCP vs. L605, PAC-
L605 and PAC+TE at 507 nm were 0.215±0.01, 0.111±0.009, 0.113±0.009 and 0.126±0.015 
respectively, figure 4.5. Cell culture density was not significantly different between the 
biomaterials, although significantly different from positive control tissue culture plastic.  
4.3.4 HCAEC proliferation on biomaterials 
HCAEC proliferation at day 3 and day 5 were quantified on L605, PAC-L605, and PAC-L605-
TE surfaces, relative to positive control TCP. Results presented in figure 4.6A and graphed in 
4.6B are relative to cell growth on biomaterials of interest only (positive control TCP, was 
higher and not shown). At 3 days of cell culture, the absorbances for TCP vs. L605, PAC-L605 
and PAC+TE at 507 nm were 0.272±0.034, 0.126±0.012, 0.135±0.013, and 0.119±0.009 
respectively (figures 4.6A and B). By day 5 of cell culture, the absorbance for TCP vs. L605, 
PAC-L605 and PAC+TE at 507 nm were 0.535±0.017, 0.194±0.014, 0.271±0.016 and 
0.304±0.048 respectively. Similar to 1 hour attachment assays in 4.3.3, the growth of cells were 
significantly higher for TCP (positive control), and not significant among the biomaterials at 3 
or 5 day culture (figures 4.6A, B).   
4.3.5 Visualizing HCAEC morphology  
4.3.5.1 F-actin distribution in HCAECs on biomaterial: DAPI/Phalloidin-TRITC 
Filamentous actin distribution and cell nuclei of HCAECs were visualized first with inverted 
fluorescent microscopy on 5 different biomaterial surfaces at day 5 proliferation. 
Autofluorescence of PAC surface did not interfere with the fluorescent dyes, as seen in figure 
4.7. At 40x magnification, homogenous distribution of F-actin was observed on PAC2 surfaces 
compared to PAC1, similar trends were also observed for PAC2 surfaces with TE. PAC2 recipe 
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was chosen for further cell experiments, and termed PAC-L605 throughout the chapter for 
interaction with cells. 
4.3.5.2 Fluorescence microscopy detection of f-actin, vWF and nuclei: triple stain 
Distribution of f-actin, vWF and cell nuclei (triple stain) were visualized for HCAECs on PAC-
L605 and L605. At 10x magnification, cells on both surfaces appeared well spread and 
flattened, with vWF visualized in cell cytoplasm as an endothelial cell marker, with well-
defined cell alignment of cytoskeleton on both surfaces, figure 4.8A. At higher magnification 
(40x), images indicated a more confluent, homogenous, distribution of the actin cytoskeleton 
for endothelial phenotypes on PAC-L605 compared to alloy L605, figure 4.8B. There was no 
difference in the vWF staining uptake between cells cultured on PAC-L605 and bare alloy 
L605, at 40x magnification, figure 4.8B.  
4.3.5.3 SEM detection of cell morphology 
Scanning electron microscopy (SEM) images of HCAECs were cultured and fixed after 2 days. 
The morphology of cells on PAC+TE surfaces were confluent and spread out overall compared 
to PAC-L605 and alloy L605. Similarly, HCAECs on PAC+TE surfaces also had the least 
spindle projections compared to PAC-L605 and L605. SEM allowed higher magnification for 
detailed morphology of cells on biomaterial surfaces, figure 4.8C. 
4.3.6 Detection of alloy L605 and PAC-L605 thrombogenicity – static 
assays 
4.3.6.1 Platelet rich plasma (PRP) assay 
Static blood assays with platelet rich plasma, isolated from heparinized whole blood were 
incubated for 1 hour at 37oC and observed with SEM, on PAC-L605, PAC-L605-TE compared 
to L605, Figure 4.9. The presence of protein in platelet rich plasma prevents platelets and fibrin 
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adherence to the modified, hydrophilic PAC-L605 and PAC-L605-TE surfaces (A, B), while 
fibrin and platelets adhered to alloy L605 cobalt chromium surface (C) (1.27 Kx Magnification) 
4.3.6.2 Ageing study with platelet rich plasma (PRP)  
The ageing study was conducted to assess variation of surface hemocompatibility on modified 
surfaces with or without protein, over time.  The SEM images post PRP assay (60 mins at 37oC) 
showed hemocompatibility sustained on PAC-L605-TE surfaces, incubated with proteins for 2 
weeks at -20oC, figure 4.10 A. Similar hemocompatibility was observed on PAC-L605-TE 
surfaces, incubated with protein overnight at 4oC, figure 4.10 B. Likewise hemocompatibility 
is retained on PAC-L605 surfaces stored airtight for 1 month, figure 4.10 C. As before, surface 
platelet adhesion and fibrin clot formation is observed on alloy L605 bare metal surfaces, figure 
4.10 D.   
4.3.6.3 Whole blood adhesion assay 
Whole blood adhesion compared PAC-L605, L605 and 316L SS surfaces at 60 mins to show 
superior hemocompatibility on plasma modified surfaces compared to thrombogenicity of both 
alloy L605 and 316LSS surfaces, figure 4.11 A. Whole blood adhesion assays on PAC-L605 
vs. L605 at 30, 60, 90 min show comparatively lower thrombogenicity on the plasma modified 
surfaces at each time point, figure 4.11 B. Representative SEM images for thrombogenicity at 
30, 60, 90 min time points, are seen in figure 4.11 C. For optimum thrombogenicity and blood 
flow assays, the 60 min time point was chosen.  
4.3.7 Detection of alloy L605 and PAC-L605 thrombogenicity – Flow assays 
4.3.7.1 Modified chandler loop optimization 
Sample dimensions for alloy L605 and PAC-L605 surfaces were optimized as 1.33 cm2 (area). 
To meet the ISO requirements, we used a blood volume range utilized by other investigators 
[252], the volume constraint was finalized at 2.5 mL/cm2 for flow assays. The wall shear rate 
 138 
 
for the model was previously defined by Gardner and Gaamangwe et al [252, 284]. We showed 
shear rate on sample surface is twice the shear rate on wall (equation 4.1), schematically 
depicted on figure 4.12. The samples were aligned perpendicular to the direction of flow. We 
used a heparin concentration of 0.5 U/mL previously optimized for PAC-316LSS flow assays 
(Anna Waterhouse, Dissertation 2011).  
4.3.7.2 Comparative thrombus formation for PAC-L605 vs L605 surfaces 
Thrombus formation at a time course of 60 min was investigated with a modified chandler loop 
flow assay, at 37oC. Initially, two PAC-L605 recipes [PAC-1 (500 V) and PAC-2 (1000 V)] 
were compared with alloy L605, lowered clot formation was observed for PAC-1 compared to 
PAC-2 and L605 surfaces; 2.5±1.1 mg, 8.63±2.5 mg and 22.2±11.4 mg respectively (p = 0.06, 
not significant), figure 4.13 A. Flow assays were repeated with PAC-1 recipe (referred to as 
PAC-L605, in reference to blood work henceforth) vs. PAC-L605-TE vs. L605, 1 week post 
modification. Significantly lowered thrombogenicity was observed with PAC-L605 and PAC-
L605-TE compared to L605; 2.26±1.0 mg, 3.56±3.6 mg and 10.33±3.3 mg respectively 
(p=0.005), figure 4.13B. Comparative flow assays were repeated with PAC-L605 vs. L605 
surfaces, five months post modification, hemocompatibility was retained with aging, PAC-
L605 surfaces had lower clot formation compared to the bare metal alloy; 7.16±3.5 mg and 
25.16±6.66 mg respectively (p=0.02), figure 4.13C.  
4.3.7.3 Surface fibrinogen deposition for PAC-L605 vs L605 surfaces. 
The amount of surface fibrinogen was visualized for n=3 samples each after modified chandler 
loop flow assay, on alloy L605 and PAC-L605 surfaces. The L605 surfaces had predominant 
fibrinogen staining uptake compared to the modified PAC-L605 surfaces, after 60 min. Surface 
fibrin clot area was quantified with image pro premier (Media Cybernetics, USA) for 5 
different areas on n=3 samples each. The PAC-L605 surfaces had significantly low fibrin area, 
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481.40±263.92 µm2 compared to bare L605 alloy surfaces 1451.82±867.83 µm2, figure 4.14.  
Results are in correlation to clot weights of the 2 surfaces after 60 min flow assay (seen in 
4.3.7.2). 
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Figure 4.3 
 
 
 
Enzyme Linked Immunoabsorbent assay (ELISA) with anti-elastin antibody to detect covalent 
binding capacity of tropoelastin to PAC-L605 surfaces compared to L605. The TE-SDS 
samples (checked) are indicative of those not subjected to SDS detergent treatment, whereas 
TE+SDS samples (stripes) indicate surfaces subject to SDS detergent treatment. The blanks 
are negative controls (no TE). 
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Figure 4.4 
 
 
 
Human coronary artery endothelial cell (HCAEC) count, visualized with DAPI after 1 hour 
attachment on alloy L605 and alloy 316L SS surfaces, and quantified with Image J. Cell 
attachment at 1 hour is not significantly different between the two material alloys of interest. 
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Figure 4.5 
 
 
HCAEC attachment (1 hour) quantified and visualized with crystal violet absorbance after 1 
hour at 37oC on PAC-L605-TE, PAC-L605, and cobalt chromium alloy L605 surfaces. 
Representative inverted microscopy images of crystal violet stained cells on biomaterials to 
visualize variability of surface cell attachment.  
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Figure 4.6 A 
A) Human coronary artery endothelial cells (HCAECs) cultured on PAC-L605-TE, PAC-L605 and cobalt chromium alloy L605 surfaces, 
visualized with crystal violet after 3 days and 5 days respectively (10x magnification, scale bar 500 µm, Olympus inverted microscope).  
Absorbance quantified next in figure 4.6B
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Figure 4.6 B 
 
 
B) Absorbance of crystal violet stained biomaterial surfaces visualized in figure 4.6A above, 
quantified for L605, PAC-L605 and PAC-L605-TE respectively. The density of cells on 
surface increased progressively from 3-5 days. The results were not significantly different 
among the biomaterial surfaces at 3 days or 5 days. 
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Figure 4.7 
 
 
Filamentous actin (F-actin) on biomaterials were identified and visualized with phalloidin-TRITC at 40x magnification (inverted fluorescent 
microscope). HCAECs were cultured for 5 days on PAC 1 and PAC 2 recipe surfaces with or without tropoelastin, and on bare cobalt chromium 
alloy L605. F-actin were more homogenously spread on PAC2 surfaces compared to PAC1 (highlighted in red, with and without tropoelastin) and 
chosen for further experiments in cell culture.  
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Figure 4.8A 
Triple stain with DAPI, vWF and Phalloidin-TRITC (merged in the final panel) to detect the nuclei, Weibel-Palade bodies and cytoskeleton 
respectively of HCAECs at day 5 proliferation on PAC-L605 and L605 surfaces. By day 5, at 10x magnification there was no visible difference 
on cell growth between the two surfaces (Olympus inverted fluorescence microscope). 
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Figure 4.8B 
 
Filamentous actin visualized on PAC-L605 and L605 surfaces at high magnification (40x) with phalloidin-TRITC and DAPI after 5 day culture 
(blue box). Well defined f-actin cytoskeleton observed on PAC-L605 surfaces compared to alloy L605. Merged triple immunofluoroscent stain 
(yellow box). There was no visible variation to the morphology of vWF in Weibel-Palade bodies, visualized on the 2 surfaces with Alexafluor 
488 (red box). Images were visualized at 40x magnification, inverted fluorescence microscope.  
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Figure 4.8C  
HCAECs on alloy L605 and PAC-L605 indicate more spindle projections compared to PAC+TE surfaces (ECM protein). PAC+TE surfaces also 
had more confluent HCAEC growth with better surface attachment (FESEM: top panel 140x/190x magnification, second panel 500x/600x 
magnification).    
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Figure 4.9 
 
Platelet rich plasma (PRP) assay (37oC, 60 mins), SEM images: Presence of protein in platelet rich plasma prevents platelets and fibrins adhering 
to the modified hydrophilic PAC-L605 and PAC-L605-TE surfaces (A, B). Fibrin and platelets adhere to alloy L605 bare cobalt chromium 
surface (C). Images were acquired with FESEM, 1.2 K magnification.   
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Figure 4.10 
Ageing study with platelet rich plasma (PRP) assay, 60 mins, 37oC; Sustained hemocompatibility seen on A) PAC-L605-TE surfaces incubated 
for 2 weeks at -20oC, B) PAC-L605-TE surfaces incubated overnight at 4oC, C) PAC-L605 surfaces stored airtight for 1 month, and surface 
platelet/fibrin clot deposition on alloy L605 bare metal surfaces (Magnification 1.08 K x). 
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Figure 4.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Static assay: whole blood adhesion comparing A) PAC-L605 vs. L605 and 316LSS at 60 mins, 
37oC. PAC shows superior hemocompatibility compared to both bare metal alloys. B) 
Comparing L605 vs. PAC-L605 at 30, 60, 90 mins show comparatively lower thrombogenicity 
at each time point for PAC.  
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Static assay: C) SEM representation of PAC-L605 vs. L605 surfaces at 30, 60, and 90 mins 
after whole blood adhesion. Modified surfaces show hemocompatibility at all 3 time points 
compared to the bare metal alloy. For optimum thrombogenicity 60 min time point (red 
highlight) was chosen for assays.
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Figure 4.12 
 
 
 
Representation of the rotating loop with biomaterial immobilized on the wall of the medical 
tubing. Since material is immobilized at the radius of tube, the shear rate on sample surface 
will be twice the shear rate present on medical tubing for our model, as theorized in 
Gaamangwe et al [252]. 
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Figure 4.13 A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow assays for thrombogenicity, modified chandler loop 60 mins, 37oC: A) Clot formation 
lower for PAC-1 recipe compared to PAC-2 and alloy L605 (p=0.06, ns).  
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Figure 4.13 B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After 1 week, clot formation was significantly lower for PAC-L605 and PAC-L605-TE 
(tropoelastin incubated at 4oC, overnight) surfaces compared to L605 (p=0.005).  
 156 
 
Figure 4.13 C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After 5 months clot formation still significantly lower for PAC-L605 compared to L605 
(p=0.02); hemocompatibility is retained.
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Figure 4.14 
 
 
 
Surface fibrinogen clot deposition visualized with fibrinogen Alexa Fluor 488 and DAPI, on 
alloy L605 and PAC-L605 samples, after 60 min flow assay at 37oC. Fibrin clot deposition 
(green) is indicated with red arrows, nuclei stained with DAPI is seen in blue. The scale bar of 
the images is 200 µm (10 x magnification). Surface fibrin area was calculated with image pro 
premier (Media Cybernetics, USA) on 5 different areas for n=3 samples each for L605 and 
PAC-L605. 
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4.4 Discussion 
Biofunctionalization of PAC-L605 surface was comparatively assessed with alloy L605 bare 
material, in vitro. Surface modifications via proprietary plasma technology confer specific 
traits including; covalent attachment of a protein candidate of interest, improved 
hemocompatibility and assisted cell attachment/proliferation in vitro. Testing 
biofunctionalization of materials is crucial prior to in vivo applications for anticipated 
biointegration. Thrombogenicity of biomaterials in vivo has proven to be complex and fatal.  
In this chapter, biocompatibility of stent coatings were assessed under ISO10993-12 standards, 
in the lab prior to intended translation in vivo.  
4.4.1 Covalent binding capacity of a plasma modified biomaterial 
4.4.1.1 ELISA 
Covalent binding of bioactive protein molecules is required for persistent biomimicry of a PAC 
surface. We demonstrated the covalent attachment of a protein to a modified surface via SDS 
washing and ELISA treatment.  Sodium dodecyl sulfate (SDS) is commonly used as a research 
tool in protein biochemistry [285, 286]; the compound works by disrupting non-covalent bonds 
in the proteins, denaturing them and causing molecules to lose their conformation or native 
shape. The detergent wash is a valid indicator to assess covalent binding capacity of a 
biomaterial, with a surface bound protein of interest. The presence of TE before and after SDS-
wash was detected with a monoclonal antibody, BA-4 anti-elastin, and a secondary HRP 
conjugated antibody in an ELISA.  The BA-4 monoclonal antibody is specific to the valine-
glycine-valine-alanine-proline-glycine (VGVAPG) repeating sequence in elastin and 
tropoelastin molecules, recognizing sequence regardless of protein conformation [287]; 
therefore suited for protein detection on biomaterials. The negative control showed low levels 
of absorbance. Higher absorbance was observed on PAC surfaces after SDS washes, compared 
to bare alloy L605, indicating covalent surface attachment on PAC-L605 (figure 4.3).  
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The covalent binding capacity of PAC surfaces, is due to the presence of surface free radicals 
on PAC, investigated in depth with PAC-316LSS [103] and characterized with PAC-L605, in 
chapter 3. The reservoir of free radicals migrate through the PAC interface, binding with the 
N-terminal region of proteins via a variety of amino acids [276]. Previously with alloy 316LSS 
a surface thickness of 200 nm was utilized (Anna Waterhouse, Dissertation 2011). In this study, 
in contrast, a 20 nm surface coating and different PAC recipe was incorporated. The difference 
in surface polymer thickness may account for the lower absorbance values observed at 450 nm 
(OD 0.15-0.20), compared to previous PAC-316LSS surfaces with higher absorbances in the 
range of OD 0.4-0.5 (Anna Waterhouse, Dissertation 2011). Initial investigations on covalent 
binding assessment of plasma technology [145], showed a full monolayer of tropoelastin 
achieved approximately at 72 nm, for a correlating absorbance of OD 0.3-0.5 (450 nm), also in 
support of the present observation [145]. The 20 nm PAC-L605 coating used throughout this 
study, shows potential to bind a surface protein, although for applications on a cobalt chromium 
stent surface (alloy L605), it would be ideal to trial various PAC surface thicknesses, ranging 
from 20 nm-200 nm, prior to translational studies.  
4.4.2 Cell attachment and proliferation on biomaterials 
Initially we investigated the interaction of endothelial cells on two biomaterials, alloy L605 
and alloy 316LSS, prior to surface modification. The attachment of passage 3 HCAECs at 37oC 
was visualized with DAPI, and cell nuclei counted with Image J software. Similar cell 
attachment was detected on the two material surfaces. Although largely spread-out, both 
surfaces support cell attachment, as visualized, and quantified after 1 hour of incubation (figure 
4.4).  
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4.4.2.1 Tropoelastin assists EC attachment and proliferation 
We had previously established tropoelastin (ECM protein) to support human umbilical vein 
endothelial cell (HUVEC) attachment and proliferation in vitro on PAC-316LSS surfaces [105, 
138]. Based on similar principles and methods, we investigated the effect of tropoelastin on 
PAC-L605, for in vitro HCAEC attachment and proliferation. Crystal violet staining, a well-
established methodology [288], was used to visualize and quantify EC attachment and 
proliferation, on PAC-L605-TE, PAC-L605 and L605 surfaces. The attachment of EC 
visualized with crystal violet, was established to linearly correlate with the number of cells 
present on a surface. Using crystal violet we observed similar cell attachment for PAC-L605 
and L605 surfaces (figure 4.5), increased cell proliferation was observed for PAC-TE surfaces 
at 3/5 days, although values were not significantly different (figure 4.6 A, B). 
  
4.4.2.2 Cell proliferation and actin cytoskeleton in endothelial cell phenotypes 
Cells are capable of mechanosensing topography of a biomaterial for effective orientation and 
homogenous surface proliferation [225]. Studies reveal a preference of cell adherence to 
randomly organized surfaces within µm ranges of roughness to facilitate cellular anchorage 
and growth [289]. The interaction between modified biomaterials and biological elements are 
dictated by two phases at the material interface. The cell-biomaterial interaction is optimized 
via surface micro/nanofabrication to create biomimetic microsystems [290], that aid tissue 
repair after injury during medical device implantation [289].  
In the present study, we investigated two different PAC recipes with/without tropoelastin to 
visualize cellular anchorage and cell spreading in HCAECs cultured for 5 days, via phalloidin 
TRITC (f-actin marker) and DAPI (nuclei) (figure 4.7). In total 5 types of biomaterial surfaces 
were investigated at high magnification (40x) (figure 4.7).  Based on cell-biomaterial surface 
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interactions, PAC 2 surfaces favoured improved cellular anchorage, and were selected for 
further cell proliferation studies. The final response of cells to biomaterial topography is 
reflected in the organization of the actin cytoskeleton, observed with f-actin specific 
immunostaining, after proliferation. Actin cytoskeleton provides a strong, dynamic 
intracellular scaffold to organize integral membrane proteins within the cell’s interior, respond 
to environmental cues, and assist proliferation [289] . 
To establish cell support and culture exclusively between PAC-L605 and L605, multiple 
immunolabelling or triple staining was used. At 10x magnification, by day 5, cells showed 
equal expression for vWF (Weibel-Palade bodies, endothelial cell specific marker), phalloidin-
TRITC (f-actin), and DAPI (nuclei) staining seen in figure 4.8A. At higher magnification (40x), 
a well-defined alignment of cell cytoskeleton is observed for PAC-L605 surfaces, compared to 
the alignment on bare metal alloy L605, figure 4.8B. There was no difference to vWF 
expression on either surface at a higher magnification.  
As theorized by Ingber in 1993, change in cell shape in response to an applied pressure or due 
to interaction with substrates, is based on the cell’s cytoskeleton [291]. Internal tension and 
lack of cell-substrate attachment generates round/symmetrical cell and nuclei shapes, whereas 
when attached to a substratum, cytoskeleton mechanically stabilizes the cell in a coordinated 
fashion [291]. To design optimized biomaterials for tissue engineering applications, it is 
important to understand cellular cytoskeleton, for efficient tissue regeneration and assisted 
healing, while avoiding an undesirable immunological or inflammatory response [226]. 
Biomimicry is the end result of surface nano/micro fabrication, allowing surfaces to mimic the 
physiological nano/micro environment.  
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4.4.2.3 EC phenotype on different biomaterial surfaces 
Endothelial cell phenotype was investigated on three different surfaces; L605, PAC-L605 and 
PAC-L605-TE after 2 day proliferation with SEM (figure 4.8C). SEM allows higher 
magnification and detailed surface morphology of cells cultured on a non-transparent surface. 
The images reveal enhanced cell spreading and cell processes on PAC+TE surfaces, followed 
by PAC, whilst L605 surfaces show a higher consistency of spindle like projections and 
alteration to cell shape. During biological preparation for SEM, we eliminated the usual 
osmium tetroxide (OsO4) fixation on all 3 surfaces, to prevent alterations to cell morphology. 
The altered cellular structure of ECs grown on alloy L605 could be due to surface kinetics; i.e. 
hydrophobicity and low surface energy.  Results suggest that the selected PAC-L605 
composition (PAC2 recipe) with covalently bound ECM tropoelastin protein, is best suited for 
EC growth and survival.  
Overall, PAC- L605 (PAC2 recipe) with or without tropoelastin, assists anchorage dependant 
cell functions such as cell spreading and proliferation. The effects are enhanced with surface 
ECM protein, tropoelastin. Modifications to the biomaterial coupled with adhesive protein is 
suited for cardiovascular tissue engineering, which requires prior in vitro cell culture.  
4.4.3 Thrombogenicity under adhesion and flow conditions 
The in vitro model for hemocompatibility is already an over simplification of a very complex 
physiological system [252, 290]. We chose the modified chandler loop model for whole blood 
flow assays based on several previous studies and experimental standardization. To assess 
initial thrombogenicity of surfaces under static conditions, we utilized platelet rich plasma 
(PRP) incubation, and whole blood static adhesion. We chose heparin the lesser potent 
anticoagulant (section 4.1.3), as utilized previously for blood flow and static adhesion assays.  
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4.4.3.1 Platelet activation and surface fibrin clot formation 
Platelet activity, conversion of fibrinogen to fibrin clot deposition (final step in blood 
coagulation), and whole blood adhesion were investigated under static conditions [105]. As 
seen with PRP and whole blood adhesion assays (figure 4.9 and 4.11 A,B,C), PAC-L605 
surfaces with or without TE, bound fewer platelets, had less surface fibrin deposition and 
markedly lower coagulation, compared to alloy L605 and alloy 316LSS surfaces. The 
observation is rationalized as presence of protein in PRP preventing platelet/fibrin adherence 
to the modified hydrophilic PAC-L605 and PAC-L605-TE surfaces, whilst fibrin and platelets 
adhere to hydrophobic cobalt chromium and stainless steel alloys. Under physiological 
conditions, arterial thrombi formed are mainly composed of platelet aggregates bound together 
by thin fibrin strands, as observed on L605 surfaces with SEM images (figure 4.9).  
4.4.3.2 Thrombogenicity of PAC with aging  
During surface characterization investigated in chapter 3, we noted changing plasma kinetics 
of PAC-L605 surface within a period of 2 weeks. The variation was explained as a result of 
surface oxidation with time [103]. To assess impact of time/oxidation on surface 
thrombogenicity, we investigated hemocompatibility of PAC-L605 with PRP. The samples 1) 
PAC-L605-TE after 2 weeks of storage with TE (-20oC) compared to TE overnight (4oC), and 
2) 1 month airtight storage of PAC-L605 without protein were compared with alloy L605. The 
SEM images of resultant PRP assays (figure 4.10) were similar to previous observations with 
fresh PAC, with/without surface protein (figure 4.9); indicating no significant changes to 
surface hemocompatibility with time. The ability to store protein bound surfaces for an 
extended period of time at -20oC, while retaining protein conformation and surface 
hemocompatibility, is a feasible concept for tissue engineering and future clinical applications 
with a cardiovascular stent platform. We also investigated effects of surface ageing, within a 
blood flow model, discussed in 4.4.4 next.     
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4.4.4 Thrombogenicity under flow conditions  
Fluid dynamics affect parameters of flow, to determine rates of cell and protein transport to the 
surface in vivo [292, 293].  Conflicting results have been observed for shear rates on different 
substrates (relative to platelets, thrombin, fibrin, and leukocyte deposition) due to differences 
in experimental conditions; i.e. varying degrees of blood components present, properties of the 
material studied and the state of inflammatory activation  [292].    
We had previously investigated thrombogenicity of a PAC-316LSS biomaterial, within a 
modified chandler loop, in vitro [105].  Thrombogenicity of PAC-L605 was investigated for 
the first time in this study. The modified biomaterial was 10x thicker (250 µm alloy L605, 
compared to 20 µm 316LSS foil), positioned vertically within the Tygon tube (instead of in 
contact with the wall), and had a 20 nm PAC surface compared to the 200 nm coating on 
316LSS (Anna Waterhouse, Dissertation 2011) (figure 4.12). To justify novel inclusions in our 
current model, we utilized selection criterion for sample volume per surface area, and wall-
shear stress equation, theorized elsewhere [252]. The sample volume was 2.5 mL per Tygon 
tube, and wall shear rate on sample twice the value on tube wall (figure 4.12). In vitro fluid 
dynamics relate to physiological conditions, where in vivo shear rate on the stent/implant 
surface is higher than flow shear rate on arterial wall. Hemodynamics play a quantitative role 
between stent implantation and thrombosis, detailed in vivo using computer fluid dynamics 
(CFD) simulation [294]. In future, a similar biomechanical study may be conducted first in 
vitro to quantitatively measure hemodynamics for stent-blood contact with CFD software 
[295].   
4.4.4.1 Fibrinogen deposition 
Surface fibrinogen deposition after flow assays were investigated via modified chandler loop 
and fluorescent microscopy, with fibrinogen antigen attached to a fluorescent dye Alexa Fluor 
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488. After 60 min chandler loop flow, fluorescein-labelled fibrinogen were quantified in higher 
densities on alloy L605 surfaces compared to PAC-L605; in correlation to higher thrombus 
formation on L605 compared to PAC-L605. Clinically, fibrinogen adsorption onto implant 
surfaces, is known to render biomaterials into thrombogenic surfaces. The critical effect of 
fibrinogen adsorption impacts overall bio-integration of an implantable material and therefore 
investigated in biomedical and materials research [296]. Fibrinogen protein possess 
amphiphilic properties (hydrophobic and hydrophilic) allowing adsorbance on any surface, and 
facilitates platelet aggregation [297]. Fibrinogen is a precursor of the blood coagulation 
complex, converted via thrombin and factor XIIIa to fibrin, and the final product of the 
coagulation cascade, fibrin clot (figure 4.1). Highly branched networks of thin fibrin fibres, 
cross-linked by activated factor (F)XIII, improves fibrin elastic properties and resistance to 
lysis [298]. Additionally, fibrinogen adsorption leads to formation of conditioning film on 
implant surfaces in vivo, potentially resulting in problematic bacterial attachment [297]. 
Mechanisms in bioengineering employed improved material hemocompatibility, conferring 
resistance to surface fibrinogen deposition, as well as platelet aggregation, although exact 
mechanisms of action are yet unknown.  
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4.5 Conclusion 
 
We investigated biocompatibility of two different PAC recipes, with or without surface bound 
tropoelastin, in comparison to bare metal alloy L605. The proprietary plasma technology 
allowed covalent immobilization of a protein candidate of interest, enhanced surface 
endothelialization and lowered thrombogenicity compared to alloy L605. The PAC 2 recipe 
enhanced endothelial cell proliferation compared to PAC 1 recipe, this was applicable to PAC2 
+TE surfaces as well. Overall, PAC2+TE showed best surface cytocompatibility in terms of 
cell spreading. In terms of hemocompatibility, PAC 1 recipe with higher nitrogen content 
appeared to enhance surface hemocompatibility compared to PAC 2 recipe, with or without 
surface tropoelastin. Tropoelastin did not appear to markedly increase hemocompatibility of 
PAC, compared to PAC alone. Therefore the ideal PAC recipe for a stent platform should be 
optimized between the two recipes. Ideally PAC1 (C-1, N-10) with a longer deposition time 
(t>20 min) or t=10 min, may result in an optimized polymer surface for equal cell proliferation 
and hemocompatibility. The surfaces maintained biocompatibility with age.  Studies conducted 
herein on modified alloy L605 flat surfaces, assessed compatibility of the coating technology 
prior to its translation to a cobalt chromium stent platform.   
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Chapter 5 – Biological evaluation of medical devices: 
Selection of tests for interactions with blood. 
 
 
5.1 Introduction 
 
5.1.1 Objectives and Regulations of Standards in Medical Device 
Evaluation 
 
The ISO (International Organization for Standardization) is a worldwide federation of national 
standards bodies [299]. A voluntary standard for a medical device is a recommendation 
provided to the manufacturer, detailing information of the product, basic safety and 
performance criteria, qualifying the device for clinical use. The standard further represents 
techniques that can be used to measure if device conforms to a safety or performance criteria; 
in comparison to performance characteristics of different products [299]. Recommending 
disclosure of the performance characteristics of a medical device necessitates development of 
specialized tests methods for uniform assessment and reporting. Reaching consensus on these 
tests is considerable part of committee work; including Association for the Advancement of 
Medical Instrumentation (AAMI), and the food and drug administration (FDA)[300].    
All standards and recommended practices are voluntary, i.e. within discretion and professional 
judgment of the user of the document, unless adopted by government regulatory or procedural 
authorities [299]. Despite periodic review and revision, a standard or recommended practice is 
a static document, applied to a dynamic technology. Particular care should therefore be taken 
in applying a product or standard to an existing device, equipment, procedure or practice. A 
standard or recommended practice is only an important reference, and not a replacement to 
responsible decision making [299].   
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Professional judgment should be exercised in applying these criteria to existing 
equipment/devices. However, no single source of standardized information will serve to 
identify a particular product as “unsafe” [299]. In a preclinical setting, a standard or 
recommended practice should only be exercised in conjunction with other policies/guidelines 
and professional judgment.  
5.1.1.1 Selection of tests for ISO 10993-4: FDA modifications 
The ISO 10993-4 criterion was originally prepared by a technical committee for biological 
evaluation of medical devices [301], and revised last in 2013. The selection of test methods for 
the interaction of medical devices with blood should specify; device design, materials, usage 
environment and risk benefit [299]. The scope of the updated, FDA-modified, ISO-10993-4 
(2013) utilized herein is for the biological evaluation of medical device materials in contact 
with blood. However, it should be emphasized, the FDA guidelines only apply to the evaluation 
of a final, finished medical device [300]. As a result, any preliminary tests conducted and 
optimized in accordance to the International Standards on a modified biomaterial, while 
beneficial for optimization prior to stent translation, will need to be repeated with a modified 
stent in its final form; prior to preclinical testing [300].  
In general, recommended tests for medical devices include assessments on; in vitro 
cytotoxicity, acute, sub chronic and chronic toxicity, hemocompatibility, irritation, 
genotoxicity, carcinogenicity and effects on reproduction. Evaluation of any device intended 
for human use requires systemic data, ensuring that benefits provided by the final product 
exceed any potential risks of the device. The FDA’s perspective on cardiovascular devices 
extends to high risk ventricular assist devices (VADs), mechanical heart valves, stents, 
pacemakers, cardiac resynchronization therapy (CRT), and defibrillators [302]. Determination 
for clinical application of cardiovascular devices are based on FDA’s review of extensive 
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preclinical bench and animal testing, followed by data from device used in a human clinical 
trial.  
With the advancement of scientific knowledge in relation to basic mechanisms of tissue 
responses, the number and exposure of test animals is minimized with preference to chemical 
constituent testing of devices, and in vitro models [290].   
5.1.1.2 Hemocompatibility tests according to ISO 10993-4: 
The interaction of material surfaces with human blood is investigated with selected ISO 10993-
4 tests. The tests predominantly represent two biological cascades resulting in clinical 
complications during blood-material interaction; 1) hemostasis (in relation to coagulation and 
platelets) and 2) inflammation (in relation to complement and leukocytes). In the modified 
chandler loop, diverse conditions of blood circulation can be simulated to investigate 
hemostatic/inflammatory markers in plasma; including complement, platelets, leukocyte 
activation, and generation of thrombin as well as formation of fibrin [303, 304]. After chandler 
loop assay, enzyme linked immunoabsorbent assays (ELISA), were used to investigate 
coagulation and inflammatory activation markers in plasma, listed in table 5.1.  
Table 5.1. Selected tests for interaction with blood in accordance to ISO 10993-4.  
 
ELISA test Molecular marker/cascade investigated 
Thrombin-Antithrombin complex (TAT) Thrombosis/Coagulation 
Beta-thromboglobulin (β-TG) Platelet activation 
sP-selectin Platelet activation 
SC5b-9 complex Complement activation (immunology) 
PMN-elastase Leukocyte activation (hematology)  
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5.1.2 Thrombin Anti-Thrombin Complex (TAT): Critical role of thrombin 
In vivo coagulation cascade is a response to vessel injury, as schematically shown in figure 5.1 
A. Vessel injury occurs during PTCA (percutaneous transluminal coronary angioplasty), stent 
implantation, as well as atherosclerotic plaque rupture. Mechanistically, disruption of the 
vessel surface exposes subendothelial collagen and Von Willebrand factor, to which platelets 
adhere and become activated. Subendothelium exposure results in cells that constitutively 
express tissue factor; i.e. trigger the coagulation cascade [305]. A series of reactions cascade 
as a result, to form thrombin. Thrombin is the link between injury, trigger, coagulation process, 
platelet activation and inflammation [306].  
Schematic details of the laboratory coagulation cascade mimics in vivo cascade depicted in 
figure 5.1A. Tissue factor (factor Xa) generated due to vessel injury [via collagen, vWF and 
fibroblasts] converts prothrombin to thrombin. Thrombin amplifies the process, acts as a potent 
platelet agonist, and converts fibrinogen to fibrin. Once platelets are activated they aggregate 
to form platelet-fibrin-thrombus that plugs the site of injury. Within an artery (coronary or 
cerebral) this formation can fill the vessel lumen, obstruct blood flow leading to myocardial 
infarct, or in the brain, to a stroke.  
However, the cell-based model of coagulation proposed by Hoffman-Monroe [307] (figure 
5.1B), shows in vivo coagulation is regulated via cell surface properties, and occurs as three 
overlapping stages; not as a simplified laboratory-based coagulation cascade (figure 5.1A)  
[307]. The 3 stages include initiation, amplification and propagation [307]. Since we 
investigated the proportion of thrombin formed, relative to blood-material contact in vitro in 
this chapter, we focus on the laboratory-based coagulation cascade (figure 5.1A).  
The human thrombin-antithrombin in vitro ELISA is designed for quantitative measurement of 
thrombin-antithrombin complex (TAT) concentrations in plasma, isolated after whole blood 
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flow. Thrombin is a multifunctional serine protease generated at sites of vascular injury, and 
antithrombin a serine protease inhibitor; regulating the blood coagulation cascade [306]. The 
inhibitory activity of antithrombin is greatly enhanced in the presence of heparin. Heparinized 
whole blood is used prior to blood-material contact investigations, under static and flow 
conditions in vitro (chapter 4).  TAT complex formation is assisted during heparinized blood-
material contact assays. The in vitro ELISA quantifies TAT complex, while indirectly 
displaying proportion of thrombin generated and correlating proportions of antithrombin 
produced. The analysis is an important integer to measure activation of the coagulation cascade, 
and biocompatibility of materials in contact with blood, in vitro; [higher the concentration of 
TAT, higher the thrombin and antithrombin generated].    
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Figure 5.1 
 
A) The cascade model of coagulation, schematically depicted in an in vivo environment, to explain the laboratory coagulation cascade. The red 
star with integer A indicates antithrombin, a serine protease inhibitor, forming thrombin-antithrombin complex (represented as TAt). B) In the 
cell-based model of haemostasis, coagulation is regulated by the cell surface receptors, to explain aspects of haemostasis that the cascade protein-
centric model cannot explain. Images modified from [305],[306] and [307] respectively.  
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5.1.3 Beta-Thromboglobulin (β-TG): Platelet Release Reaction 
Beta-thromboglobulin (β-TG) is a platelet specific protein (molecular weight 35 kDa), 
composed of 4 identical subunits [308]. The protein is synthesized in the cells as a biologically 
inactive precursor - platelet basic protein (PBP), stored in alpha-granules and released in large 
amounts after platelet activation. The released protein stimulates various processes including 
synthesis of plasminogen activator [308]. Measurement of plasma levels of secreted platelet 
protein β-TG, is suggested as an effective means of detecting increased platelet activation in 
vivo and in vitro [309].  
The clinical measurement of platelet materials released, provide a better index of platelet 
activation in atherosclerotic vascular disease and arterial thrombosis [309]. A high plasma level 
of β-TG is equated with increased platelet release both in vitro and in vivo. Heparin infusion 
does not usually change the level of β-TG in laboratory tests [309]. In vivo, patients with 
abnormal coronary angiograms without previous myocardial infarction (MI) did not show 
elevated levels of β-TG, although values were significantly elevated in whom MI had occurred 
6 months previously [310]. In patients with ischemic heart disease, platelet release is attributed 
to prior occurrence of MI, than to patients with atherosclerotic coronary arteries [310, 311]. 
Platelet adhesion and aggregation form important features of blood-material interaction [312], 
and platelet release reactions occur during this process. The release of platelet contents is also 
induced by thrombin during the coagulation cascade [312]. Quantifying platelet release factors 
after blood-material contact is therefore an index of biomaterial hemocompatibility. 
Assessments of material hemocompatibility have also previously been quantified, with platelet 
specific protein β-TG in vitro [312]. The in vitro ELISA assay uses an antibody specific to β-
TG to enable quantification of platelet release using a standard curve, in plasma isolated after 
whole blood flow assay. In vitro β-TG assessment is further supported by previous 
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investigations in cardiovascular disease in vivo [310, 311], and material/cardiovascular stent 
hemocompatibility investigations in vitro [313, 314]. 
5.1.4 Soluble P-selectin: Platelet Activation 
The glycoprotein P-selectin is localized in α-granules of platelets and Weibel-Palade bodies of 
endothelial cells [315]. The P-selectin protein expressed at 10x higher concentration on 
platelets than on ECs, is clinically defined as a marker of platelet activation in vivo. P-selectin 
has been evaluated in patients with coronary symptoms; at elevated levels with unstable angina 
[316], acute coronary syndrome [317] and coronary stenting [318].  P-selectin is also elevated 
in patients with congestive heart failure, stroke and peripheral artery disease [315]. Notably, 
increased levels of soluble P-selectin predict major cardiovascular events in patients with 
existing peripheral or coronary artery disease [319], and future risk of cardiovascular events in 
apparently healthy women with mean levels of P-selectin significantly higher at base level 
[320]. 
As mentioned previously in 5.1.3, plasma markers such as beta thromboglobulin and platelet 
factor 4, also secreted from α-granules define platelet activation. However, P-selectin remains 
activated for 1 hour on platelet surface, while other plasma markers such as β-TG and platelet 
factor 4 have a comparatively shorter half-life [315]. Soluble form of P-selectin is thought to 
be directly secreted from platelet cells into plasma [321].  
Mice engineered to have high levels of soluble P-selectin, exhibit a pro-coagulant state [322], 
while P-selectin deficient mice show prolonged bleeding [323], highlighting its central role in 
hemostasis. Further studies indicate the molecule’s association as a direct inducer of 
procoagulant activity in vascular and thrombotic diseases [315]. However, 3 independent 
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studies have shown platelets that have already shed their P-selectin, continue to circulate; 
therefore not all functional platelets are defined by P-selectin positivity [324]. Further, platelet 
leukocyte aggregates, mediated in part by P-selectin, are a more positive marker of platelet 
activation, compared to P-selectin-positive platelets, because of their longer duration in blood 
circulation [324], investigated via the complementary and leukocyte activation pathways, 
introduced next.  
5.1.5 SC5b-9 Complex: Soluble terminal complement complex 
Inflammation plays a key role in cardiovascular disease, contributing to the development of 
atherosclerotic lesions, plaque rupture and thrombosis [325]. The primary role of soluble 
terminal complement complex (TCC, SC5b-9) formed via activation of the complement 
system, is pathogen cell lysis and foreign body elimination [326]. An inflammatory response 
is elicited via formation of the membrane attack complex (MAC). The soluble terminal 
complement complex TCC, SC5b-9, seen in figure 5.2 (circled in red) [327], is generated by 
solubilization of C5 to C9 proteins of the membrane attack complex (MAC). The physiological 
role of complement system, as a rapid effector after vessel injury, contributes to its involvement 
in inflammation and thrombosis, in cardiovascular disease (CVD). 
Three established mechanisms of complement activation exist, namely; classical, lectin and 
alternative pathways, leading to formation of the membrane attack complex (MAC) for effector 
responses on pathogen’s membrane (highlighted orange, figure 5.2) [327]. Functional effects 
of complement activation are implemented by TCC (SC5b-9 complex). This quantifiable 
complex forms via another multistep process, that includes initiation (C5-C7 molecules), 
polymerization (C8-C9 molecules) for SC5b-9  formation, and its inhibition with CD59 present 
on healthy body cells (not shown), to prevent an autoimmune response [326].  The intended 
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biological outcome of the systematically regulated cascade is membrane perturbation of 
invading pathogens/foreign particles  (figure 5.2) [327].   
In vitro investigation of  TCC, is an ISO recommended test after blood-material contact to 
assess biocompatibility of a material [252]. Clinically, increased complement activation after 
cardiopulmonary bypass intervention represent post-operative organ dysfunction [328]. 
Reduced complement activation is a marker of biocompatibility, as observed with heparin-
coated cardiopulmonary bypass devices, in vitro [328]. Complement activity is therefore a 
common clinical complication that contributes to cardiovascular disease. Its role in the 
development of atherosclerosis, ST segment elevation, as well as non ST segment elevation 
acute coronary syndrome, and coronary bypass graft surgery has been investigated to 
understand molecular basis, for new therapeutic interventions that modulate complement 
activity [329]. In vitro investigation of an activated complement system is represented by 
terminal complement cascade (TCC, SC5b-9) ELISA quantification - after blood-material 
contact, to allow assessment of material biocompatibility.  
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5.1.6 Polymorphonuclear neutrophil (PMN) elastase: Leukocyte Activation 
Angioplasty/stent implantation provoke local vascular injury during endothelial denudation, 
and plaque crushing, to promote leukocyte recruitment for local inflammation [330]. 
Recruitment and activation of polymorphonuclear neutrophils (PMN) following endothelial 
damage is observed after percutaneous coronary interventions (PCI), and plays a role in 
pathophysiology of acute coronary syndromes (ACS) [331]. Polymorphonuclear neutrophils 
(PMNs) are abundant blood circulating leukocytes, secreting proteolytic enzyme neutrophil 
elastase; activated during inflammation to destroy bacteria and host tissue [332]. Resulting 
chronic inflammation has direct cytotoxic effects, with ability to destroy human endothelial 
cells during neointimal hyperplasia [330]. Neutrophils potentiate platelet activation, and 
amplify endothelial damage, to play a significant role in the pathogenesis of restenosis after 
PCI [330, 331]. Activated inflammatory cells are present in atherosclerotic plaques, as well as 
in peripheral circulation [331]. Activated inflammatory cells also initiate production and 
expression of acute phase inflammatory proteins such as interleukin (IL)-6, and β2 integrin 
MAC-1 on the surface of PMNs to regulate firm leukocyte adhesion to platelets, and to 
fibrinogen at site of injury [332]. These in turn have been linked to plaque formation and 
rupture, support neointimal thickening, clinical restenosis after stenting, as well as subsequent 
cardiovascular events in patients already suffering from acute coronary syndrome (ACS) [332, 
333].  
Contact with biomaterials in vivo, activates both monocytes and neutrophils. Degranulation 
leads to release of elastase, resulting in extracorporeal circulation due to leukocyte activation 
[334]. Material-induced leukocyte activation is dependent on exposed surface area, protein 
ligands present on the interface, and the presence of adherent platelets [334]. Hydrophobic 
surfaces tend to promote leukocyte adhesion and activation, compared to hydrophilic surfaces. 
In vivo studies have shown activated leukocyte adherence to stents, oxygenators and 
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hemodialysis membranes [331]. The primary aim of leukocyte activation is to engulf a 
pathogen/infiltrating foreign particle. Since a biomaterial cannot be engulfed by leukocytes, 
surface adhering neutrophils and monocytes attempt phagocytosis [334]. This results in 
extracellular release of   proteolytic enzymes, reactive oxygen intermediates which potentiate 
injury, promote smooth muscle cell proliferation, migration and extracellular matrix deposition 
[335]. Down-regulation of leukocyte activation may therefore reduce inflammation-associated 
neointimal thickening, platelet adhesion and clinical restenosis commonly observed post PCI.   
Material-induced leukocyte activation is mediated via several factors; including thrombin 
formation, platelet activation and complement activation already introduced within the chapter. 
Inhibition of one pathway alone is therefore insufficient to inhibit leukocytes [334].  In vitro 
investigation of material-induced leukocyte activation is quantified via PMN elastase released 
after degranulation. Comparative studies with in vitro ELISA allow PMN elastase 
quantification to estimate surface induced inflammation, and thereby estimate 
biocompatibility.  
The study aimed at establishing an in vitro model foremost, to test hemocompatibility of PAC-
L605 surfaces, in accordance with ISO 10993-4. The tests were performed with heparinized 
human whole blood. After flow assays in a modified chandler loop, blood plasma was analyzed 
for coagulation, platelet activation, complement activation and leukocyte activation with 
relevant enzyme linked immunosorbent assays (ELISAs). The ISO recommended tests allow a 
robust criterion to determine clinical markers in vitro, prior to translating PAC technology to 
an ML8 commercial stent (alloy L605, cobalt chromium), and subsequent translational studies 
in vivo. 
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Figure 5.2 
Soluble terminal complement complex (TCC, SC5b-9), is generated by the solubilization of 
the C5 through C9 membrane attack complex (MAC): circled in red. Formation of MAC is a 
consequence of activation of the complement system, by the classical pathway (seen in purple), 
lectin pathway (blue) or alternative pathway (green). The final outcome of MAC formation, is 
an inflammatory response resulting in membrane perturbation of invading pathogens, to disrupt 
target cells, cell lysis and death (highlighted in orange). Measurement of SC5b-9 complex after 
blood-material contact, comparatively quantifies initiation of biomaterial induced 
inflammatory response via all the complement pathways. Image is modified from [327] and 
what-when-how.com/acp-medicine/innate-immunity-part-2/ website. 
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5.2 Materials and Methods 
 
5.2.1 Materials, Equipment, Suppliers and Facilities 
A list of chemicals, reagents, materials and their suppliers are presented in Table 5.2 
Table 5.2 Materials and their suppliers 
 
Chemical/Reagent/Material Supplier/Facility 
6 mm Tygon tubing ND-100-65, Class VI 
(ID 6.35 mm, O.D. 7.93, 50 FT) 
Saint-Gobain Performance Plastics, PA, 
USA 
Beta-Thromboglobulin (β-TG) ELISA kit MyBioSource Inc. San Diego, CA, USA 
Citrate (CTAD) 4.5 mL, 0.109M (blue cap) BD vacutainer, Macquarie University 
Research Park, NSW, Australia 
EDTA (K3EDTA), 3 mL (lavender cap) BD vacutainer, Macquarie University 
Research Park, NSW, Australia 
Heparin sodium salt (porcine intestinal 
mucosa, H3393, 180 U/mg) 
Sigma-Aldrich, St. Louis, MO, USA 
Polymorphonuclear elastase (PMN elastase) 
ELISA kit 
Abcam, Cambridge, MA, USA 
Silicon tubing (ID 10 mm, 10 FT) 
Masterflex 
John Morris Scientific Pty Ltd, NSW, 
Australia 
Soluble P-selectin (sP-selectin) ELISA kit Life Technologies Australia, Victoria, 
Australia 
Soluble terminal complement complex – 
SC5b-9 (plus EIA) ELISA kit 
MicroVue Quidel, San Diego, CA, USA 
Thrombin-Antithrombin (TAT) ELISA kit Abcam, Cambridge, MA, USA 
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5.2.2 Preparation of alloy L605 and PAC-L605 
Preparation of alloy L605 and PAC deposition was carried out as described in chapter 3.2.2. 
For the blood-material contact experiments in this chapter, we chose PAC1-L605 recipe (C-1, 
N-10, 500 V, t=20 min), referred throughout as PAC-L605. Prior to all experiments the two 
materials were cleaned and sterilized.  
5.2.3 Modified Chandler Loop: Flow Assay  
Prior to plasma isolation for each enzyme immunoassay (EIA), modified chandler loop flow 
tests were conducted, to investigate clot formation as described in section 4.2.10.5. Plasma was 
isolated after 60 min flow, for each EIA at different centrifugation speed and time limits, as 
recommended in commercial kits and previous literature. After flow assay, 1000 µL of 
heparinized whole blood was added to microcentrifuge tubes with 1/10th volume of 
citrate/EDTA for plasma isolation (100 µL). The varied plasma isolation conditions for each 
ELISA is shown in table 5.3. All aliquots were stored at -20oC overnight, for each ISO 
recommended ELISA. Each experiment was conducted in duplicate.   
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Table 5.3 Specific conditions of plasma isolation after 60 min chandler loop flow assay 
for individual ELISAs.  
 
5.2.4 Thrombin-Antithrombin Complex (TAT) Human ELISA 
The Thrombin-Antithrombin complex (TAT) concentrations in plasma isolated from 60 min 
flow (stored at -20oC), was quantified according to manufacturer’s instructions (abcam, 
Cambridge, MA, USA). Plasma samples were not diluted prior to ELISA, 50 µL of the sample 
and standards were added to the wells in duplicates. The standard range was from 1.48 ng/mL-
120 ng/mL with a sensitivity of 1.5 ng/mL.  Standards were prepared according to protocol. 
Samples were subsequently incubated with TAT-specific biotinylated detection antibody, 
followed by wash buffer, as recommended. Biotinylation was followed by streptavidin 
peroxidase conjugation, and TMB (tetramethylbenzidine) to visualize enzymatic reaction 
(Streptavidin-Peroxidase). The density of the colour compound formed after stopping the 
reaction was representative of the TAT concentration captured within the plate; corresponding 
to the biomaterial of interest. Reading was performed in a 96 well plate at 450 nm with a 570 
nm wavelength correction.   
 Plasma Isolation Conditions 
ELISA test Centrifugation 
speed 
Time (mins) Anticoagulant 
Thrombin-Antithrombin 
complex (TAT) 
3000 x g 10  10% citrate 
Beta-thromboglobulin (β-TG) 1000 x g 20 10% citrate 
sP-selectin 1000 x g 15 10% citrate 
SC5b-9 complex 10,000 x g 5 10% K2EDTA 
PMN-elastase 1500 x g 10 10% K2EDTA 
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5.2.5 Beta Thromboglobulin (β-TG) Human ELISA 
The human Beta-Thromboglobulin (β-TG) concentration in plasma isolated from 60 min flow 
(stored at -20oC), was quantified according to manufacturer’s instructions (MyBioSource, San 
Diego, CA, USA). Plasma samples were not diluted prior to ELISA, 50 µL of the sample and 
standards were added to the wells in duplicates.  The standard range was from 100 ng/mL to 
3.12 ng/mL, prepared at manufacture, with a sensitivity of 1.0 ng/mL. To increase sensitivity, 
we prepared a 7th standard of 1.57 ng/mL [250 µL of standard 6 (3.12 ng/mL) in 250 µL 
standard diluent]. The assay was carried out according to the manufacturer’s instructions. 
Optical density, representative of the β-TG concentration captured within the 96 well plate was 
measured at 450 nm.   
5.2.6 Soluble P-selectin (sP-selectin) Human ELISA 
The soluble P-selectin (sP-selectin) concentration in plasma isolated from 60 min flow (stored 
at -20oC), was quantified according to manufacturer’s instructions (Life Technologies, 
Victoria, Australia). In the initial experiment, the plasma samples were diluted 1/10th in assay 
buffer as recommended in the protocol, in repeat experiments the plasma samples were diluted 
1/30th with assay buffer. The sP-selectin stock standard was reconstituted by addition of 360 
µL of distilled water. The homogenized standard was diluted sequentially in assay buffer as 
instructed, to prepare a standard range from 40 ng/mL to 0.63 ng/mL, with a sensitivity of 0.2 
ng/mL. The assay was carried out according to manufacturer’s instructions. Optical density, 
representative of sP-selectin concentration captured within the 96 well plate was measured at 
450 nm with a 620 nm reference wavelength.  
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5.2.7 Terminal Complement Complex (TCC, SC5b-9) Human ELISA 
The soluble C5b-9 complex/TCC concentration in plasma isolated from two separate flow 
assays at 10 min and 60 min (stored at -20oC), was quantified according to manufacturers’ 
instructions (MicroVue, Quidel, San Diego, CA, USA). The plasma samples were diluted 
1/10th with specimen diluent as recommended in the protocol. The SC5b-9 complex standard 
range was from 185 ng/mL to 0 ng/mL, prepared at manufacture. High controls (106-156 
ng/mL) and low controls (15-33 ng/mL) were also provided for the assay, and used in similar 
dilution to the samples. The assay was carried out according to the manufacturer’s protocol. 
Optical density, representative of SC5b-9 concentration, captured within the 96 well plate was 
measured at 450 nm. 
5.2.8 Polymorphonuclear Elastase (PMN-elastase) Human ELISA 
The PMN-elastase concentration in plasma isolated from 60 min flow (stored at -20oC), was 
quantified according to manufacturer’s instructions (abcam, Cambridge, MA, USA). The 
plasma samples were diluted 1/10th with sample diluent as recommended in the protocol, in 
trial experiments the plasma samples were diluted 1/100th  (1:100) with sample diluent. The 10 
ng/mL stock standard was prepared by reconstituting PMN elastase standard with 2700 µL 
sample diluent, and held at room temperature for 30 min. The PMN elastase standard range 
was from 10 ng/mL to 0 ng/mL, with a sensitivity of 1.98 pg/mL. High controls and low 
controls were provided for the assay, used in similar dilution to the samples. The assay was 
carried out according to manufacturer’s protocol. Optical density representative of PMN-
elastase concentration within the 96 well plate was measured at 450 nm with a 620 nm reference 
wavelength.  
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5.2.9 Statistics 
For flow results and ELISA data, the averages, statistical significance and unknown 
concentration of 6 pairs of variables, were calculated with Microsoft Excel (Office 2013, DC, 
USA) and GraphPad PRISM 6 for Mac OS X software (Version 6a; GraphPad Software, La 
Jolla, CA, USA). Unknown concentrations were calculated with nonlinear regression (curve 
fit). Standard curves to interpolate hyperbola (X is concentration) were selected with fitting 
method (least squares ordinary fit), to interpolate unknowns from the standard curve. Statistical 
significance was estimated with paired t-tests for grouped data between two variables, and 
ordinary one-way ANOVA with multiple comparisons for >2 variables, as appropriate. All 
results corresponding to ELISA concentrations are presented in figures in their experimental 
dilution. The interpolated concentration for unknown variables is multiplied by appropriate 
dilution factor, within context describing results, as appropriate. 
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5.3 Results 
5.3.1 Comparative flow and EIA for PAC-L605 vs. L605 surfaces 
Five consecutive flow assays were conducted for each plasma isolation event for ELISA. 
Depending on conditions of centrifugation (table 5.3), 200-500 µL of plasma was isolated and 
stored at -20oC for utilization in ELISAs. All results corresponding to EIA concentrations, are 
presented in figures in their initial experimental dilution. The interpolated concentration is 
multiplied by appropriate dilution factor, within context.   
5.3.2 Quantification of Thrombin Antithrombin (TAT) complex for PAC-
L605 vs L605 surfaces: [TAT complex] is lower on PAC 
Thrombus formation at a time course of 60 min was investigated with a modified chandler loop 
flow assay prior to plasma isolation for TAT. Significantly lowered clot formation was 
observed for PAC-L605 compared to alloy L605 surfaces; 8.36±4.38 mg and 35.9±7.88 mg 
respectively (p=0.001), figure 5.3 A. The TAT complex was identified and quantified with a  
standard curve to derive test results, figure 5.3 B. Significantly lowered concentration of TAT 
was observed with plasma isolated after contact with PAC-L605 surfaces compared to L605; 
7.22±1.33 ng/mL vs. 15.93±2.55 ng/mL respectively (p=0.002), figure 5.3 C.  
5.3.3 Quantification of Beta-Thromboglobulin (β-TG) for PAC-L605 vs. 
L605 surfaces: [β-TG] is lower on PAC 
Thrombus formation at a time course of 60 min was investigated with a modified chandler loop 
flow assay prior to plasma isolation for β-TG. Plasma was isolated from the 60 min flow assay 
for SC5b-9 ELISA as well, investigated next (5.3.5). Significantly lowered clot formation 
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observed for PAC-L605 vs L605; 3.93±2.86 mg vs. 30.70±1 mg respectively (p=0.025), figure 
5.4 A. The β-TG complex was identified and quantified with a standard curve to derive test 
results, figure 5.4B. Significantly lowered concentration of β-TG observed with plasma 
isolated after contact with PAC-L605 surfaces compared to L605; 16.61±3.33 ng/mL vs. 
27.16±3.75 ng/mL respectively (p=0.025), figure 5.4C. 
5.3.4 Quantification of soluble P selectin (sP-selectin) for PAC-L605 vs 
L605 surfaces: [sP-selectin] lower on PAC 
Thrombus formation at a time course of 60 min was investigated with a modified chandler loop 
flow assay, prior to plasma isolation for sP-selectin. Significantly lowered clot formation was 
observed for PAC-L605 vs. L605 surfaces; 4.56±3.65 mg vs. 43.95±9.95 mg respectively 
(p=0.014), figure 5.5 A. The sP-selectin complex was identified and quantified with a standard 
curve to derive test results, seen in figure 5.5B. A dilution of 1:10 yielded absorbances higher 
than the standard curve, therefore the experiment was repeated with a 1:30 dilution. The sP-
selectin concentration was quantified after contact with PAC-L605 surfaces compared to L605. 
Due to variability of results, only the average absorbance was used to calculate concentration, 
presented in figure 5.5C. Concentration interpolated from the standard curve was multiplied by 
a dilution factor (x30) presented in parentheses. The average sP-selectin after PAC-L605 
contact was 4.87±0.07 ng/mL (146.19±2.1 ng/mL), and the average concentration after L605 
contact was 10.575±020 ng/mL (317.25±6 ng/mL) (p=0.0138). Absorbances for the high 
control was above the standard curve, concentration could not be interpolated at 1:30 dilution. 
Concentration of the low control was 2.078 ng/mL±0.090 (62.34±2.7 ng/mL) (not included in 
graph). Experiments should be repeated at higher dilution, to interpolate concentration for high 
control and minimize unknown concentration variability.  
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5.3.5 Quantification of soluble terminal complement complex (SC5b-9) for 
PAC-L605 vs L605 surfaces: at 60 mins [SC5b-9] lower on PAC 
Thrombus formation at a time course of 60 min was investigated with a modified chandler loop 
assay - prior to plasma isolation for SC5b-9. Significantly lowered clot formation was observed 
for PAC-L605 vs. L605 surfaces at 60 min, figure 5.6 A (results are the same as those for 5.3.3, 
since flow assay was common to both. Conditions of plasma isolation were different – see table 
5.3). Clot formation at 10 min was very low, as expected, and not significantly different 
between the two surfaces. Although trends show lower clot formation for PAC-L605 compared 
to alloy L605; 0.6±0.35 mg vs. 2.5±1.04 mg respectively, figure 5.6A. The SC5b-9 complex 
was identified and quantified with a standard curve to interpolate test results, figure 5.6B. 
Concentration interpolated from the standard curve was multiplied by a dilution factor (x10) 
presented in parentheses. Concentration of SC5b-9 at 60 min was significantly lower for PAC-
L605 surfaces compared to alloy L605; 98.18±21.88 ng/mL (981.91±218.84 ng/mL) vs. 
120.27±15.05 ng/mL (1202.77±150.53 ng/mL) respectively (p=0.032). The high control 
yielded a concentration of 113.66±1.41 ng/mL (1136.6±14.16) and the low control yielded a 
concentration of 34.20±1.98 ng/mL, (342.0±19.80) figure 5.6C. Concentration of SC5b-9 at 10 
min was not significantly different between PAC-L605 and L605 surfaces; 42.06±0.38 ng/mL 
(420.66±3.8 ng/mL) vs. 43.51±1.93 ng/mL (435.19±19.33 ng/mL) respectively (p=0.444), 
figure 5.6C.  
5.3.6 Quantification of Polymorphonuclear elastase (PMN elastase) for PAC-
L605 vs L605 surfaces:  
Thrombus formation at time course of 60 min was investigated with a modified chandler loop 
assay prior to plasma isolation for PMN-elastase. Significantly lowered clot formation was 
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observed for PAC-L605 vs. L605 surfaces at 60 min; 1.8±0.48 mg vs. 9.4±1.65 mg respectively 
(p=0.015), figure 5.7A. The PMN elastase enzyme was identified and quantified with a 
standard curve to interpolate test results, seen in figure 5.7B. Concentration interpolated from 
the standard curve were multiplied by a dilution factor (x100) presented in parentheses. 
Concentration of PMN elastase at 60 min was not significantly different between L605 and 
PAC-L605 surfaces; 2.72±0.45 ng/mL (272.75±45.17 ng/mL) vs. 3.26±0.26 ng/mL 
(326.84±26.03 ng/mL) (p=0.149) respectively. The high control yielded a concentration of 
10.67±2.9 ng/mL (1067.52±296.83 ng/mL) and low control yielded a concentration of 
1.19±0.41 (119.66±40.82 ng/mL), figure 5.7C.   
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Figure 5.3 
A) Flow assay (60 min) for L605 vs. PACL05 shows 
significantly lowered thrombus formation on modified 
surfaces (p=0.001) B) Standard curve for TAT ELISA 
to interpolate unknown concentrations at 450/570 nm 
C) TAT complex is significantly lower for PAC 
surfaces compared to L605 (p=0.002). Graphs 
presented with initial experimental dilution. 
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Figure 5.4 
A) Flow assay (60 min) for L605 vs. PACL05 
shows significantly lowered thrombus 
formation on modified surfaces (p=0.025) B) 
Standard curve for β-TG ELISA to interpolate 
unknown concentrations at 450 nm C) β-TG is 
significantly lower for PAC surfaces 
compared to L605 (p=0.025). Graphs 
presented with initial experimental dilution. 
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Figure 5.5 
 
 
 
 
 
 
 
 
 
 
 
A) Flow assay (60 min) for L605 vs. PACL05 shows 
significantly lowered thrombus formation on modified 
surfaces (p=0.014) B) Standard curve for sP-selectin 
ELISA to interpolate unknown concentrations at 
450/620 nm C) The average sP-selectin (1:30) 
concentration between the two surfaces was 
significantly different (p=<0.0001). Graphs presented 
with initial experimental dilution. 
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Figure 5.6
A) Clot weight at 10 min for L605 vs. PACL05 
was not significant (p=0.176), at 60 min the values 
were significantly lowered for PAC-L605 vs. 
L605 (p=0.025) B) Standard curve for SC5b-9 
ELISA to interpolate unknown concentrations at 
450 nm C) The SC5b-9 complex (1:10) 
concentration between the two surfaces was not 
significantly different at 10 min (p=0.444) but 
significantly lowered for PAC-L605 vs.  L605 at 
60 min (p=0.032). Graphs presented with initial 
experimental dilution. 
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Figure 5.7
A) Flow assay (60 min) for L605 vs. PACL05 
shows significantly lowered thrombus 
formation on modified surfaces (p=0.015) B) 
Standard curve for PMN elastase ELISA to 
interpolate unknown concentrations at 450/620 
nm C) The average PMN elastase (1:100) 
concentration between the two surfaces was not 
significantly different (p=0.150). Graphs 
presented with initial experimental dilution. 
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5.4 Discussion  
 
During first 2 weeks of stent implantation, sub-acute stent thrombosis and an early 
inflammatory response are two main clinical complications that occur after undesired blood-
stent interactions [252, 331]. We investigated plasma biomarkers of coagulation and 
inflammation; TAT, β-TG, sP-selectin, SC5b-9, and PMN elastase, after modified chandler 
loop, with enzyme immunosorbent assays (EIA) in vitro. In contrast to animal models, an in 
vitro model allows early investigation of blood-material contact in relation to several 
biochemical cascades. Plasma isolated after blood-material contact was used for investigations, 
in accordance to ISO 10993-4 recommendations [299]. Key findings of this study include; 
significantly reduced TAT complex, β-TG and sP-selectin (markers of coagulation/platelet 
activation) for PAC-L605 compared to bare metal alloy L605. Further findings include 
significantly reduced SC5b-9 complex; marker of complement activation for PAC compared 
to L605. There was no significant difference between plasma levels of PMN elastase; leukocyte 
activation for the two biomaterials.   
5.4.1 Dynamics of blood-biomaterial contact – A hypothesis 
It is generally accepted that hydrophobic surfaces adsorb more proteins than hydrophilic 
surfaces (Bergs Law) [259]. Proteins thus adsorbed form a monolayer on the surface, with up 
to 1000-fold higher concentration than in solution [336]. Platelet adhesion is promoted in the 
presence of surface proteins fibrinogen, von Willebrand factor, fibrin, and reduced in the 
presence of surface proteins; albumin and/or high density lipoprotein (HDL) [337]. Adsorbed 
proteins are subject to change over time, in a phenomenon termed Vroman effect [338]; largely 
applicable to hydrophilic surfaces [339, 340]. According to the phenomenon, plasma proteins 
compete for occupation on a surface, resulting in competitive adsorption, more effective on 
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hydrophilic materials. With hydrophobic surfaces, proteins undergo conformational changes 
on surface, become immunologically undetectable, and adsorb irreversibly [341, 342]. 
To explain results of the present study, we hypothesize that modified hydrophilic PAC-L605 
conform to Vroman effect, and may predominantly adsorb plasma proteins albumin and HDL. 
Keeping in mind both proteins reduced surface platelet aggregation and activation [337], as 
also observed with PAC-L605, in this chapter. In support of hypothesis, previous studies have 
shown significantly higher levels of plasma HDL adsorption to hydrophilic surfaces [342], and 
significantly higher adsorption of surface albumin, compared to hydrophobic surfaces [343]. 
Fibrinogen, the more abundant plasma protein promotes platelet adhesion, but as observed in 
chapter 4, has lower adsorption on hydrophilic PAC-L605 compared to bare alloy L605. 
Fibrinogen exists in two distinct experimentally observed conformations; irreversible and 
reversible adsorption, replaced by other proteins [344]; in further agreement with our results.  
5.4.1.1 Thrombosis and TAT ELISA: Reduced coagulation marker on PAC 
Active thrombin formed via conversion of prothrombin by tissue factor Xa (TF Xa), is a main 
effector protease of the coagulation cascade [305] (figure 5.1). TF is also expressed at low 
levels on circulating monocytes and leukocytes in vivo. When blood contacts a material, the 
surface triggers coagulation activation (and complement systems) via intrinsic, extrinsic and 
common pathways (figure 4.1) [345]. Materials widely incorporated for implants are generally 
biocompatible, although clinical complications [213] lead to adverse outcomes, and should be 
avoided. Under physiological conditions, we demonstrated ability of PAC to significantly 
reduce TAT complex formed after blood-material contact, using flow assays and EIA in vitro.  
In vivo TAT complex is formed when prothrombin is converted to thrombin during blood 
clotting, and both antithrombin III and antithrombin IV, neutralize the thrombin formed [346]. 
Antithrombin III (AT) is a high-capacity inhibitor of both thrombin and autoprothrombin C 
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(precursor of thrombin) proteases in blood coagulation [347]. However, under special 
conditions/disease, thrombin may regenerate from the TAT complex [347], forming a positive 
feedback loop.  
In the presence of  anticoagulant heparin, capacity of antithrombin (AT) to inhibit thrombin is 
accelerated [346]. In the presence of heparin, TAT complex is hypothesized to form  via 3 
different pathways (both in vivo or in vitro) [348]; 1) heparin may first bind to AT - enhance 
the rate of inhibitor-protease reaction [349], 2) heparin may bind to thrombin first - form a 
complex and be rapidly inactivated by free AT [350], 3) finally, heparin may act as a template 
- bringing the protease and inhibitor closer [351]. The second hypothesis has been proven 
correct on evaluating the role of heparin in TAT complex formation [350]. Systematically 
therefore, increased levels of plasma TAT complex is a marker of coagulation; indicating high 
levels of the serine protease thrombin and its corresponding inhibitor AT in plasma. 
Normal human plasma levels of TAT are estimated to be at a range of 0.5-10 ng/mL (abcam 
ELISA manual, Cambridge, MA, USA). In our study, after 60 min flow within physiological 
conditions, the plasma levels of TAT after PAC-L605 contact was 7.22±1.33 ng/mL (within 
the normal TAT complex range). Within same conditions, plasma levels of TAT after L605 
contact was 15.93±2.55 ng/mL; ~50% above the normal plasma range of TAT. It appears PAC 
surfaces are hemocompatible, lowers clot formation within a modified chandler loop at 60 min 
and contributes to lowered plasma markers of coagulation in vitro. The present study shows 
that aside from hemocompatibility, modified surfaces are also cytocompatible, compared to the 
bare metal alloy. 
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5.4.2 Reduced levels of platelet activation marker β-TG on PAC surfaces 
Plasma beta-thromboglobulin (β-TG) is a platelet-specific protein marker released via platelet 
degranulation [352]. In atherosclerotic vascular disease and arterial thrombosis, platelet 
materials released are measured, to provide a clinical index of platelet activation [353].  A 
number of effects on platelet function predispose to atherosclerosis, coronary thrombosis and 
ischemic heart disease [354]. The primary role of platelets (bone marrow megakaryocytes), is 
recognition of vascular injury. Platelets stimulated via different ligand-receptor signals activate 
in four stages 1) development of stickiness (from non-sticky resting state), 2) changes in cell 
shape i.e. extend pseudopods to adhere to surface, 3) contraction and release granule contents, 
and 4) irreversible aggregation (most common on hydrophobic surfaces) [355]. We 
investigated two plasma markers relating to platelet degranulation and activation in plasma 
isolated via blood-material contact; β-TG and sP-selectin. We demonstrated the ability of a 
plasma modified surface to significantly reduce β-TG released and sP-selectin expressed on 
platelets, after blood-material contact using flow assays and EIA in vitro. 
Clinical studies have shown contribution of platelet degranulation towards intima-media 
thickness of common carotid artery, in patients with diabetes mellitus type 2 [354]. 
Measurement of β-TG in vitro is an indirect index of platelet activation. Granule contents 
released to the surrounding medium during platelet activation include ADP, ATP, calcium, 
serotonin, platelet factors, β-TG, fibrinogen, fibronectin etc. [355]. The release promotes 
platelet/fibrin aggregate formation, previously observed via SEM and fluorescent staining on 
L605 (chapter 4). Consequently, higher concentrations of β-TG were quantified for L605 
herein. Comparatively we observed a 38.84% reduction of β-TG expression on PAC-L605 
surfaces.  
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5.4.2.1 Mechanisms of platelet degranulation: theory for hydrophilic surfaces 
Platelet adherence to a surface is dependent on surface roughness (width of spaces between 
surfaces), charge, wettability, and flow conditions (characterized in chapter 3 & 4). Plasma 
proteins and their initial concentration/dilution, also promote platelet activation. Plasma 
proteins; albumin, fibrinogen and globulin rapidly deposit on artificial surfaces, replaced over 
time with high-molecular weight kininogen (HMWK) and hagmeman factor [338]. Protein-
surface interaction dictates degree of platelet activation. For instance; laminin induces platelet 
focal adhesion, fibronectin promotes spreading and activation, and collagen supports 
aggregation/secretion [338]. Fibrinogen has higher adsorbance affinity, higher concentration 
on surfaces than in the bulk plasma, and promotes platelet response to surface. Fibrinogen plays 
a key role in platelet-surface attachment, aggregation and secretion (degranulation), 
extensively detailed by Vroman during initial evaluation of blood-surface interactions [356].  
However, on hydrophilic surfaces “an entire parade of protein may adhere and leave the 
substrate” (after fibrinogen adherence and displacement), due to high turnover rate [356]. On 
the basis of data, Vroman concludes the sequence of adsorption is based on plasma proteins 
available from higher to lower concentration; i.e. albumin, immunoglobins (IgG), fibrinogen 
and fibronectin, followed by factor XII and high molecular weight kininogen (HMWK, 
coagulation initiator). On hydrophilic surfaces, such interactions cause a rapid turnover of 
adsorbed albumin, so that sites it occupies will be often but only briefly available to other 
proteins [356]. This has been further verified with a mathematical model for Vroman’s effect 
[340].   
5.4.3 Marker of platelet activation sP-selectin ELISA on PAC vs. L605 
The concentration of plasma P-selectin circulating in normal human blood is about 100 ng/mL, 
which can rise to as much as 1 µg/mL during pathological disorders and arterial thrombosis in 
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vivo, suggesting clinical relevance of the plasma isoform [315, 321]. In our study, we showed 
an increased level of soluble P-selectin in plasma (diluted 30x), isolated from whole blood after 
material contact, although values were significantly lower for PAC-L605 surfaces compared 
to L605 (p=<0.0001). However, both values were above normal concentration of plasma P-
selectin (~31.5% higher with PAC-L605 and 68.45% with L605) indicating platelet activation 
for both surfaces. The sP-selectin ELISA assay was chosen to detect soluble isomer of P-
selectin biomarker since: it’s an ISO recommended marker for surface hemocompatibility, and 
has a longer half-life (1 hour). Length of its activity in circulation also correlates to length of 
in vitro flow assay; therefore a better estimate of platelet activation than  β-TG with shorter 
half-life [315].  
In vitro, the activation dependent increase in platelet surface P-selectin is not reversible over 
time [357]. In vivo, circulating platelets tracked via biotinylation showed they; 1) rapidly lose 
surface P-selectin, yet continue to circulate and function 2) were degranulated by thrombin 
very rapidly (~1 minute) to form circulating aggregates with monocytes (half-life 30 mins) and 
neutrophils (half-life 5 mins). While P-selectin expressed on activated platelets is known for 
its role in platelet aggregation and coagulation, studies have failed to identify the physiological 
role of circulating forms of soluble P-selectin in vivo [358].  
Independent in vivo studies also confirmed circulating monocyte-platelet aggregates were more 
sensitive of platelet activity, than platelet surface P-selectin [324]. In vivo circulating 
degranulated platelets rapidly lose their surface P-selectin yet continue to circulate, indicating 
sP-selectin was not a robust biomarker of platelet activation. Clinical studies in human PCI and 
platelet activation, were also in agreement with the hypothesis, showing lower levels of P-
selectin positive platelets, in comparison to circulating monocyte/neutrophil-platelet 
aggregates [324]. In lieu of previous investigations, plasma levels of sP-selectin quantified in 
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this study are therefore debatable. Biocompatibility of materials was assessed with more 
sensitive biomarkers of complement activation and inflammation, next, in accordance to ISO 
tests.  
5.4.4 Reduced levels of complement activation marker SC5b-9 on PAC  
The human complement system is part of the body’s innate immunity, comprised of 3 distinct 
pathways to eliminate microorganisms and other foreign substances in circulation [327].  The 
three pathways lead to formation of terminal complement complex (TCC) also known as C5b-
9, via membrane attack complex (MAC), illustrated in figure 5.2. All forms of stable TCC, 
investigated in this study are termed (soluble) SC5b-9. Not all MAC formed are inserted into 
pathogen cell membrane (as illustrated, figure 5.2), sublytic concentrations of the MAC 
stimulate various cells including platelets [359]. Complement activation after blood-material 
contact is broadly a marker of inflammatory host response to implantation [360]. 
Plasma samples were diluted x10 from the initial concentration for SC5b-9 ELISA. Although 
complement activation was observed for both surfaces, an 18% reduction of SC5b-9 
concentration was observed after PAC-L605 contact, compared to alloy L605 (p=0.0321). 
Direct and continuous activation of the alternative pathway (AP) is the driving force behind 
complement-related effects for biomaterials/foreign surfaces [360], with classical and lectin 
pathway contributions. Pathway of complement activation varies depending on properties of 
biomaterial; physical/chemical properties and hydrophobicity/hydrophilicity [361].  
Hydrophobic surfaces are more potent activators than hydrophilic, as seen in our study. 
However, chemical groups such as NH3, OH, or COOH also influence activation, via the lectin 
pathway[361]. The lectin pathway is physiologically activated by certain carbohydrates on 
microbial surfaces [327] (figure 5.2, blue highlight). Regardless of surface composition, plasma 
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proteins cover all biomaterials in vivo [361], the adsorbed C3 in this initial protein layer, is 
formed via all three pathways, and will generate C3 convertase. Bioengineering surfaces to 
regulate innate immune recognition can prevent an adverse immune response after implanting 
biomaterials.  
5.4.4.1 Mechanism of Alternative Pathway (AP) activation in the presence of a 
biomaterial 
Studies investigated if complement activation after blood contact with a model biomaterial, 
occurred directly on material surface or on top of its adsorbed protein layer [362]. In the 
presence of a biomaterial, complement activation is first triggered by the classical pathway 
activation, via adsorption of protein film (figure 5.2, highlighted in purple). Adsorbed albumin, 
IgG, but not fibrinogen allowed covalent C3b binding, convertase assembly and amplification, 
mediated by AP next, on top of the adsorbed protein film (AP = alternative pathway, figure 
5.2, green highlight).  
Main event in the activation of complement is therefore, proteolytic cleavage of C3, detailed 
in [362] mediated by biomaterial surface protein aggregates, and not biomaterial itself. A model 
C3 activation and SC5b-9 complex formation (measured in this study), is schematically 
presented on a biomaterial surface in figure 5.8 [361] to explain AP activation mechanism.  
Initiation of biomaterial associated AP amplification process loop, is triggered by C3 
convertase enzymes from all 3 pathways (discussed above). A hydrophilic biomaterial that 
conforms to the Vroman effect, and binds low levels of plasma proteins, will therefore be a 
poor activator of the complement system, as seen herein, and verified in previous investigations 
[363]. We conducted a 10 min and 60 min flow assay respectively, for plasma isolation for 
EIA, to understand variation of sC5b-9 complex concentration, with time. With time (10-60 
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min), the concentration of sC5b-9 complex increased by 57% on PAC-L605 surfaces and 
63.82% on bare alloy L605. The generated complement activation in turn triggers platelets (as 
mentioned before) [324], polymorphonuclear leukocytes (PMNs), and 
monocytes/macrophages, to elicit a thrombotic and inflammatory response (figure 5.8). 
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Figure 5.8 
 
 
 
 
 
 
 
 
 
 
Model modified from [361], shows the initiation of complement activation on a biomaterial surface via alternative pathway-AP. Activation is 
triggered by protein film adsorbed initially to surface, including immunoglobins, fibrinogen, and human serum albumin (A) - highlighted in red, 
since it is predominantly involved in the catalysis of C3 to C3b. The generated C5a and SC5b-9 complex (yellow highlight, quantified in 5.2.7), 
activate platelets (red highlight, markers quantified in 5.2.5&6) as well as granulocytes (blue/dotted, quantified in 5.2.8), and monocytes. The 
complexes bind again to protein-bound iC3b (purple) to release proteolytic enzymes, more details in [361]. 
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5.4.5 Factors contributing to PMN elastase - marker of leukocyte activation  
Activation of each pathway discussed in this chapter, trigger amplification reactions and 
contribute to coagulation and inflammation [364]. PMN elastase, released via 
polymorphonuclear (PMN) granulocytes, is a marker of leukocyte activation. Concentration of 
PMN elastase was not significantly different between PAC-L605 and L605 surfaces 
(p=0.1499) (figure 5.7). The initial concentration of PMN elastase was relatively high requiring 
x100 dilution of original plasma content, for ELISA. The values were still comparatively lower 
than markers of complement SC5b-9 complex; which triggered the leukocyte activation 
(PMNs) and subsequent PMN elastase (proteolytic enzyme) release.   
Mechanistically, the material-induced alternate pathway (AP) of complement cascade triggers 
leukocyte activation (figure 5.8). Note the complement-granulocyte-platelet aggregates formed 
(blue dotted line, figure 5.8), adhere to artificial surfaces via albumin-ic3b complexes (purple 
highlight, figure 5.8). The adherent neutrophils and monocytes then release their array of 
oxygen metabolites, growth factors, cytokines and proteolytic enzymes (PMN elastase) [365].   
Hydrophobic surfaces are presumed to adhere, activate and release higher leukocyte proteases 
and cytokines [366], but we observed relatively higher PMN elastase concentration on 
hydrophilic PAC-L605 (values were not significant). This could be due to the higher turnover 
rate of albumin protein (Vroman effect) proposed on hydrophilic PAC-L605, compared to 
fibrinogen (abundant on L605). Given that leukocyte aggregates adhere to biomaterial surfaces 
specifically via ic3b bound to albumin protein (seen in figure 5.8), albumin may be 
predominant on PAC-L605, leading to observed higher PMN elastase concentrations on PAC-
L605. 
Overall, the highest concentration of biomarkers calculated in chapter 5, is in relation to 
complement activation (SC5B-9 complex). Complement activation occurs via 3 different 
 206 
 
pathways, including AP, therefore higher concentration observed for L605 is as theoretically 
predicted. Furthermore, the complement cascade promotes leukocyte activation (figure 5.8, 
AP) [361], previous studies have shown inhibiting complement activation reduces material 
induced leukocyte activation in vivo [366]. Events occurring after blood-material contact 
quantified in this chapter, are schematically summarized in figure 5.9. 
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Figure 5.9   
 
Summary: Incompatibility reactions 
triggered via biomaterials upon 
exposure to blood and their in vitro 
quantification. The highlighted 
pathways and products were 
quantified in this study and 
presented respectively on adjacent 
table. Image modified from (68). 
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5.5 Conclusion and Future directions 
 
The ISO10993-4 are a selection of recommended tests for hemocompatibility of biomedical 
devices after contact with human blood. The principle of in vitro flow assays is to quantify 
specific biological markers of coagulation, and inflammation, after blood-material contact 
under physiological conditions, via enzyme linked immunoabsorbent assays (ELISA).  
PAC-L605 showed superior hemocompatibility compared to alloy L605, for clot formation at 
60 mins via chandler loop assay, for all 5 assays. Plasma markers for TAT complex (thrombin-
antithrombin formed), β-TG (platelet activation/degranulation), sP-selectin (1:30, platelet 
activation) and SC5b-9 (1:10, complement activation) were significantly low for PAC-L605 
compared to alloy L605 bare metal. Markers of leukocyte activation, PMN elastase (1:100) 
were not significantly different between the two materials, although PAC-L605 surfaces 
showed an unexpected, and slightly higher concentration of the protease. As explained within 
context, high turnover rate of surface albumin (and HDL) proposed (Vroman effect), may 
contribute to overall results observed on hydrophilic PAC-L605 surfaces, including increased 
concentration of PMN elastase. This can be verified via comparative immunofluoroscent 
staining specifically for albumin protein, on PAC vs. L605 surfaces after 60 min flow assay, 
with anti-albumin antibody (ab106582, abcam, Cambridge MA, USA). 
Since sP-selectin is not a reliable marker of platelet activation, due to soluble isoform shedding 
off in circulation, a platelet count (in accordance to ISO10993-4) can be conducted instead. 
Furthermore, ISO 10933-4 tests only apply to the evaluation of fabricated devices in their final 
form, not the modified material itself. Preliminary tests conducted here, should therefore be 
repeated after PAC technology is transferred to alloy L605, cobalt chromium commercial stents 
ML8 in vitro, to assess biocompatibility, prior to translation in vivo.    
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Chapter 6 – General Discussion 
 
Two biomaterials of interest, alloy L605 and 316LSS, used to fabricate commercial stents were 
investigated in this study, with predominant focus on cobalt chromium metal alloy L605. The 
thesis initially describes a preliminary in vivo study of commercial 316L stainless steel (SS) 
stents modified with PAC, in a rabbit bilateral iliac artery model of endothelialization. 
Comparative physiological responses of PAC vs. BMS at the stent/artery interface, assessed 
degree of stent biointegration after implantation.  The second biomaterial investigated was 
alloy L605, chosen for its composition as bare metal for new generation multi-link 8 (ML8) 
cobalt chromium stent system (Abbott Vascular). We conducted extensive in vitro 
investigations on PAC-L605 surfaces, coated with an optimized plasma recipe. The aim was 
improving surface biocompatibility, prior to transferring PAC technology to a commercial 
ML8 alloy L605 stent platform for in vitro/in vivo investigations, thereafter. 
A biofunctionalized material for cardiovascular devices aim to promote desired physiological 
responses and achieve biointegration of the stent following implantation. Stents are used 
increasingly to treat coronary artery disease (CAD), a leading cause of death worldwide. 
Cardiovascular disease, its causes, intervention, stent incompatibility and novel stent 
modification techniques were detailed in chapter 1. Clinically, stents are limited by their 
potential to trigger biological responses in relation to coagulation, inflammation and restenosis 
in vivo. The work in this thesis examines a bioengineering approach to achieve a biomimetic 
stent coating. Initial PAC vs. BMS (316LSS stent) histopathology studies were followed by 
PAC-L605 vs. L605 mechanical characterization, at the molecular/atomic levels of cobalt 
chromium material. The study further investigated plasma kinetics, and in vitro 
biofunctionalization; via cytocompatibility, hemocompatibility and standardized tests, under 
physiological conditions.  
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6.1 Covalent immobilization of TE on PAC 
Plasma modification of a material confers the unique ability to covalently bind a biomolecule 
of interest, in its bioactive state, on material surface [103]. Controlled covalent attachment of 
a protein candidate – tropoelastin (TE) (freely available in the subendothelial ECM), influenced 
material biocompatibility of both PAC-316LSS and PAC-L605, as predicted [187]. Prior to 
pilot in vivo study, in vitro covalent binding capacity of PAC-316LSS stents were investigated 
in chapter 2 with ELISA and radiolabelled TE. We showed increased levels of tropoelastin 
bound to PAC-316LSS stent surfaces after SDS wash, confirming covalent surface protein 
attachment (figure 2.2). The thesis next characterized covalent immobilization of TE, on PAC-
L605 surfaces for the first time in chapter 4 with ELISA and SDS, showing similar results 
(figure 4.3).  
However, recipe for PAC on L605 flat surfaces was markedly different from previous deposits 
on 316LSS stents/flat metal, due to present optimization and changed conditions of treatment. 
The previous plasma coating on alloy 316LSS was 200 nm in thickness; allowing a full 
monolayer of TE binding at ~50 nm [145]. In the present study, optimized PAC recipe for L605 
was 20 nm in thickness. Absorbance values of covalent attachment after SDS were therefore 
markedly higher for PAC-316LSS compared to PAC-L605. The ability to control surface 
protein density allows customized applications of the material for specific uses. In the context 
of coronary stents, binding a monolayer of TE to encourage rapid in vivo endothelialization 
was beneficial. Even with a 20 nm PAC on L605, we observed improved covalent binding 
capacity and long-term biocompatibility, compared to bare alloy L605. In future, new PAC-
L605 recipe could be tested over a range of deposition thicknesses, to assess density of TE 
molecules - forming a monolayer in vitro.  
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6.2 Biocompatibility of PAC-316LSS stent surfaces in vivo 
In chapter 2, plasma technology was applied to a custom-built BMS (316LSS) with an altered 
deposition method, to that used on flat 316LSS surfaces. The surface deposition method 
produced a nodule-like nanomorphology combined with an ion stitched grading from 316LSS 
to PAC. The approach provided additional stability to the layer to prevent large scale 
delamination. The altered structure for PAC stents retained unique covalent protein binding 
capacity in vitro (chapter 2). In chapter 3, resistance to delamination was characterized, and 
verified on flat PAC-L605 (same plasma technology, different recipe and thickness), with 
focused ion beam (FIB) and transmission electron microscopy (TEM), for the first time on a 
cobalt chromium metal (figure 3.14).  
Also for the first time, in vivo evaluation of PAC and PAC+TE was performed, in a well-
established rabbit iliac artery model within chapter 2. In the pilot study, PAC, PAC+TE stents 
and BMS were implanted for 7-10 days. In this study, we focused only on 7 day, animal model 
comparing PAC+TE vs. BMS (chapter 2). Initial SEM, histology (H&E) and 
immunofluorescence analyses, revealed feasible implantation for both stent types, with no 
gross inflammatory reaction observed.  Additionally PAC did not show evidence of significant 
delamination after implantation. Both stent types were analyzed for strut cell coverage with 
SEM and immunofluorescence with CD31 marker, specific to endothelial cells to confirm 
endothelialization at 7 days. Extent of endothelialization and cell coverage were equivalent for 
both stent types. This was the first in vivo investigation of a monomeric TE layer in a blood-
contacting environment.  
The stented artery segments were embedded in MMA resin for stent/artery interface 
histopathology. Methods of segmenting and deplasticizing resin-artery were trialled prior to 
staining. We used H&E to quantify early neointimal hyperplasia – NIH (neointimal thickness 
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and area), followed by Carstairs’ staining to detect early markers of thrombosis (collagen, 
RBC, fibrin).  Immunohistochemistry (IHC) with molecular markers for surface 
endothelialization (CD31) and macrophage/neutrophil infiltration (MAC387) was conducted 
on stent-artery cross sections thereafter. 
The sectioning procedure was optimized using automated microtomes, for decreased section 
thickness, and increased staining uptake. Section adhesion was trialled to improve hydrophobic 
resin retention on a hydrophilic glass slide, throughout >3 hour protocols. At day 7, NIH was 
small for both stent types, but significantly low for PAC compared to BMS; in relation to 
thickness and area (figure 2.7).  Carstairs staining showed significantly lowered fibrin on PAC 
vs. BMS, with no significant difference for collagen and RBC (figure 2.8). Immunostaining for 
MMA resin, followed by protein induced epitope retrieval (PIER) was trialled herein also for 
the first time, requiring multiple optimizations. The CD31 marker of endothelialization 
indicated presence of an incomplete monolayer of luminal endothelium at 7 days, as expected 
within the timeframe. However results were inconsistent on sections, potentially due to short 
timeline for healing and the resin type, as discussed in detail within chapter 2. Markers of 
macrophage/neutrophil (MAC 387) infiltration were similarly inconsistent and observed on 
both L605 and PAC+TE -artery cross sections. Markers of smooth muscle cell α actin were up 
taken non-specifically (figure 2.10) requiring further optimization of protocols. 
Inflammatory neutrophil infiltration observed on PAC (day 7), resonates with high levels of 
plasma inflammatory marker PMN elastase (protease released from leukocytes), observed in 
vitro for PAC-L605 compared to bare L605 (chapter 5, figure 5.7). Even though markers of 
inflammation in the thesis appear to indicate an inflammatory response towards PAC or 
PAC+TE (potentially elicited via high surface albumin turnover rate), overall results of 
hemocompatibility and cytocompatibility quantified, significantly outweigh this observation 
(chapter 2/4/5 in vivo and in vitro).  
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Implanting PAC+TE stents was feasible at 7 days (0% mortality rate after PCI, until 
euthanasia). Future studies may increase timeline (28 days) for complete endothelialization, 
and animal number for a statistically robust outcome. Furthermore, biomarkers of inflammation 
(PMN elastase) could be measured from arterial blood collections at euthanasia (stored at -
20oC or -80oC until ELISA), to assess in vivo inflammatory response.  [Results here presented 
sequentially at the Scientific Sessions: American Heart Association; Dallas, Texas, USA 2013 
[367], and World Congress of Cardiology, Melbourne, Australia, 2014 [368]]. 
6.3 Characterization of surface modification with PAC-
L605 
 
In chapter 3, for the first time herein, we addressed a key question on how plasma modified 
surfaces do not delaminate. At present, polymer delamination of DES has presented itself as a 
key issue, contributing to adverse clinical complications in vivo [192]. In contrast, PAC stent 
surfaces have shown to remain intact after compressive stress, both in vitro and after 
implantation in vivo [106]. Although the principle of delamination is outlined in plasma physics 
[103], the concept had not been experimentally confirmed, with the novel PAC recipe on a 
novel CoCr material. We therefore sought to analyze surface coating integrity on an alloy L605 
surface via traditional technique of nanoindentation [202]. With increasing external load, the 
plasma coating stiffness increased, however at highest load, it did not surpass stiffness of the 
metal alloy, confirming coating integrity (figure 3.12). No delamination was seen at interface, 
and no plateau seen in load-displacement raw data (used to compute coating stiffness).   
Furthermore, we investigated the interface of PAC-L605, via extensive techniques in material 
science characterization. The methods included tripod polishing, focussed ion beam (FIB) 
milling, and high resolution transmission electron microscopy (HRTEM) with inverse fast 
Fourier transform (IFFT), and selected area electron diffraction (SAED) method. The 
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techniques allowed visualization of surface modification at the PAC-L605 interface, to explain 
deposition methods in plasma physics that contributed to the unique, non-delaminating nature 
of this plasma coating - PAC (figure 3.14-3.16). [Initial results presented at the Arteriosclerosis, 
Thrombosis, Vascular Biology conference, 2015, San Francisco, California [369]]. 
Prior to extensive characterization of PAC modification, we quantified surface hydrophilicity 
of PAC on alloy L605, in accordance to previous investigations in applied plasma physics 
[209]. The results indicated decreased water contact angle and increased correlating surface 
energy, 15 mins post PAC deposition, confirming hydrophilicity of surface modification 
(figure 3.5-3.6). The surfaces were described as “functionalized” or activated via free radicals 
[103]. However, with time, on exposure to air, surface hydrophilicity decreased, as observed 
in preceding investigations [103, 209, 370] . Bilek et al, previously explained variation of 
surface free energy of PAC, with time, in relation to electron spin resonance (ESR) [103, 371]. 
With time, the PAC modification showed increased ESR for carbonyl (C=O) groups, and 
decreased ESR for free radicals (R*) [103, 371]. Investigations on surface energy variation of 
PAC-L605 herein, showed significantly decreased levels of polar surface free energy, in 
agreement with decreased levels of surface free radical (R*) ESR previously observed. The 
dispersive energy component correlating to surface oxidation, did not vary significantly from 
the calculated total surface energy (figure 3.7); also in agreement to increased levels of surface 
carbonyl groups (C=O) previously observed [103], as a result of oxidation with time. We did 
not quantify surface chemistry of ageing PAC-L605 via ESR in this study, since the substrate 
on which PAC was deposited is a metal alloy.     
6.4 Enhanced endothelial cell interaction on PAC-L605-
TE in vitro 
Alloy L605, cobalt chromium metal was deposited with PAC for the first time in chapters 3-4. 
Two different PAC recipes were investigated on alloy L605, to assess plasma-based 
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biofunctionalization in vitro. PAC1: C-1, N-10, 500 V, t=20 min was compared with PAC2: 
C-2, N-10, 1000 V, t=10 min, via several methods including human coronary artery endothelial 
cell (HCAEC) culture. Biomaterial assisted-endothelialization aims to assist healing after the 
single layer of endothelial cells lining the vascular wall lumen [236], undergo injury during 
PCI, initiating coagulation and inflammation cascades [237]. Delays in healing vascular injury, 
mainly observed with DES, led to neointimal thickening and hyperplasia [114, 183, 237]. As a 
result, surface engineering materials aim to produce devices that promote endothelialization 
and assist natural healing process. Initially HCAEC proliferation on biomaterials at 3-5 days 
were visualized and quantified with crystal violet on PAC (with or without TE) vs. bare alloy 
L605. The quantified absorbance was highest for PAC+TE surfaces, followed by PAC and 
L605 (figure 4.6 A, B).   
Bright field crystal violet staining showed HCAEC aggregates without specific organization 
on all material surfaces (Chapter 4, figure 4.6A). To identify intracellular organization, and 
visualize surface anchorage at 5 days, cellular cytoskeleton was stained with f-actin specific 
antibody phalloidin-TRITC. At high magnification, material surfaces best supporting cell 
attachment were PAC2-L605 and PAC2-L605-TE (Chapter 4, figure 4.7). In chapter 4, we 
conclude that surfaces with PAC2 surfaces, coupled with an ECM protein TE, supported 
homogenous cell proliferation compared to uncoated L605 and uncoated PAC1. Improved cell 
proliferation also proved that covalently bound TE remained bioactive on a material surface. 
Further, change in cell shape in response to substrate interaction is based on the cell’s 
cytoskeleton. The HCAEC cytoskeleton seen on PAC2 with/without TE, mechanically 
stabilized the cell in a coordinated manner, compared to other biomaterial surfaces investigated 
(figure 4.7).   
Further, we investigated endothelial cell specific marker vWF, present in Weibel-Palade bodies 
via vWF antibody, on PAC2 and alloy L605, at day 5. Morphology of vWF on the two surfaces 
 216 
 
was not different. The protocol was optimized with 5% bovine serum albumin (BSA), to reduce 
background fluorescence, and optimize/heighten visualization of vWF. Although vWF is a 
prothrombogenic protein, similar antigen expression observed on both surfaces is a result of 
enhanced staining protocol. High magnification SEM showed improved surface integration of 
HCAECs on PAC+TE surfaces, followed by PAC alone, compared to bare metal (figure 4.8 
C).   
6.5 Thrombogenicity assessment of PAC-L605 and 
PAC+TE 
In chapter 4, thrombogenicity of bioengineered surfaces investigated was in accordance to ISO 
10993-12 standards [252]. Surface engineered biocompatibility was assessed via static and 
flow experiments with whole blood, and plasma, under physiological conditions in vitro. 
Platelet rich plasma (PRP) isolated from whole blood, was used to determine surface 
thrombogenicity, followed by static whole blood adhesion, within defined timelines. We 
confirmed improved surface hemocompatibility for PAC-L605 with or without TE, compared 
to L605. Superior hemocompatibility was observed in relation to platelet/fibrin aggregates, and 
whole blood adhesion (Figures 4.9 and 4.11). For the first time, we conducted an ageing study 
of TE incubated surfaces stored long term, by assessing hemocompatibility, in chapter 4. We 
saw no changes to surface hemocompatibility of PAC+TE stored overnight (4oC), and 
PAC+TE stored for 2 weeks (-20oC). Results were also similar to uncoated PAC aged for 1 
month, and as before fibrin/platelet deposition was observed on alloy L605 (figure 4.10). 
Retention of activity over time, has implications for long-term storage, prior to preclinical 
studies in future. 
For chandler loop assessments under flow we investigated hemocompatibility of PAC1 and 
PAC2 recipes, with or without tropoelastin and alloy L605. We chose PAC1 surfaces for future 
flow assays, due to improved hemocompatibility seen (lower clot formation than PAC2; results 
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not significant) (figure 4.13 A). All blood-material experiments were conducted with 
heparinized whole blood. Heparin was chosen as the suited anticoagulant, due to minimal 
inhibition of coagulation components and platelets.  
Overall, PAC2 (C-2, N-10, t=10 min) surfaces showed higher cytocompatibility, while PAC1 
(C-1, N-10, t=20 min) surfaces showed higher hemocompatibility (chapter 4). For an ideal 
PAC surface, the 2 recipes could be merged to form; C-1, N-10, t>20 min deposition (PAC3). 
The resulting surface would have a stoichiometry of C: N similar to PAC1 (1:10), but with 
higher deposition thickness, for equivalent cytocompatibility and hemocompatibility.  
6.6 ISO tests for modified materials prior to L605 stent 
evaluation 
 
In chapter 5, a series of enzyme linked immunoabsorbent assays (ELISAs), were conducted 
after in vitro whole blood flow. The aim was to investigate markers of coagulation and 
inflammation, after blood-material contact, in accordance to ISO10993-4 regulations.  
Modified chandler loop flow assays were conducted prior to each plasma isolation, for PAC1 
vs. L605. PAC1 was chosen due to superior hemocompatibility, observed in chapter 4 (ISO 
10993-12 tests). Individual plasma biomarkers for TAT complex, β-TG, sP-selectin, SC5b-9 
and PMN elastase were quantified.  
As observed in chapter 4, PAC surfaces had significantly lower clot formation at 60 min, 
compared to alloy L605. Plasma biomarkers for TAT, β-TG, sP-selectin and SC5b-9 were 
significantly lower on PAC, indicating lowered coagulation, platelet activation and 
complement activation respectively (figures 5.3-5.6). Results for sP-selectin were widely 
variable between the two surfaces, therefore average values were chosen for GraphPad prism 
(figure 5.7). However, overall quantification of sP-selectin as a biomarker of plasma activation 
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was debated, based on previous in vivo data. For instance former studies showed the 
physiological role of circulating soluble P-selectin wasn’t determined in vivo [358], and 
circulating platelets rapidly lost their surface P-selectin in vivo [324]. Platelet count after blood-
material contact and plasma isolation, was suggested as an alternative to quantify levels of 
plasma protein, also in accordance to ISO 10993-4 tests. 
Plasma levels of PMN elastase, proteolytic enzyme released by leukocyte activation, were not 
significantly different between the two surfaces (figure 5.7). Trends were however indicative 
of increased levels of PMN elastase, for PAC vs. L605. This was an unexpected result. 
Previously, we explained results of hemocompatibility in relation to reduced markers of initial 
coagulation and complement activation on PAC, via the Vroman effect [338]. The same effect, 
may result in a high turnover rate of albumin on PAC, contributing to activation of leukocytes 
via the alternative pathway (AP) discussed in 5.4.5 (figure 5.8). Additionally, surfaces can be 
investigated for albumin in future, as conducted with fibrinogen after flow experiments in 
chapter 4. In future, PAC-L605 incubated with tropoelastin (PAC-L605-TE) can be included 
as a variable, to investigate impact of TE on plasma biomarkers and surface biocompatibility. 
6.7 Implications and future development for stent 
platform 
 
The series of investigations in this thesis intend to modify commercially available biomaterials 
for biocompatibility. The proprietary plasma technology, aimed at surface modification to 
create a strong, non-delaminating plasma-material interface that covalently bound a protein, in 
its bioactive conformation. The two biomaterials of interest; commercially available stainless 
steel (alloy 316L), and cobalt chromium (alloy L605), are presently used in stenting technology 
[372]. Alloy 316LSS stents were investigated initially in an in vivo stent platform, to indicate 
PAC+TE stent feasibility. A longer time point, larger study cohort, and optimized technical 
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methods would allow assessment of complete NIH, including extensive histopathological 
studies for markers of endothelialization, and inflammation - in future. Reduction of restenosis 
would be apparent at 28 days, and should be investigated in vivo, since no reliable in vitro 
model exists. 
The technology was modified and optimized on alloy L605 surfaces for the first time. Alloy 
L605 with ASTM F90 specifications was chosen - for its composition is the same as bare metal 
for new generation multi-link 8 (ML8) cobalt chromium stent system (Abbott Vascular). This 
study was a first to investigate PAC-L605 interface via TEM, to show ionic stitching and 
confirm non-delaminating features of PAC, unique to plasma technology. Also for the first 
time for PAC-L605, we investigated surface biofunctionalization, and proposed optimum 
conditions for PAC recipe to equally meet in vitro cytocompatibility and hemocompatibility. 
The PAC recipe will be translated to a coronary stent platform, in future, to comparatively 
assess biocompatibility of PAC-ML8 vs. ML8 (Abbott Vascular). As mentioned, ISO 10993-
4 biocompatibility tests should be repeated on PAC-ML8 stents, prior to translational studies 
in vivo.    
Recent developments on stent design (since five years - leading to 2012), to prevent restenosis 
and LST are outlined in table 6.1, from [372]. Bioeresorbable stents, biodegradable polymers 
and biocompatible permanent polymer stents have received much medical attention due to their 
innovative technologies [372-374]. When a stent polymer coating disintegrates after its defined 
period of drug elution in vivo, or delaminates due to flow shear [192], the underlying bare metal 
will be exposed to coronary artery flow. The underlying metal should therefore biointegrate, 
for sustained biocompatibility. An optimized PAC stent surface aims to maintain long-term 
biocompatibility, and is therefore an ideal candidate as an underlying stent for a DES platform, 
such as with Polyzene-F Nanocoated cobalt-chromium stents [373], or in its bare PAC-cobalt 
chromium form.   
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For future directions in vitro, chandler loop model of a stent requires additional flow 
characterization, since level of shear stress can influence platelet, endothelial cell activation, 
and coagulation rates [252]. Key fluid mechanics parameters characterize curved blood flow, 
fluid friction, and sample volume in a chandler loop-stent model. All parameters should be 
investigated to determine model sensitivity and outcome. 
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Table 6.1. Developments in preventive measures for restenosis, from [372] 
Target Development  Status 
Antiproliferative drug Sirolimus derivatives (biolimus A9[375, 376] and novolimus[377] Clinical 
Polymer Biolinx® (Medtronic Vascular, Inc, Santa Roasa, CA, USA)[378]  Clinical 
preliminary 
Polymer Polyzene-F [373], [379] Clinical 
preliminary 
Polymer Biodegradable (polylactic acid, polylactic-co-glycolic acid, [380, 381] Synbiosys® [InnoCore 
Technologies, Groningen, Netherlands], Eureka® SOLO [Surmodics, Inc., MN, USA] 
Clinical 
Stent design Polymer free stent (Biofreedom®, Biosensors International Group, Hamilton, Bermuda) [382] Clinical 
preliminary 
Coating Endothelial progenitor cell capturing stent (Genous®[383, 384], Combo stent® [385] [OrbusNeich 
Medical, Inc., FL, USA]) 
Clinical 
Coating  Titanium-nitride-oxide-coated stents (Titan2™ stent [Hexacath, France])[386-389] Clinical 
Stent platform Bioabsorbable stent (magnesium stent [Biotronik, Berlin, Germany])[390-392] Clinical 
Drug delivery Nanomedicine[393, 394] Preclinical 
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Stent platform/metal alloys Platinum-chromium alloy stents (Promus Element® and Taxus Element® (Boston Scientific, MN, 
USA) [176, 395] 
Clinical 
Drug delivery Magnetic targeting stents [374] Preclinical 
Miscellaneous  Gene-based therapy[396-399] Preclinical 
Miscellaneous  Systemic treatment[400-402] Clinical 
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6.8 Conclusions 
 
The plasma technology - PAC is robust, hemocompatible and cytocompatible, capable of 
binding a monolayer of tropoelastin on biomaterial surfaces. In vivo stenting was feasible for 
PAC316LSS stents at 7 days, and has potential for future translational studies within an 
increased timeframe. In vitro PAC-L605 showed non-delaminating coating technology and 
superior biocompatibility, to the bare metal alloy L605. Prior to translating PAC technology to 
a new generation alloy L605 cobalt chromium coronary stent, it was essential to experimentally 
prove coating integrity, and biological superiority of PAC-L605 surfaces; so a cost-effective 
flat biomaterial was chosen. We now have promising implications to modify a commercially 
available cobalt chromium stenting technology - ML8, composed of the alloy L605, in future. 
This was the overall aim and outcome of the present study.
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Appendix A 
 
Matlab Code 1 used to calculate the surface stiffness based on unloading displacement vs 
load for 21 indents from nanoindentation data.   
Indentation_code.m 
n=1; 
x=1; 
for n=1:1:10 
    C=zeros(11,2); 
    for x=1:1:11 
        C(x,1)=B((P(n,1)+x-1),1); 
        C(x,2)=A ((P(n,1)+x-1),1); 
end 
    fit=polyfit(C(:,1),C(:,2),1); 
    S(n,2)=fit(1,1); 
end 
 
figure(1) 
loglog(S(:,1),S(:,2),’K.’)  
 
